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General introduction
The past few years have witnessed the explosive enthusiasm on genome ed-iting. Scientists are better equipped with molecular tools to answer hard-to-answer questions, to cure incurable diseases, and to redefine pre-defined ge-
netic code. Typically, genome editing is based on generating targeted chromosomal 
double-stranded DNA breaks (DSBs) in living cells. In response to such targeted 
DSBs, cells have evolved DNA repair mechanisms that can be exploited for genome 
editing purposes. The non-homologous end joining (NHEJ) pathway, which ligates 
broken chromosomal ends, can lead to gene knockouts after the incorporation of dis-
ruptive small insertions and deletions (indels);  the homology-directed repair (HDR) 
pathway, in turn, copies the genetic information into the target sites from exoge-
nous donor DNA templates that share homology with the target genomic sequence. 
Designer nucleases (a.k.a. programmable nucleases) are the molecular tools that 
generate the site-specific chromosomal DSBs necessary for genome editing. These 
tools include zinc-finger nucleases (ZFNs) and transcription activator-like effector 
(TALE) nucleases (TALENs), whose DNA recognition is mediated by protein-based 
zinc finger motifs and TALE repeats, respectively. Recently, designer nucleases 
based on prokaryotic CRISPR (clustered regularly interspaced short palindromic re-
peats)-Cas9 systems have been introduced. In contrast to their ZFN and TALEN pre-
decessors, the CRISPR-Cas9-based platforms, consisting of RNA-guided nucleases 
(RGNs), do not require protein engineering efforts as their target DNA recognition 
is mediated by RNA-DNA hybridization, as opposed to protein-DNA interactions.     
The adaptation of CRISPR-Cas9 nucleases to eukaryotic cells not only propels the 
development of genome editing, but also facilitates the engineering of a broad range 
of molecular tools for targeted transcriptional regulation, epigenetic remodeling 
and cellular imaging. Owing to their ease-of-use and cost-effectiveness, RNA-guid-
ed molecular tools based on CRISPR-Cas9 systems have, in a short time span, be-
come the most widely used genome, transcriptome and epigenome manipulating 
platforms. Moreover, encouragingly, a number of clinical trials which make use of 
RGNs have recently been granted the green light by regulatory authorities. Exam-
ples include clinical trials aiming at the genetic engineering of chimeric antigen re-
ceptor T-cells and CD34+ cells from cancer patients and HIV-infected individuals, 
respectively. Nevertheless, one of the biggest concerns on the clinical translation of 
CRISPR-Cas9 nucleases is off-target activity and related potential adverse effects, 
e.g., deleterious or unpredictable mutations possibly compounded with oncogenic 
chromosomal translocations. Indeed, a number of studies have revealed that RGNs 
can cleave not only the chromosomal DNA at the intended target site, but also at 
off-target sequences bearing a varying number of mismatches. Therefore, whenever 
genome editing is meant to be applied in clinical settings, its specificity and accuracy 
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will be paramount and, as a result, potential deleterious effects caused by off-target 
activity should be thoroughly assessed. Although a great amount of efforts have 
been made to improve the safety profiles of RGNs, the fact that conventional ge-
nome editing strategies rely on DSB formation confers them a non-negligible risk. 
Of note, this risk is associated with unwanted mutations at not only, off-target, but 
also on-target sites. 
In this thesis, Chapter 1 reviews the fast-paced investigations aiming at improv-
ing the efficiency and specificity of genome editing procedures, covering the strat-
egies based on protein engineering, gRNA design and donor DNA optimization. 
Chapter 2 focuses on investigating a DSB-free genome editing principle that trig-
gers seamless genetic modifications in human cells after the recruitment of the HDR 
pathway. This hereafter called in trans paired nicking strategy is based on induc-
ing single-stranded DNA breaks (SSBs), or nicks, at genomic target sites and donor 
DNA templates. In this work, I present experimental evidence showing that, when 
compared to conventional DSB-dependent approaches, in trans paired nicking can 
improve the efficiency, specificity and accuracy of chromosomal DNA insertion at 
different human loci, including the dystrophin-encoding DMD gene, and the pur-
ported “safe harbor” loci AAVS1 and CCR5. The extent of the site-specific genetic 
modifications varied from small restriction enzyme polymorphisms to whole trans-
gene expression units. Taken together, these data bode well for the applicability of in 
trans paired nicking to settings in which non-disruptive and high-fidelity genetic 
manipulation of complex genomes is key.
Hitherto, it remains ill-defined how, and to what extent, the nuclear DNA archi-
tecture and the epigenetically regulated chromatin compaction affect genome edit-
ing endeavors based on designer nucleases. Hence, next to investigating DSB-free 
high-fidelity genome editing strategies, in this thesis, I have also probed the im-
pact of alternate higher-order chromatin conformations on (i) the performance of 
TALENs and RGNs (Chapter 3); (ii) the performance of high-specificity designer 
nuclease constructions (Chapter 4); and (iii) the balance between NHEJ and HDR 
events during the gene editing interventions (Chapter 5). In this regard, I carried 
out genome editing experiments in complementary gain-of-function and loss-of-
function cellular models in which the chromatin states of isogenic reporter loci are 
tightly regulated by small-molecule drug availability (i.e. doxycycline). The reporter 
genes in these cellular models are flanked by TetO sequences and are subjected to 
epigenetic regulation by the chimeric tTR-KRAB protein which, in the absence of 
doxycycline, binds to its cognate TetO recognition sites, inducing a local heterochro-
matic environment. This experimental setup has enabled the unbiased evaluation of 
the relative impact of “closed” heterochromatin and “open” euchromatin on both 
NHEJ- and HDR-mediated gene editing at isogenic target sequences. Gene editing 
experiments performed in these cellular models showed that NHEJ-mediated tar-
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geted gene knockouts induced by TALENs and RGNs are significantly hampered 
at heterochromatic target sites (Chapter 3). Chapter 4 further extends the investi-
gations in Chapter 3 by describing the differential impact of alternate higher-order 
chromatin conformations on different high-specificity RGN constructions, in par-
ticular those based on (i) offset RGN “nickase” pairs, (ii) improved Cas9 variants, 
(iii) truncated gRNAs and (iv) the ortholog S. aureus Cas9 protein. The experimental 
section of this thesis ends with Chapter 5, which investigates the impact of chroma-
tin on genome editing outcomes resulting from the action of the HDR and NHEJ 
pathways with donor DNA templates of synthetic, non-viral and viral origins.
Another important aspect of genome editing is to ensure that the delivery of de-
signer nucleases and donor DNA constructs is specific, robust and non-disruptive 
to the target cell’s genome. This key “delivery” issue remains challenging especially 
when patient cells are to be modified either ex vivo or in vivo. Given their integra-
tion-defective character and well-established cell entry mechanisms, episomal viral 
vectors, i.e., engineered replication-defective viruses, might constitute ideal delivery 
vehicles for introducing in a targeted and efficient manner gene editing reagents into 
therapeutically relevant cells. In this regard, Chapter 6 summarizes the principal 
characteristics, advantages and drawbacks of the main viral vector systems that are 
being adapted for genome editing purposes, namely, integration-defective lentivi-
ral vectors (IDLVs), adeno-associated viral vectors (AAVs) and adenoviral vectors 
(AdVs). As a case-in-point, Chapter 7 discusses the emerging role of viral vectors in 
repairing defective dystrophin-encoding genes in mouse models and human cells, 
whose mutations cause the lethal muscle-wasting X-linked disorder Duchenne mus-
cular dystrophy (DMD). 
In conclusion, by investigating the interaction between different types of nucleases 
(i.e. nicking versus cleaving), donor DNA structures and target chromatin environ-
ments, this thesis provides important insights into how to improve the three crucial 
parameters of genome editing: efficiency, specificity and fidelity. Hence the work 
presented in this thesis expand the range of possibilities for high-fidelity genetic 
manipulation of human cells. 
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Up until about five years ago, when speaking of genome editing using de-signer nucleases, scientists were mostly referring to transcription activa-tor-like effector nucleases (TALENs) and zinc-finger nucleases (ZFNs); 
now RNA-guided nucleases (RGNs) based on clustered regularly interspaced short 
palindromic repeats (CRISPR) systems are, undoubtedly dominating the field [1]. 
Native type II CRISPR-Cas9 nucleases from S. pyogenes were the first to be adapted 
into genome editing tools [2-4] and, similarly to other prokaryotic CRISPR systems, 
confer adaptive immunity by detecting, recording and degrading foreign DNA from 
invading viruses and plasmids [5, 6]. Soon after the discovery in 2012 that S. pyogenes 
CRISPR-Cas9 nucleases could cleave DNA in an RNA-guided manner [5, 6], re-
searchers hijacked this defense system and turned it into a powerful tool to edit the 
genomes of eukaryotic cells, in a targeted and permanent basis [2-4]. These genome 
engineering technologies have wide implications for basic and applied research and 
bioethics, especially in the context of genetically modifying human somatic and 
germ cells. With the introduction and ongoing refinement of RGNs, it seems that 
the scientific community is on track to tackle the root cause of genetic and infectious 
diseases. Nevertheless, RGNs suffer from, amongst other shortcomings, off-target 
activities and relatively low homology-directed repair (HDR) efficiency. To over-
come these hurdles, and hence unleash the full potential of RGN-based therapies, 
researchers are rationally engineering Cas9 variants, de novo-isolating Cas9 proteins, 
fine-tuning gRNA and donor DNA structures, and devising improved protocols for 
obtaining specific genome editing outcomes. This chapter reviews these efforts that, 
when combined, might overcome the main limitations of current genome editing 
technologies. 
Genome editing in a nutshell
Efficient genome editing relies on designer nucleases, which, by making site-specific 
chromosomal double-stranded DNA breaks (DSBs), trigger cellular DNA repair path-
ways to establish specific genome editing outcomes., e.g., targeted gene knockouts 
and knock-ins [1, 7, 8]. The non-homologous end joining (NHEJ) can knockout cis- or 
trans-acting elements after the introduction of small insertions and deletions (indels); 
the homology-directed repair (HDR) can knock-in new genetic information using ex-
ogenous DNA as surrogate DSB-repairing templates (donor DNA) [1, 7]. It is notewor-
thy mentioning that, in mammalian cells, DNA repair often favors NHEJ over HDR, 
with the HDR machinery largely restricted to the G2/S phases of the cell cycle [9, 10].
Among the designer nucleases used in genome editing, ZFNs and TALENs share 
a similar architecture in that a sequence-specific DNA-binding protein domain is 
fused to the nuclease domain of the type IIS FokI restriction enzyme. Moreover, 
ZFNs and TALENs work in pairs, cleaving their target DNA after the in situ dimer-
ization and ensuing catalytic activation of their FokI domains [1, 7]. The vertebrate 
Cys2-His2 zinc-finger motif is the basic unit of the DNA-binding domain of ZFNs 
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with each zinc-finger typically recognizing a specific DNA triplet. Thus, assem-
bling 4-6 zinc-finger motifs per ZFN monomer generally provides enough target 
site specificity within complex eukaryotic genomes [11-16]. TALENs recognize DNA 
through an array of repeated domains of TALE proteins found in certain phytopath-
ogenic bacteria, e.g., Xanthomonas sp. [17, 18]. Each TALE repeat is composed of 33-
35 conserved amino acids with variable residues dubbed repeat variable di-residues 
at positions 12 and 13, recognizing a specific nucleotide on the DNA double-helix 
[17, 18]. Researchers have been exploiting ZFNs and TALENs not only for gener-
ating transgenic animal models [19], but also for treating diseases, including AIDS 
[20], hemophilia B [21] and certain leukemia [22]. Nevertheless, many laboratories 
flinch from using ZFNs and TALENs because making these protein-guided nucleas-
es requires more expertise and higher costs than those of RGNs.  
RGNs from the prototypic S. pyogenes type II CRISPR-Cas9 system and, more re-
cently, those from other species, are offering unprecedented speed and versatility 
with which robust genome editing tools can be built [1, 7]. The RGNs from S. pyo-
genes consist of a fixed Cas9 nuclease (SpCas9), and two RNAs, i.e., a sequence-spe-
cific CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA). Together 
these two RNAs form a crRNA:tracrRNA duplex that binds the SpCas9 nuclease 
and directs it to a target site consisting of an NGG triplet called protospacer-ad-
jacent motif (PAM) and a 20-nt long sequence complementary to the 5’ end of 
the crRNA (spacer) [5, 6, 23]. The recognition of the NGG triplet by the PAM-in-
teracting domain of SpCas9 is followed by double helix melting, local RNA-DNA 
hybridization, R-loop elongation and PAM-dependent allosteric activation of 
the HNH and RuvC-like nuclease domains [24]. This series of events lead to the 
generation of a blunt DSB mostly positioned 3-bp distal from the PAM [5, 6, 24].
The initial adaptation of the native S. pyogenes CRISPR-Cas9 nuclease system into 
a powerful genome editing tool involved expressing human codon-optimized Cas9 
ORF and single guide RNAs (sgRNAs) formed by the fusion of crRNA and tracr-
RNA moieties that mimic the original crRNA:tracrRNA structure [2, 4]. Hence, by 
simply swapping the spacer sequence in the sgRNA, researchers can target virtually 
any genomic sequence with unprecedented flexibility. Depending on the target cells 
—cultured in vitro or located in a living organism—RGNs can be delivered as ribo-
nucleoproteins (RNPs) or encoded in mRNA, plasmid DNA or viral vector genomes; 
and depending on the purposes, they can be designed to induce (i) disruption of 
specific sequences (knockout), (ii) gene knock-ins, (iii) targeted DNA deletions, (iv) 
directed chromosomal translocations and (v) single nucleotide substitutions.
Notable bottlenecks of CRISPR-Cas9 technologies
Admittedly, there are no perfect designer nucleases. As for ZFNs and TALENs, 
RGNs can cleave at unintended off-target sites, which can only be partially identified 
CRISPR-Cas9 Genome Editing, Five Years on 
Chapter 1  /  016
through in silico-guided and genome-wide assays [1, 25]. Given the complexity and 
very large size of the human genome (~3 billion base pairs per haploid genome), the 
generation of off-target DSBs poses a non-negligible risk, which might knockout es-
sential genes or mutate cancer-associated genes [26-30]. These outcomes must espe-
cially be avoided when the goal is to develop genetic therapies that exploit the NHEJ 
or the HDR pathways. In the context of gene knockout approaches, the unpredict-
able indel footprints from NHEJ might produce aberrant products, e.g., truncated 
or misfolded proteins or proteins displaying immunogenic epitopes. In the context 
of genome editing strategies involving multiple DSBs at different loci, chromosom-
al rearrangements might arise contributing to genomic instability [31]. Regarding 
HDR-based genome editing, RGNs, next to faithfully integrating the exogenous 
DNA at one allele, often also disrupt the other allele due to the prevalence of NHEJ 
over HDR in mammalian cells [32]. Moreover, HDR-mediated chromosomal DNA 
insertion triggered by site-specific DSB formation often is not efficient enough (< 
1%), especially when donor templates encompass entire transcription units stretch-
ing several kilobases. Finally, the native chromatin environment in eukaryotic cells 
poses yet another hurdle compromising the efficiency and predictability of genome 
editing efforts [33, 34]. 
To address the aforementioned issues, many researchers are investigating a broad 
range of strategies that are as diverse as engineering or mining for new nucleas-
es, redesigning sgRNA moieties and testing new donor DNA structures aiming at 
achieving efficient and accurate genetic manipulations in complex (epi)genomes. 
Isolating and engineering new Cas9 proteins
Although the SpCas9 PAM sequence NGG occurs in the human genome every 8 bp 
on average, it can nonetheless constitute a limitation, especially when the genomic 
sequences of interest have a high A/T content. Using a selection-based SpCas9 sys-
tem in bacteria, Kleinstiver et al. isolated the VQR and VQER variants of SpCas9, 
each of which recognizing the PAMs NGAN and NGCG, respectively [35]. Impor-
tantly, their directed evolution system has also yielded the D1135E SpCas9 variant 
which displays a superior discriminating profile between canonical NGG and cryp-
tic NGA PAMs than that of the wild-type SpCas9 protein [35]. 
Multiple CRISPR-Cas systems isolated from different species have been adapted for 
genome editing in human cells, including those from S. aureus and Acidaminococcus 
sp.. Often, the resulting RGNs display an improved or complementary set of attrib-
utes when compared to the SpCas9. For instance, in contrast to the 4.1-kb ORF of the 
SpCas9 nuclease (1368 amino acids), the ORF coding for the S. aureus Cas9 (SaCas9) 
protein (1053 amino acids) spans only ~3.2 kb, making it easily packaged within 
the limited confinements of commonly-used viral vectors, e.g., adeno-associated vi-
ral vectors [36]. In addition, Cas9 orthologs offer alternative specificity profiles and 
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genomic targeting ranges owing to their different PAM sequences, e.g., SaCas9 has 
as PAM the NNGRRT motif instead of NGG [36]. To further increase the versatility 
of SaCas9-based RGNs, Kleinstiver et al. generated the KKH SaCas9 variant, which 
recognizes the degenerate PAM sequence NNNRRT and, as a result, has broadened 
the genomic coverage of these RGNs [37]. Different from the RGNs based on type 
II CRISPR-Cas9 systems of S. pyogenes and S. aureus, those adapted from type V 
CRISPR-Cpf1 systems recognize T-rich PAM sequences, generate staggered DSBs 
with 5’-overhangs, display enhanced specificities and do not have a tracrRNA com-
ponent [38]. Similarly to the development of Cas9 proteins with altered PAMs, using 
structure-guided mutagenesis, Gao and colleagues engineered mutants of Acidami-
nococcus sp. Cpf1 (AsCpf1) which recognize the PAMs TYCV and TATV instead of 
the native PAM sequence TTTV [39]. 
In parallel to modifying the target range of RGNs, recent research is also leading 
to improvements in reducing RGN off-target activities. Previous studies on the de-
velopment of ZFNs and TALENs have set the stage for optimizing the specificity of 
RGNs by mimicking the modus operandi of ZFNs and TALENs, which encompass FokI 
nuclease domain dimerization [13, 40]. Tsai et al. and Guilinger et al. fused the FokI 
nuclease domain to the N-terminus of a catalytically inactive SpCas9 protein to form 
FokI-dCas9 monomers (where “d” stands for “dead”) [41, 42]. The binding of a pair of 
these monomers to their bipartite target sequences forms a dimeric RNA-guided FokI 
nuclease (RFN), offering a higher specificity profile when compared to conventional 
RGNs as the target sequences of RFN span up to 44 bp. Despite of its improved speci-
ficity, the RFN approach has limited genomic DNA coverage due to their strict gRNA 
design and spacing requirements. In particular, RFNs require a so-called PAM-out 
gRNA design with their activities peaking within a 14-17 bp spacing between the two 
hemi-nucleases [41, 42]. These limitations, together with the fact that RFNs are larger 
than conventional RGNs, are keeping this approach at the proof-of-principle stage. 
The nuclease domains of SpCas9, HNH and RuvC, cut the target and non-target 
strands, respectively. Mutating catalytic residues in each of these nuclease domains 
yields the RuvC mutant D10A and the HNH mutant H840A “nickases”, which 
cleave the target and non-target strands, respectively [6]. Delivering into cells a Cas9 
“nickase” together with two different gRNAs targeting opposite DNA strands of a 
bipartite recognition sequence induces a DSB owing to the local coordinated action 
of both RGN “nickases”. Should either of the nicking complexes cleave at off-target 
sites, the resulting SSBs are, for the most part, faithfully repaired. Thus, this confers 
an overall high specificity to the dual nicking approach. When compared to con-
ventional RGNs, this dual nicking strategy can reduce off-target activities (up to 
1,500-fold) [43, 44]. Similar to RFNs, the relative positions and spacing of the two 
gRNAs are important for efficient target DNA cleavage. Usually, dual RGN “nick-
ases” yielding 5’-overhangs and a spacing between the 5’ ends of the two gRNAs 
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between -4 and 20 nt result in the highest DSB formation activities [43, 44]. Of note, 
SaCas9 “nickases” bearing a D10A or an N580A mutation were also compatible with 
the dual nicking strategy, although in this case, the optimal distance between the 
gRNAs seems to lie between 0 and 125 bp [45]. One drawback of the dual nicking 
strategy is that, often, there is a trade-off in which the gains in specificity are accom-
panied by a decrease in efficiency [43-45].  
To obviate the need for a pair of suitable gRNAs for dual nicking to increase the spec-
ificity of RGNs, researchers have generated high-specificity SpCas9 variants through 
structure-guided protein engineering involving mutations-to-alanine of specific 
DNA-interacting residues [46, 47]. They reasoned that the resulting reduction in the 
RGN-DNA binding energies would be adequate to cleave the target site but insuffi-
cient to cleave at off-target sites [46, 47]. Slaymaker et al. reported enhanced specific-
ity of the SpCas9 variants eSpCas9(1.0) and eSpCas9(1.1) containing triple mutations 
(i.e., K810A/K1003A/R1060A and K848A/K1003A/R1060A, respectively) at the posi-
tively charged nt-groove of SpCas9, which plays a role in stabilizing the non-target 
DNA strand [47]. Kleinstiver et al. generated in turn quadruple mutant SpCas9-HF1 
(i.e., N497A/R661A/Q695A/Q926A). These mutations-to-alanine are thought to at-
tenuate hydrogen bonds between SpCas9 and the phosphate backbone of the target 
DNA strand [46]. Both strategies significantly reduce off-target chromosomal DNA 
cleavage while retaining on-target activities similar to those of wild-type SpCas9 for 
the majority of target sequences tested [46, 47]. However, it is noteworthy mention-
ing that the eSpCas9(1.1) and SpCas9-HF1 variants are less efficient than wild-type 
SpCas9, when the gRNAs contain a 5’-mismatched nucleotide (e.g. 21-mer spacer 
with a 5’ end “G” extension) or are truncated (i.e. < 19- to 20-mer spacers) [33, 48]. 
Interestingly, the SpCas9 variant HeFm2SpCas9, harboring combinatorial mutations 
from eCas9(1.1) and SpCas9-HF1, albeit more specific than their parental proteins, 
suffers from low activity at most target sites tested [49]. More recently, Chen et al. 
showed that the specificity gains of eSpCas9(1.1) and SpCas9-HF1 were likely due to 
a failure in the conformational change of the REC3 domain necessary for HNH cat-
alytic activation at off-target sites [50]. Based on this information, they engineered a 
SpCas9 protein containing the REC3 mutations N692A/M694A/Q695A/H698A, and 
showed that this so-called HypaCas9 has comparable or higher specificity than Sp-
Cas9-HF1 and eSpCas9(1.1) [50].
To circumvent DSB formation and the undesirable NHEJ-derived mutations, re-
searchers are developing strategies that resort to the induction of SSBs instead of 
DSBs to facilitate targeted genome editing [32, 51, 52]. Komor et al. and Nishida et 
al. introduced the base editing concept, which ultimately replaces one base pair for 
another [51, 52]. The rationale behind base editors is that the cytidine in a C:G pair 
can be converted to a U:G pair by cytidine deaminases, e.g.,  APOBEC1 [51] and AID 
[52]. After mismatch repair the U:G becomes a U:A pair, which finally turns into a 
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T:A pair after DNA replication. The first generation of base editors made by Komor 
et al. has the cytidine deaminase APOBEC1 fused to the dSpCas9 (BE1). To avoid 
removal of uracil by uracil glycosylases, a uracil glycosylase inhibitor (UGI) was 
added to their second generation base editor (BE2). To increase the base editing effi-
ciency, the dSpCas9 was replaced by a SpCas9 “nickase”, yielding a third generation 
base editor (BE3) consisting of a fusion between APOBEC1, a UGI and the SpCas9 
D10A “nickase” scaffold. BE3 generates an SSB in the G-containing strand convert-
ing any C:G base pair to a T:A (C to T) within a 5-nt window about 12 bp away from 
the PAM [51]. More recently, a BE3 mutant named YEE-BE3 with a weaker cytidine 
deaminase activity has narrowed the peak of C-to-T transitions from a 5-nt to a 2-nt 
window [53]. In addition, base editors containing as scaffolds SpCas9 variants or Sa-
Cas9 have either expanded the PAM requirements of base editors [54] or improved 
their specificity [55]. With a fine-tuned design, the fourth generation base editor, 
BE4, has larger linkers between the SpCas9 “nickase”, APOBEC1 and UGI, and in-
corporates a second copy of UGI [54]. This construction enriches for the intended 
C-to-T transitions and reduces unwanted conversions likely mediated by uracil gly-
cosylases. Other BE3 and BE4 base editors (e.g. BE3-Gam, SaBE3-Gam, BE4-Gam, 
and SaBE4-Gam) incorporate the bacteriophage Mu Gam protein which purport-
edly, by binding to DSBs, reduces the residual levels of nick-derived chromosomal 
breaks [54]. Finally, The recent development of adenine base editors (ABEs) nicely 
complements their BE counterparts as these new based editors can convert A:T to 
G:C pairs (A to G) in a highly efficient manner [56, 57]. Theoretically, with current 
base editors, many pathogenic single base mutations can be corrected and, in ad-
dition, ATG start codons can be disabled for targeted and precise gene knockouts. 
Redesigning and modifying gRNAs 
sgRNAs have secondary structures forming hairpins and stem loops which mimic 
the architecture of native gRNAs consisting of the sequence-specific crRNA (42 nt) 
and the scaffolding tracrRNA (89 nt) [2, 6]. The 5’-terminal 20 nts of the sgRNA 
(spacer) and the Cas9-interacting scaffold function as essential elements in sgRNA 
molecules [2]. Truncated gRNAs (tru-gRNAs) displaying 17-19 mer spacers instead 
of the typical 20 mer spacers, have a weaker DNA-binding potential which, presum-
ably, biases the cleaving activity to fully complementary target sites in detriment 
of mismatched (off-target) sequences. Indeed, Fu et al. showed that RGNs bearing 
tru-gRNAs and wild-type SpCas9 can display greatly decreased off-target effects 
(up to 5,000-fold) while maintaining their on-target activity [58]. 
The most commonly used sgRNA structure has (i) a shorter crRNA:tracrRNA du-
plex region next to the spacer sequence when compared to that of the native crR-
NA:tracrRNA duplex, potentially impairing stable Cas9:gRNA complex assembly, 
and (ii) a continuous stretch of four uridines, which might serve as a premature 
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RNA polymerase III termination signal. On the basis of this information, Chen et al. 
and Dang et al. optimized the gRNA scaffold by extending the duplex region next 
to the 5’ spacer region by 5 bps, and showed significantly enhanced dSpCas9-based 
chromosomal imaging and SpCas9-mediated gene knockout, respectively [59, 
60]. By combining the sgRNA duplex extension with the disruption of the uridine 
stretch, Dang and coworkers demonstrated higher CCR5 and CD4 gene knockout 
frequencies when compared to those achieved by the original sgRNA scaffold [60]. 
Considering that these optimized scaffolds seem to yield more stable and full-length 
sgRNAs, they might also be compatible with different (epi)genome editing tools, 
e.g., Cas9 variants, dCas9-based transcriptional regulators and base editors. 
Adding functional RNA elements into sgRNA secondary structures can repurpose 
RGN-based tools, without diminishing their DNA targeting proficiency [43, 61]. For 
instance, hairpin aptamers can be inserted into the sgRNA scaffold at the tetraloop 
and lower stems, so that sgRNAs bind the MS2 bacteriophage coat protein. When 
such aptamer-containing sgRNAs are delivered together with Cas9 and MS2 fused 
to effector domains (e.g. VP64 transcription activator or Tet1-CD demethylation do-
mains), potent transcription activation and epigenetic remodeling of target loci can 
be achieved [62, 63].         
Currently, RNA polymerase III (Pol III) promoters are the most widely used ele-
ments for sgRNA synthesis as they evolved for expressing short, unprocessed, tran-
scripts in eukaryotic cells. Although highly active, Pol III promoters require a G 
(e.g., U6 and 7SK promoters) or an A or a G (e.g., H1 promoter) to efficiently initiate 
transcription, therefore the most suited sgRNAs have spacers starting with a G or an 
A at their 5’ terminus [64, 65]. Of note, there is an impairment on the activity of the 
eSpCas9(1.1) and SpCas9-HF1 variants when the 5’ terminal G does not hybridize to 
the target site [33, 48]. Although RNA polymerase II (Pol II)-driven transcripts are 
subjected to complex downstream processes and nucleus-to-cytoplasm transloca-
tion, they offer the possibility for conditional or tissue-specific expression or for the 
expression of multiple sgRNAs from a single template. In this regard, Nissim and 
coworkers designed Pol II expression units containing the sgRNA coding sequence 
flanked by recognition sites for the RNA endonuclease Csy4 (Csy4-gRNA-Csy4), so 
that single or multiple sgRNAs can be released after Csy4 cutting [66]. The Csy4-gR-
NA-Csy4 unit was also inserted into an artificial intron construct with splicing sites 
and branching point. Hence, after splicing, the Csy4-gRNA-Csy4 module can be set 
free as an intron [66]. However, inserting the sgRNA sequence alone (i.e., without 
the flanking Csy4 sites and Csy4 expression) into the artificial intron construct did 
not yield stable sgRNA due to rapid degradation [66]. To avoid the concomitant 
delivery of the RNA endonuclease Csy4, the sgRNA sequence can be put after a 5’ 
hammerhead ribozyme (HH) or in-between a 5’ HH and a 3’ HDV ribozymes (HH-
gRNA-HDV), which generate mature sgRNAs through self-cleaving [66-68]. Of note, 
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however, Yoshioka et al. showed that ribozyme-flanked sgRNAs expressed from the 
RNA Pol II CAG promoter (CAG-HH-gRNA-HDV) induced less genome editing 
events than those from the commonly used U6-driven sgRNA [68]. Alternatively, 
Xie et al. hijacked the endogenous tRNA maturation mechanism, and constructed 
a Pol III promoter-driven tRNA-sgRNA tandem array, which, after cleavage by en-
dogenous RNAses, yielded functional sgRNAs in rice [69]. Follow-up studies con-
firmed that sgRNAs produced from the tRNA-gRNA module could achieve efficient 
genome editing in Y. Lipolytica, maize and, more recently, in Drosophila [70-72]. 
Pre-assembling Cas9 and gRNA ribonucleoprotein complexes in vitro before their 
delivery into target cells bypasses chromosomal integration of foreign DNA encod-
ing these RGN components, and ensures a more transient activity window of the 
nucleases [73, 74]. The gRNAs are usually made from in vitro transcription or by 
solid-phase chemical synthesis [73, 74]. Unlike in vitro transcribed gRNAs, chemi-
cally synthesized gRNAs bypass the difficult-to-upscale enzymatic reactions. Lately, 
several groups extensively investigated the chemical modification of the gRNA at 
different positions of the nucleotide (base, ribose sugar and phosphate group), to 
increase their stability and genome editing efficiency [75-78]. Hendal et al. showed 
that sgRNAs modified with 2’-O-methyl, 2’-O-methyl-3’-phosphorothioate or with 
2’-O-methyl-3’-thioPACE at both ends of the sgRNA induced robust genome edit-
ing at the CCR5 and HBB loci in the CD34+ hematopoietic stem and progenitor cells 
[75]. In addition, Rahdar and co-workers systematically screened crRNAs modified 
at different positions with chemical substitutions in their phosphate and/or sugar 
groups. They identified a shortened, yet equivalently functional, 29 nt-long crRNA 
containing 2’-fluoro (2’-F) and 2’-S-constrained ethyl (2’-cEt) at their 5’ and  3’ ends, 
respectively [76]. Interestingly, in addition to improving the stability and reducing 
the size of gRNA components, chemical modifications are also paying off in terms 
of generating reagents with enhanced specificity. A recent study demonstrated that 
2’-O-methyl-3’-phosphonoacetate modifications at positions 5 or 11 of sgRNAs can 
remarkably reduce off-target activity while maintaining on-target cleavage [77]. In-
stead of substituting chemical groups in the ribose-phosphate backbone, Lee and 
co-workers added large groups at the termini of crRNAs  (e.g. 5’-Rhodamine and 
5’-Amine) to endow them with new functions, i.e., fluorescence for enriching edited 
cells [78]. 
Manipulating donor DNA templates
As aforementioned, when partnered with designer nucleases, donor DNA mole-
cules can act as DSB-repairing templates to precisely incorporate customized DNA 
changes into specific genomic positions through the HDR pathway [1]. Regardless 
of their foreign nucleic acid composition, conventional donor DNA templates have 
sequences identical to those framing a designer nuclease target site (“homology 
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arms”). These “homology arms” serve as strand invasion regions that allow for ho-
mology-directed insertion of foreign DNA, whose size can vary from single base 
pairs to whole transgenes [1]. For the targeted insertion of large transgenes, the do-
nor DNA is often provided in recombinant plasmids or viral vector genomes. Yet, re-
gardless of the delivery method, HDR occurs mainly during the late G2 and S phases 
of the cell cycle, and is particularly inefficient in human cells, such as hematopoietic 
stem/progenitor cells and iPSCs [1, 9, 10]. Moreover, the competing and constantly 
available NHEJ pathway leads to a large fraction of heterozygous edited alleles due 
to the concurrent action of HDR and NHEJ, or NHEJ alone.
Studies on the design and testing of different types of donor DNA molecules un-
veiled attractive research avenues to increase the efficiency, specificity and/or 
accuracy of HDR-based genome editing [1]. Holkers and coworkers demonstrat-
ed that the donor templates delivered in protein-capped adenoviral vector ge-
nomes greatly enhance the specificity and fidelity of HDR-based genome editing 
[79]. By using a “double-cut” donor DNA design in which the “homology arms” 
are flanked by sgRNA target sites, Zhang et al. achieved 8 % and 12 % transgene 
knock-ins in human iPSCs at the CTNNB1 locus with 300 bp and 600 bp “homol-
ogy arms”, respectively [80]. These targeted DNA insertion frequencies were 2- 
to 5-fold higher than those achieved by the standard covalently-closed plasmid 
templates [80]. Chen et al. repoted a similar effect after comparing “double-cut” 
with standard donor plasmids at the DMD and AAVS1 loci in human cells [32]. 
To bypass the HDR pathway, researchers are also looking into “double-cut” donors 
containing no or short “homology arms” (e.g., 10-40 bps) for DNA insertions, which 
are achieved by NHEJ and microhomology-mediated end joining (MMEJ) pathways 
instead [81-83]. By using RGNs together with homology-free “double-cut” donors, 
He et al. showed up to 20 % and 1.7 % of a 4.6-kb transgene insertion at the GAPDH 
locus in LO2 cells and ESCs, respectively [83]. Suzuki et al. also applied the homol-
ogy-free “double cut” donors and inserted different expression units in post-mitotic 
mouse neurons, both in vitro and in vivo [84]. Alternatively, “double-cut” donors 
with short “homology arms” were efficient substrates for MMEJ-mediated trans-
gene insertion in zebrafish [85] and, more recently, in mice [82]. However, it is of 
note that free DNA termini generated from “double-cut” donors increase the risk 
of random and/or foreign DNA insertions resulting from imprecise recombination 
processes [32, 79, 80]. 
Albeit at low levels, SSB-induced HDR using designer “nickases” can yield targeted 
and accurate chromosomal insertion of foreign DNA in mammalian cells without 
the attendant catalytic induction of DSBs [32, 86, 87]. Recently, Chen and co-work-
ers have developed an efficient SSB-induced HDR approach, which can place large 
DNA segments into specific genomic target sites without provoking the mutagenic 
NHEJ [32]. The key aspect to this approach, named in trans paired nicking, consists 
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of combining a Cas9 “nickase” with a modified donor DNA in which the “homolo-
gy arms” are framed by the sgRNA recognition site [32]. This arrangement assures 
concomitant SSB formation at target and donor sequences, generating homologous 
recombination DNA substrates as postulated by Holliday in 1964 [88]. The in trans 
paired nicking not only increased HDR at the human AAVS1, CCR5 and DMD loci 
in different cell types, including iPSCs, but also facilitated multiplexing HDR [32]. 
Single-stranded oligodeoxyribonucleotides (ssODNs) are commonly used donors 
for small genomic modifications, e.g., point mutations, polymorphisms or short pro-
tein-tagging motifs. Typical ssODN donors are symmetrical in that they harbor sim-
ilarly sized “homology arms” at both ends. Recent studies have shown that, when 
compared to symmetric ssODNs, asymmetric ssODNs can induce more efficient 
RGN-assisted genome editing [89]. Specifically, optimal ssODN donors should be 
complementary to the sgRNA non-target strand and encompass shorter homology at 
the PAM distal end [89]. Biophysical data indicate that this configuration favors do-
nor-target hybridization owing to the generation of a 3’-ended flap on the non-target 
strand after DNA cutting [89]. Liang et al. confirmed the superiority of asymmetric 
ssODNs and, in addition, tested short double-stranded ODNs (dsODNs) consisting 
of annealed ssODNs displaying either 3’ or 5’ 30-nt overhangs [90]. They showed 
that dsODN donors with 3’ overhangs lead to higher frequencies of RGN-induced 
genome editing than those achieved with asymmetric ssODNs or with dsODNs con-
taining 5’ overhangs [90]. 
Similarly to sgRNA components, donor DNA templates are also substrates for 
chemical modifications to improve the performance of genome editing. For instance, 
chemically modifying the terminal nucleotides of ssODNs with phosphorothioate 
increased the efficiency of genome editing by 2-3 fold [91]. In another study, Mang et 
al. introduced the CAB system, short for Cas9-Avidin-Biotin ssDNA, in which Avi-
din is fused to Cas9 and binds Biotin-conjugated ssODNs inside cells [92]. Equally 
relying on high-affinity Biotin-Avidin interactions, Carlson-Stevermer et al. devel-
oped the S1mplex system, where Biotin-conjugated ssODNs are tethered in vitro 
to RGNs containing sgRNAs displaying a Streptavidin-binding S1m aptamer [93]. 
Both the CAB and S1mplex systems increased the frequencies of HDR and the ratio 
of HDR to NHEJ in mammalian cells [92, 93]. 
Tweaking experimental conditions for improving genome editing 
outcomes
Besides engineering novel genome editing components, e.g., the above-described 
Cas9 proteins, sgRNA structures and donor DNA templates, researchers are also op-
timizing experimental protocols to improve the efficiency and predictability of ge-
nome editing procedures. A simple methodology involves modulating the temper-
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ature at which the designer nucleases operate. When compared to the normal 37°C 
mammalian cell culture condition, ZFN and TALEN induced higher gene knockout 
frequencies under a transient, 30°C hypothermic period [94, 95]. In contrast, at least 
in certain mammalian cell lines, transfection of RGN-encoding plasmids at 39°C trig-
gered significantly higher targeted gene knockout frequencies, presumably owing 
to increased sgRNA expression in these lines [96]. Other protocols entail enriching 
for cells that have undergone genome editing - by co-delivering reporter units that 
reflect the expression of designer nucleases [97], or by co-targeting an endogenous 
gene (i.e., ATP1A1) whose loss-of-function is selectable [98]. 
Steering DNA repair machineries in favor of HDR over NHEJ is also being exploited 
when targeted gene knock-ins are the desired genome editing outcomes. One can 
distinguish two main strategies: genetic manipulations or pharmacological inter-
ventions. Regarding the former, Chu and colleagues expressed short hairpin RNAs 
to silence the genes encoding the NHEJ factors KU70, KU80 or DNA ligase IV or 
co-expressed adenovirus serotype-4 E1B55K and E4orf6 proteins to induce proteas-
omal degradation of DNA ligase IV [99]. These and other authors have also applied 
the small-molecule DNA ligase IV inhibitor Scr7 to bias the repair of site-specific 
DSBs towards the HDR pathway in mammalian cell lines [99, 100], as well as in ferti-
lized mouse and rat zygotes [100, 101]. Robert and co-workers have equally applied 
a pharmacological approach to dampen the rate of NHEJ and increase the frequency 
of HDR, but used the DNA-PKcs inhibitors NU7441 and KU-0060648 instead [102]. 
Next to testing NHEJ inhibitors, researchers are also evaluating HDR-enhancing 
agents as well. For instance, RS-1, a molecule previously shown to activate RAD51, 
which play a role in homology search and strand exchange, increased knock-ins by 
2- to 5-fold in cell lines and pronuclear stage rabbit embryos [103]. This enhance-
ment on HDR was observed after DSB formation by RGNs and TALENs [104, 105]. 
By screening a library of roughly 4,000 small molecules, Yu and coworkers found 
that the β3-adrenergic receptor agonist L755507 stimulates HDR-mediated Nanog 
targeting by 3-fold in murine PSCs [106]. Alternatively, timed delivery of in vitro as-
sembled ribonucleoprotein RGNs together with ssODN donors to cells that are syn-
chronized at the cell cycle  G1/S phase border by aphidicolin or at the G2/M phase by 
nocodazole, enhanced HDR-mediated genome editing up to  6-fold when compared 
with unsynchronized cells [107]. Of note, whether the use of specific genetic and/
or pharmacological agents for modulating HDR/NHEJ ratios have long-term pleio-
tropic effects on target cells or organisms will require further investigations.
Concluding remarks
The ongoing discovery of Cas9 orthologs combined with structure-guided and di-
rected evolution-based protein screens are yielding an ever-increasing number of 
Cas9 variants with new properties, e.g., strand-specific cleaving activities, alternative 
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PAM requirements and higher target DNA specificities. In addition, albeit not suited 
for large genomic DNA changes, base editors promise precise, DSB-free, genome 
editing. Next to isolating and engineering new Cas9 proteins, reshaping the native 
gRNA architecture and chemically modifying the gRNA composition are improving 
the activity and specificity of RGNs. By the same token, manipulating the structure 
and composition of donor DNA molecules is paying off in terms of enhancing the ef-
ficiency and specificity of HDR-based genome editing. To expand and complement 
hypothesis-driven studies for identifying HDR-enhancing agents, high-throughput 
screenings of small-molecule drug libraries should yield new compounds for mod-
ulating DNA repair pathways. Finally, sensitive and unbiased genome-wide assays 
will become ever-more important to thoroughly access the global mutation levels 
upon the application of the constantly improved genome editing tools.
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Abstract
Precise genome editing involves homologous recombination between do-nor DNA and chromosomal sequences subjected to double-stranded DNA breaks made by programmable nucleases. Ideally, genome editing should 
be efficient, specific, and accurate. However, besides constituting potential trans-
location-initiating lesions, double-stranded DNA breaks (targeted or otherwise) 
are mostly repaired through unpredictable and mutagenic nonhomologous re-
combination processes. Here, we report that the coordinated formation of paired 
single-stranded DNA breaks, or nicks, at donor plasmids and chromosomal tar-
get sites by RNA-guided nucleases based on CRISPR-Cas9 components, triggers 
seamless homologydirected gene targeting of large genetic payloads in human 
cells, including pluripotent stem cells. Importantly, in addition to significantly 
reducing the mutagenicity of the genome modification procedure, this in trans 
paired nicking strategy achieves multiplexed, single-step, gene targeting, and 
yields higher frequencies of accurately edited cells when compared to the stand-
ard double-stranded DNA break-dependent approach.
Introduction
Programmable nucleases, and in particular RNA-guided nucleases (RGNs), are 
rendering genome editing applicable to numerous basic and applied research set-
tings1–3. RGNs are ribonucleoprotein complexes formed by a guide RNA (gRNA) 
and a Cas9 protein with two nuclease domains, i.e., HNH and RuvC. RGNs cleave 
DNA complementary to the 5′ end of the gRNA when a contiguous protospacer ad-
jacent motif (PAM) is present3. The fact that target DNA cutting is ultimately dictated 
by simple RNA-DNA hybridization rules confers versatility to RGN technologies1–3. 
A major drawback of conventional DNA editing stems, however, from the fact that 
double-stranded DNA break (DSB) repair in mammalian cells often takes place via 
mutagenic non-homologous end joining (NHEJ) instead of accurate homologous 
recombination (HR)4. As a result, allelic and non-allelic mutations, loss-of-heterozy-
gosity, translocations, and other unwarranted genetic changes caused by on-target 
and off-target DSBs, are frequent5. Moreover, NHEJ also contributes to random and 
imprecise chromosomal insertion of the donor DNA1, 6. As a whole, these unpredict-
able genome-modifying events complicate the interpretation of experimental results 
and reduce the safety profile of candidate genetic therapies. Despite this, in certain 
experimental settings, such as those amenable to cell isolation and screening, homol-
ogy-independent chromosomal DNA insertion is a valuable genetic modification 
strategy owing to its efficiency and applicability to non-dividing target cells7–9.
Following from the above, developing new genome-editing principles that favor 
not only efficient but also precise homologydirected gene targeting in detriment of 
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mutagenic NHEJ are in demand. Indeed, emergent genome-editing research lines 
involve testing small RNAs, drugs, or viral proteins that steer DSB repair towards 
the HR pathway by inhibiting the competing NHEJ10–12. Parallel research lines ex-
ploit sequence-specific and strand-specific programmable nucleases (“nickases”)13–17 
for generating single-stranded DNA breaks (SSBs), or nicks, which are noncanonical
NHEJ substrates4. Besides bypassing DSB formation, “nickases” do not alter the 
regular cellular metabolism as small RNAs, drugs and viral proteins do. Howev-
er, genome editing based on “nickases” is inefficient13, 15–17. In fact, the investigation 
of site-specific SSBs as triggers for homology-directed targeting of large DNA seg-
ments (e.g., entire transcriptional units) has not been explored.
Here, we investigate the feasibility of exploiting nicking RGNs containing the RuvC 
Cas9 mutant Asp10Ala (Cas9D10A) or the HNH Cas9 mutant His840Ala (Cas9H840A) to 
trigger genome editing via the simultaneous formation of SSBs at endogenous and 
exogenous DNA. We report that this strategy based on coordinated in trans paired 
nicking can improve the three main parameters of DNA editing, i.e., efficiency, spec-
ificity, and fidelity1, 2 and achieves multiplexing homology-directed DNA addition 
of large genetic payloads.
Results
Mutagenesis caused by cleaving Cas9 vs. nicking Cas9
We started by confirming that unwarranted, potentially adverse, genome-modify-
ing events (i.e., target allele mutagenesis and chromosomal translocations)1 do oc-
cur more frequently in cells exposed to cleaving Cas9 than in those subjected to 
nicking Cas9 proteins. Firstly, we assessed the mutation rates resulting from RGN 
complexes consisting of cleaving (i.e., Cas9:gRNAX) or nicking Cas9 nucleases (i.e., 
Cas9D10A:gRNAX or Cas9H840A:gRNAX), where “X” symbolizes the target locus. The 
Cas9D10A and Cas9H840A proteins differ from wild-type Cas9 in that they have ami-
no-acid substitutions disrupting the catalytic centers of their RuvC and HNH nucle-
ase domains, respectively. As a result, RGN complexes with Cas9D10A and Cas9H840A 
induce sequence-specific and strand-specific breaks on opposite DNA chains, name-
ly, on the chain complementary and non-complementary to the gRNA, respectively. 
The AAVS1 locus at 19q13.42 was selected for these experiments owing to its frequent 
use as a “safe harbor” for the targeted chromosomal insertion of exogenous DNA18. 
This assessment is based on a series of studies showing that AAVS1 integrants are 
neither disturbed by, nor disturb the surrounding genomic environment, providing 
for long-term and stable transgene expression in different cell types18. A target site 
genotyping assay in human embryonic kidney 293 T cells showed that Cas9:gRNAS1 
complexes targeting the AAVS1 locus readily yielded substantially higher levels of 
DSBs than their Cas9D10A:gRNAS1 counterparts (Supplementary Fig. 1a). To aug-
ment the stringency of the genotyping assay, we next carried out dose–response 
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experiments in human cervix carcinoma HeLa cells using increasing amounts of ad-
enoviral vectors encoding either Cas9 or Cas9D10A, each mixed with a fixed amount 
of an adenoviral vector expressing a gRNA addressing each Cas9 protein to AAVS1. 
A direct relationship between the detection of small insertions and deletions (in-
dels) and nuclease concentrations could be readily established after Cas9:gRNAS1 
delivery, whereas this was much less so upon Cas9D10A:gRNAS1 transfer (Supple-
mentary Fig. 1b). These data directly correlated with the much higher frequencies 
of indel-derived EGFP disruption in EGFP+ H27 reporter cells triggered by cleaving 
Cas9:gRNAGFP2 when compared to those induced by nicking Cas9D10A:gRNAGFP2 or by 
Cas9H840A:gRNAGFP2 complexes (Supplementary Fig. 1c).
Secondly, we setup a PCR assay to compare the assembly of chromosomal translo-
cations caused by the formation of DSBs vs. SSBs at two distinct loci. To this end, 
HeLa cells were transfected with plasmids coding for cleaving or nicking RGNs tar-
geting DMD and AAVS1 sequences. Amplicons diagnostic for translocation events 
between DMD and AAVS1 were exclusively detected in cells exposed to the cleav-
ing RGNs (Supplementary Fig. 1d). Sanger sequencing of individual amplicons es-
tablished their origin at t(X;19)(p21;q13) (Supplementary Fig. 1e). Taken together, 
these experiments formally demonstrate that unwarranted, potentially adverse, ge-
nome-modifying events occur more frequently in cells receiving RGNs containing 
cleaving Cas9 than in those harboring nicking Cas9D10A.
In trans paired nicking yields seamless DMD gene targeting
Next, we sought to investigate homology-directed gene targeting based on induc-
ing DSBs vs. SSBs not only at acceptor chromosomal sequences but also at donor 
DNA templates. The DMD gene at Xp21.2 was chosen as target locus. By spanning 
over 2.4 Mb, DMD is the largest human protein-coding gene known. Of note, defec-
tive DMD alleles cause Duchenne muscular dystrophy (DMD), a progressive lethal 
neuromuscular disease affecting ~1 in 3500–5000 boys19, 20. For these experiments, 
we generated plasmid pgRNADMD, to address Cas9 proteins to DMD intron 43, and 
EGFP-encoding constructs pDonorDMD and pDonorDMD.TS to serve as exogenous HR 
substrates (Fig. 1a). Construct pDonorDMD.TS differs from pDonorDMD in that it has a 
target site (TS) for gRNADMD next to its targeting module (Fig. 1a). Importantly, all 
transgene-containing donors used in the present study have autonomous transcrip-
tion units, which in contrast to splice acceptor-containing gene trapping construc-
tions, avoid biased selection of on-target integrants21. Genome-editing experiments 
were initiated by exposing HeLa cells to pDonorDMD and cleaving Cas9:gRNADMD 
complexes (standard setting) or to pDonorDMD.TS and nicking Cas9D10A:gRNADMD 
complexes (in trans paired nicking; Nick2). After eliminating episomal DNA by 
sub-culturing, genetically modified cells were quantified through flow cytometry. 
This analysis revealed that the in trans paired nicking strategy led to significantly 
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Fig. 1
Homology-directed DMD-targeting using standard and in trans paired nicking strategies. 
a Schematics of standard and in trans paired nicking (Nick2) procedures. The former involve 
DSB formation only at the target sequence; the latter comprise SSB formation at target plus 
donor sequences. pDonorDMD and pDonorDMD.TS have their transgenes flanked by sequences 
identical to those framing the gRNADMD target site (TS). Open and solid magenta arrowheads, 
position of the phosphodiester bond cleavage induced by Cas9’s RuvC and HNH nuclease 
domains, respectively. Solid arrowhead, position of the SSB induced by Cas9D10A. The mod-
ified pDonorDMD.TS differs from pDonorDMD in that it has the gRNADMD TS next to its targeting 
module. The transgene is formed by human PGK1 promoter, EGFP ORF, and bovine GH1 pol-
yadenylation signal sequences. Cas9:gRNADMD and Cas9D10A:gRNADMD are cleaving and nick-
ing RGN complexes, respectively. PAM protospacer adjacent motif. An integrant generated 
by HR events at both ends of the targeting module is depicted. The amplicons specific for 
telomere-sided and centromere-sided transgenic-DMD junctions (jT and jC, respectively), 
are equally shown. Horizontal arrowheads, primers. b Quantification of stable transfection 
levels by flow cytometry. Flow cytometry of long-term HeLa cell cultures initially exposed to 
the indicated plasmids. The bars correspond to mean ± s.d. of three independent biological 
replicates done on different days. **P = 0.006 (two-tailed t-test). c Cumulative molecular 
characterization of integrants generated by the conventional vs. the in trans paired nicking 
strategies. The frequencies of clones with random insertions (jT−/jC−), HR-derived telo-
higher percentages of genetically modified cells when compared to those obtained 
through the standard approach (Fig. 1b). Similar results were obtained by using 
donor constructs whose DMD-targeting modules were flanked by the gRNADMD TS 
in a direct or inverted repeat orientation (Supplementary Fig. 2). These data are 
consistent with earlier theoretical models and more recent experimental systems in-
dicating a role for nicked HR partners as recombination-initiating substrates22, 23. Of 
note, although at this target sequence paired DSB formation (in trans paired break-
ing; DSB2) yielded the highest frequencies of EGFP+ cells, the resulting free-end-
ed HR substrates are prone to aberrant concatemer assembly (see below). Indeed, 
it has been previously shown that the DSB2 strategy results in higher frequencies 
of random chromosomal insertions through illegitimate recombination processes 
when compared to those obtained by the standard DSB-dependent gene targeting 
approach6. Conversely, consistent with previous studies13, 15–17, generating SSBs ex-
clusively at chromosomal DNA yielded the lowest frequencies of stably transfected 
cells.
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In trans paired nicking yields seamless AAVS1 gene targeting
We next examined the performance of in trans paired nicking and standard gene 
targeting at AAVS1 (Fig. 2a). As aforementioned, this locus is commonly used as a 
“safe harbor” for the chromosomal insertion of exogenous DNA in human cells18. 
These experiments were initiated by transfecting HeLa and 293 T cells with pDonor.
ES1 or pDonor.ES1.TS each mixed with plasmids encoding either Cas9:gRNAS1 or Cas-
9D10A:gRNAS1 (Fig. 2a). The pDonor.ES1.TS construct has its targeting module flanked 
by two gRNAS1 TS (Fig. 2a). The rationale for this donor design was provided by 
the experiments showing that such arrangement yields significantly higher frequen-
cies of stably transfected cells when compared to isogenic templates containing a 
single gRNAS1 TS (Supplementary Fig. 4). In agreement with the DMD-targeting 
experiments, when compared to experiments involving single DSBs (standard set-
ting) or single SSBs, in trans paired nicking of AAVS1 and pDonor.ES1.TS led to sig-
nificantly higher percentages of genetically modified cells (Fig. 2b). Similar results 
were gathered by using different gRNA and donor DNA reagents or the alternative 
nicking Cas9H840A variant whose inactivated HNH domain assures that SSBs occur 
at the DNA chain opposite to that hydrolyzed by its RuvC-disabled Cas9D10A coun-
terpart (Supplementary Fig. 5). Importantly, amplicons diagnostic for HR-derived 
integrants were readily retrieved not only from cells subjected to inaccurate DNA 
editing by paired DSB formation but also from cells exposed to the accurate in trans 
paired nicking procedure (Fig. 2c). Indeed, in striking contrast to inducing in trans 
paired DSBs (DSB2), generating in trans paired SSBs (Nick2), did not result in the 
assembly of disruptive donor DNA concatemers (Fig. 2c), presumably emerging 
through ligation of free-ended termini generated in cellula by Cas9:gRNAS1 6. Final-
meric junctions (jT+/jC−), HR-derived centromeric junctions (jT−/jC+) and HR-derived tel-
omeric and centromeric junctions (jT+/jC+) are plotted. The corresponding PCR screening 
data are presented in Supplementary Fig. 3
Subsequently, we compared in trans paired nicking with standard gene targeting 
in terms of their relative specificities and fidelities. The specificity is ascertained by 
detecting donor sequences at the target site; the fidelity is established by demon-
strating that telomere-sided and centromere-sided junctions between donor and tar-
get DNA are formed through error-free HR (jT+ and jC+, respectively). Randomly 
selected EGFP+ HeLa clones (n = 98) were screened via PCR assays targeting both 
junctions (Fig. 1c and Supplementary Fig. 3). In the set of clones modified through 
the delivery of pDonorDMD, pCas9 and pgRNADMD (n = 51), the DMD-targeted frac-
tion was 27.5% with 21.6% of these integrants being accurately targeted (jT+/jC+). 
Notably, in the set of clones modified via the transfer of pDonorDMD.TS, pCas9D10A and 
pgRNADMD (n = 47), these fractions were 93.6% and 42.6%, respectively (Fig. 1c). We 
conclude that, when compared to conventional DSB-induced gene targeting, in trans 
paired nicking was more efficient, specific, and accurate at the DMD locus.
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ly, we probed an alternative in trans paired nicking gene targeting strategy in which 
two different gRNAs generate tandem SSBs within the interacting homologous se-
quences. This strategy, tandem paired nicking, yielded stable transfection levels that 
Fig. 2
Homology-directed AAVS1 targeting using standard and in trans paired nicking strategies. 
a Diagram of standard and in trans paired nicking (Nick2) procedures. The former involve 
DSB formation only at the target sequence; the latter comprise SSB formation at target 
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To complement the previous gene targeting experiments involving sizable and tran-
scriptionally active donor constructs, we next asked whether short, transcriptionally 
inert donor constructs, can equally serve as in trans paired nicking substrates. To 
this end, AAVS1-targeting plasmids pS.DonorS1 and pS.DonorS1.TS, resistant and sus-
ceptible to RGNs, respectively (Fig. 2e, left panel), were transfected into human cells 
together with constructs expressing Cas9:gRNAS1 or Cas9D10A:gRNAS1 (Fig. 2e, mid-
plus donor sequences. pDonorS1 and pDonorS1.TS have their transgenes framed by sequences 
homologous to AAVS1. pDonorS1.TS differs from pDonorS1 in that it has the gRNAS1 target site 
(TS) bracketing its EGFP-encoding targeting module. Cas9:gRNAS1 and Cas9D10A:gRNAS1 
are cleaving and nicking RGNs, respectively. Open and solid magenta arrowheads, position 
of the phosphodiester bond cleavage induced by Cas9’s RuvC and HNH nuclease domains, 
respectively. Solid arrowhead, position of the SSB induced by Cas9D10A. Amplicons diagnostic 
for telomere-sided and centromere-sided transgenic-AAVS1 junctions (jT and jC, respec-
tively), are depicted. b Quantification of stably transfected cells. Flow cytometry of long-
term HeLa and 293 T cell cultures initially transfected with the indicated plasmids. The bars 
correspond to mean ± s.d. of six biological replicates from two independent experiments 
(three biological replicates per experiment). ****P < 0.0001 (two-tailed t-tests). c Probing 
for wanted (gene targeting) and unwanted (concatemerization) genome-modifying events. 
Amplicons diagnostic for gene targeting (jC) and head-to-tail concatemers (jH-T) in 293 T 
cell populations transfected with the indicated constructs are presented. This assay was 
also run on EGFP-sorted cells (post-sorted). EGFP served as an internal control template. d 
Cumulative molecular characterization of integrants generated by the conventional and in 
trans paired nicking strategies. The frequencies of clones with random insertions (jT−/jC−), 
HR-derived telomeric junctions (jT+/jC−), HR-derived centromeric junctions (jT−/jC+) and 
HR-derived telomeric and centromeric junctions (jT+/jC+) are plotted. The respective PCR 
screening data are presented in Supplementary Fig. 7. e Homology-directed AAVS1 edit-
ing after inducing DSBs or SSBs. pS.DonorS1 and pS.DonorS1.TS have a restriction-fragment 
length polymorphism (RFLP) flanked by 300-bp AAVS1 sequences (“arms”). pS.DonorS1.TS 
has the gRNAS1 TS flanking its targeting module (orange boxes). RFLA restriction-fragment 
length analysis; half arrows primers; PAM boxed sequence. RFLA products diagnostic for un-
edited and HR-edited AAVS1 alleles retrieved from HeLa cells transfected with the indicated 
plasmid combinations are identified by open and closed arrowheads, respectively
were within the range of those achieved by using the standard, DSB-dependent, 
gene targeting procedure (Supplementary Fig. 6).
To gauge the specificity and fidelity resulting from in trans paired nicking vs. stand-
ard gene targeting at AAVS1, randomly selected EGFP+ clones (n  = 275) were isolat-
ed from HeLa and 293 T cell populations and were screened through junction PCR 
(Fig. 2d and Supplementary Fig. 7). We observed that 63.9% and 66.7% of the HeLa 
and 293 T cells exposed to the standard setting underwent accurate homology-di-
rected gene targeting (jT+/jC+), respectively (Fig. 2d). In the remaining clones, ille-
gitimate recombination led instead to off-target integrants (jT−/jC−) and to on-target 
integrants lacking HR-derived junctions either from the centromeric or telomeric 
side (jT+/jC− or jT−/jC+, respectively). Remarkably, the fraction of properly targeted 
HeLa and 293 T cells subjected to in trans paired nicking was as high as 97.2 and 
100%, respectively (Fig. 2d). Finally, Sanger sequencing established that precisely 
targeted integrants resulting from in trans paired nicking and conventional gene 
targeting were undistinguishable (Supplementary Fig. 8).
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dle panel). HR engaging pS.DonorS1 or pS.DonorS1.TS sequences should result in the 
targeted chromosomal insertion of 18-bp DNA fragments incorporating restriction 
enzyme polymorphisms (Fig. 2e, middle panel). Detection of these genome-editing 
events by restriction enzyme fragment length analysis (RFLA) revealed that in trans 
paired nicking is compatible with the use of short, transcriptionally inert, donor 
DNA templates (Fig. 2e, right panel).
Paired RGNs inducing offset nicks on opposite chromosomal DNA strands ensure 
that DSBs are mostly restricted to their bipartite target sequences owing to the coor-
dinated and local formation of SSBs on both polynucleotide chains24, 25. The resulting 
gains in DNA cutting specificity render this dual RGN approach appealing, hereaf-
ter named in cis paired nicking for the sake of consistency. Hence, albeit dependent 
on two gRNAs and on the generation of mutagenic DSBs, we sought nonetheless to 
compare in cis with in trans paired nicking as stimuli for site-specific chromosomal 
DNA insertion (knock-in). Therefore, in addition to the four experimental condi-
tions tested before (Fig. 2b), in these new experiments, we transfected human cells 
with pDonorS1 and pCAG.Cas9D10A mixed with constructs expressing two different 
AAVS1-specific gRNA pairs (i.e., gRNAS1/gRNAS1.2 or gRNAS1/gRNAS1.3). Consistent 
with the previous data (Fig. 2b), the in trans paired nicking setup yielded the high-
est frequencies of genetically modified cells. The in cis paired nicking strategy led, 
in turn, to frequencies of genetically modified cells that were in the range of those 
obtained by inducing DSBs or SSBs exclusively at the target site (Supplementary 
Fig. 9).
In trans paired nicking in pluripotent stem cells
Despite their patent scientific and biomedical importance, genetic manipulation of 
human pluripotent stem cells (PSCs) remains limited by the typically low efficiency, 
specificity, and accuracy of homology-directed gene targeting, even when using pro-
grammable nucleases (see e.g., ref. 21). Therefore, we investigated the performance of 
in trans paired nicking in human induced PSCs (iPSCs; Supplementary Fig. 10) and 
human embryonic stem cells (ESCs)26. In addition to pDonorS1 and pDonorS1.TS (Sup-
plementary Fig. 4a), we included in these experiments, pDonor.EPS1 and pDonor.
EPS1.TS encoding PuroR.T2A.EGFP instead of EGFP. The data generated with these 
new HR substrates in HeLa cells (Supplementary Fig. 11) were similar to those of 
previous experiments showing the superiority of in trans paired nicking over stand-
ard gene targeting in achieving efficient cell engineering at AAVS1 (Fig. 2b and Sup-
plementary Figs. 4b–6 and 9). Importantly, this superiority was equally established 
in iPSCs and ESCs by using dual-color flow cytometry and colony-formation assays 
involving the detection of EGFP+/TRA-1-81+ cells (Fig. 3a, b) and puromycin-re-
sistant colonies stained for alkaline phosphatase, respectively (Fig. 3c). In addition, 
when compared to in trans paired nicking, DSB-triggered AAVS1 targeting induced 
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higher frequencies of apoptotic Annexin V+ cells in ESC cultures (Supplementary 
Fig. 12). These results are consistent with the well-established sensitivity of PSCs to 
DSBs27. 
To determine the precision of genome editing in iPSCs subjected to in trans paired 
nicking vs. standard genome-editing protocols, puromycin-resistant clones (n  = 80) 
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Fig. 3
Comparing RGN-induced gene targeting based on standard and in trans paired nicking in 
human PSCs. a Quantification of genetically modified PSCs by flow cytometry. Cultures of 
iPSCs (A, B, and E) and ESCs (C and D) were exposed to AAVS1-specific cleaving Cas9:gR-
NAS1 (standard) or nicking Cas9D10A:gRNAS1 (Nick2) complexes mixed with RGN-resistant or 
RGN-susceptible donor constructs, respectively, encoding either EGFP or PuroR.T2A.EGFP. 
The frequencies of gene-modified PSCs were determined by flow cytometric quantification of 
EGFP+ and TRA-1-81+ dually labeled cells. b Representative flow cytometry dot plots corre-
sponding to RGN-induced gene targeting experiments in PSCs. c Detection of gene-modified 
PSCs by colony-formation assays. ESCs (top) and iPSCs (bottom) were co-transfected with 
the indicated plasmids. After puromycin selection, alkaline phosphatase staining identified 
genetically modified PSC colonies. d RGN-induced gene targeting frequencies at AAVS1 in 
iPSCs. Junction PCR analyses of puromycin-resistant colonies from iPSC cultures initially 
co-transfected with pDonor.EPS1 and pCas9.gRNAS1 (standard) or with pDonor.EPS1.TS and 
pCas9D10A.gRNAS1 (Nick2). The respective PCR screening data are presented in Supplemen-
tary Fig. 13. e Differentiation potential of gene-edited PSCs. ESC and iPSC lines were tar-
geted at AAVS1 by in trans paired nicking. Cell types characteristic of ectoderm, endoderm, 
and mesoderm were identified by confocal immunofluorescence microscopy for TUBB3, AFP, 
and CD31, respectively. f Characterization of indel footprints in iPSCs subjected to stand-
ard vs. in trans paired nicking. Nucleotide sequencing of AAVS1 target alleles in randomly 
selected iPSC clones (n = 68) genetically modified by DSB-dependent and in trans paired 
nicking methodologies (Standard and Nick2, respectively). Indel footprints were exclusively 
identified in iPSCs subjected to the standard gene targeting approach (15/28). The gRNAS1 
target site is indicated underneath the sequence reads. Open box PAM; vertical dashed line 
position of expected RGN-induced phosphodiester bond cleavage; Ctrl reference wild-type 
nucleotide sequence from unedited cells
were screened with a PCR assay specific for HR-derived junctions (Fig. 3d and Sup-
plementary Fig. 13). The gene targeting specificity in iPSCs exposed to standard and 
in trans paired nicking procedures was 65 and 93%, respectively (Fig. 3d and Sup-
plementary Fig. 13). Contributing to the difficulty in isolating iPSC lines that un-
dergo seamless genome editing is the fact that a sizable fraction of cells, in addition 
to the intended genetic modification at one of the target alleles, harbor mutations 
at the other allele28. These mutations correspond to unpredictable indel footprints 
created after NHEJ-mediated repair of targeted DSBs28. Hence, to further charac-
terize the genetically modified iPSCs, nucleotide sequence analysis of target DNA 
was performed in individual iPSC clones subjected to standard and in trans paired 
nicking protocols. This analysis revealed the presence of a range of indel footprints 
exclusively in the iPSC lines generated by standard gene targeting (Fig. 3f). Indeed, 
the AAVS1 target site remained pristine in all of the randomly selected iPSC lines 
obtained after applying the in trans paired nicking protocols (Fig. 3f). These results 
are in agreement with our previous data (Supplementary Fig. 1) and the fact that, in 
contrast to DSBs, SSBs are not canonical substrates for NHEJ.
Finally, iPSC lines genetically engineered through standard and in trans paired nick-
ing remained pluripotent (Fig. 3e and Supplementary Fig. 14). We conclude that, 
instead of generating DSBs, targeted DNA integration at the AAVS1 “safe harbor” in 
different cell types is best achieved via coordinated RGN-induced paired nicking of 
donor and acceptor DNA.
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Fig. 4 Competition for gene targeting between donor DNA resistant and sensitive to RGN-in-
duced nicking. a Schematics of the experimental design. HeLa cells were co-transfected with 
the indicated donor templates together with plasmids encoding nicking Cas9D10A:gRNAS1. b 
Quantification of stably transfected cell populations. The frequencies of genetically modified 
cells were determined at 27 days post-transfection by EGFP-directed and mTurquoise2-di-
rected flow cytometry. The ratios between the frequencies of the various gene-modified 
subpopulations are presented. c Flow cytometry dot plots corresponding to the end-point 
of the experiments. Mock-transfected cultures served to set the thresholds for background 
fluorescence (negative control). d Gene targeting in cells containing donor DNA resistant 
and susceptible to RGN nicking. Amplicons diagnostic for homology-directed gene targeting 
involving EGFP-encoding and mTurquoise2-encoding donor templates are indicated. HPRT1 
provided for an internal control target sequence
Multiplexing gene targeting by in trans paired nicking
To confirm that AAVS1-targeting donor DNA subjected to RGN nicking is a supe-
rior substrate for site-specific chromosomal DNA insertion, we setup competition 
experiments involving the co-targeting of two donors each encoding a different re-
porter, i.e., EGFP or mTurquoise2 (Fig. 4a). For these experiments, one of the two 
donors contained TS sequences, whereas the other did not (Fig. 4a). Flow cytometry 
showed that pDonorS1.TS and pDonor.TurqS1.TS subjected to RGN-induced nicking led 
to 15-fold and 23-fold higher frequencies of genetically modified cells, respectively, 
when compared to their competitor, RGN-resistant, donor counterparts pDonorS1 
and pDonor.TurqS1 (Fig. 4b, c). Consistent with these results, homology-directed 
gene targeting in cells containing both RGN-resistant and RGN-susceptible donors 
involved primarily the latter substrates, independently of the product that they en-
coded (Fig. 4d).
Hitherto, multiplexing genome editing has primarily entailed NHEJ-based manip-
ulations such as those involving RGN pairs for knocking-out two genes simultane-
ously or for creating chromosomal deletions1. Such approaches are, however, not 
applicable for the targeted addition of new genetic information. For this purpose, 
multiplexing homology-directed DNA insertion based on different donor constructs 
can, in principle, be used instead. Unfortunately, HR-dependent chromosomal 
knock-in of two different donors in individual cells is a very rare event. Moreover, 
in addition to generating high frequencies of indel footprints, the necessary pro-
grammable nuclease pairs can induce loss-of-heterozygosity and/or translocations 
(Supplementary Fig. 1). Therefore, engineering cells with exogenous DNA inserted 
at two different loci or at two alleles of a single locus (bi-allelic targeting) is normally 
a complex and time-consuming procedure. Indeed, these procedures include con-
structing donors with positive/negative selection markers for isolating and screen-
ing the few cells that undergo seamless gene targeting, often followed by marker 
removal. This lengthy process is subsequently repeated on the selected cell clone(s) 
using, this time, a second donor construct.
We thus sought to capitalize on the higher efficiency, specificity and accuracy of 
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Fig. 5 Multiplexing homology-directed DNA addition. a Diagram of the experimental design. 
HeLa cells were co-transfected with the indicated donor constructs together with plasmids 
encoding either cleaving Cas9:gRNAS1 or nicking Cas9D10A:gRNAS1 complexes. b Quantifi-
cation of stably transfected cell populations. The frequencies of genetically modified cells 
were determined at 27 days post-transfection by EGFP-directed and mTurquoise2-directed 
flow cytometry. The ratios between the frequencies of the double-positive cell populations 
generated by standard and in trans paired nicking multiplexing, are presented. Numerals 
between brackets correspond to the fraction of each gene-modified subpopulation. c Flow 
cytometry dot plots corresponding to the end-point of the experiments. Parallel cultures 
transfected with a single donor construct mixed with plasmids expressing Cas9:gRNAS1 or 
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in trans paired nicking over the conventional DSB-dependent strategy at AAVS1, 
for testing one-step co-targeting of different alleles. These multiplexing knock-in 
experiments were initiated by exposing HeLa cells to pDonorS1.TS, pDonor.TurqS1.
TS, and nicking Cas9D10A:gRNAS1 (Fig. 5a). Controls consisted of treating HeLa cells 
with pDonorS1, pDonor.TurqS1, and cleaving Cas9:gRNAS1 (Fig. 5a). Remarkably, in 
comparison with the control setting, the multiplexing approach based on in trans 
paired nicking yielded one order of magnitude higher amounts of doubly-labeled 
EGFP+/mTurquoise2+ cells as measured by flow cytometry (Fig. 5b, c). These results 
directly correlated with the detection of HR-specific amplicons in parallel genom-
ic DNA samples (Fig. 5d). After flow cytometry-assisted sorting of these EGFP+/
mTurquoise2+ cells (Supplementary Fig. 15), single-cell clonal analysis (n = 35) re-
vealed that 89% of them underwent AAVS1-targeting events, of which 94% were 
bi-allelic events involving both donor DNA templates (Supplementary Fig. 16a, b). 
An independent assay based on Southern blot analysis confirmed co-targeting of 
both expression units in individual cells without evidence for random chromosomal 
DNA insertion (Supplementary Fig. 16a, c). Taken together, these data show that 
simultaneous in trans paired nicking of independent donor substrates can provide 
for a simpler and faster strategy for achieving, in a seamless manner, multiplexed 
addition of foreign DNA into the genome of human cells.
In trans paired nicking yields seamless gene editing at CCR5
The product of the C–C motif chemokine receptor 5 gene CCR5, located at 3p21.31, 
serves as an HIV-1 co-receptor on macrophages and T cells29. Crucially, individuals 
homozygous for a 32-bp deletion disrupting CCR5 function (CCR5Δ32) are healthy 
and refractory to R5-tropic HIV-1 infection29. Hence, this locus is an appealing tar-
get for testing HIV therapies based on viral co-receptor knockout and site-specif-
ic “stacking” of restriction factor genes29. In addition, similarly to AAVS1, CCR5 is 
frequently used as a generic “safe harbor” for the targeted chromosomal insertion 
of foreign DNA in human cells18. Thus, we next sought to compare DSB-depend-
ent vs. SSB-dependent genome-editing approaches at CCR5 after delivering RGNs 
together with CCR5-targeting constructs pS.DonorR5 or pS.DonorR5.TS marked with 
restriction enzyme polymorphisms (Fig. 6a). In these experiments, RFLA and mis-
match-sensing T7 endonuclease I (T7EI) genotyping assays were deployed for as-
sessing genomic changes through HR and/or NHEJ (Fig. 6b). Human cells treated 
with in trans paired nicking (Nick2) and in trans paired breaking (DSB2) protocols 
readily yielded noticeable HR-specific RFLA products (Fig. 6c, top panel). A prepon-
Cas9D10A:gRNAS1 served as controls for setting the thresholds for EGFP and mTurquoise2 de-
tection. d Gene co-targeting in cells containing a mixture of two donors resistant or suscep-
tible to RGN nicking. PCR products specific for homology-directed gene targeting involving 
EGFP-encoding and mTurquoise2-encoding donor templates are indicated. HPRT1 provided 
for an internal control target sequence
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Fig. 6
Homology-directed CCR5 editing after DSB vs. SSB generation. a Diagram of the different 
DSB-dependent and SSB-dependent genome-editing strategies. pS.DonorR5 and pS.DonorR5.
TS have a restriction-fragment length polymorphism (RFLP) flanked by 400-bp CCR5 se-
quences (“arms”). pS.DonorR5.TS has the gRNAR5.1 target site (TS) bracketing its targeting 
module (orange boxes). Combining Cas9D10A:gRNAR5.2 and Cas9D10A:gRNAR5.1 complexes gen-
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erates a targeted DSB by nicking on opposite DNA strands (in cis paired nicking strategy). 
PAMs boxed sequences; magenta arrowheads, positions of the DSBs and SSBs generated 
by Cas9 and Cas9D10A, respectively. b Schematics of the CCR5 genotyping assays. DNA 
products diagnostic for unedited, edited, and mutagenized CCR5 alleles are indicated. RFLA 
restriction-fragment length analysis; T7EI mismatch-sensing T7 endonucleases I assay; half 
arrows, primers c CCR5 genotyping assays. Genotyping of CCR5 sequences by RFLA and 
T7EI assays in HeLa cells transfected with the indicated plasmid sets. RFLA products spe-
cific for unedited and HR-edited CCR5 alleles are identified by open and closed arrowheads, 
respectively; T7EI digestion products diagnostic for genetic changes induced at CCR5 by 
HR and NHEJ are equally indicated. The genomic DNA analyses were performed at 3 days 
post-transfection. d Comparing genome-editing strategies based on single vs. dual RGNs. 
HeLa cells were co-transfected with the indicated plasmids and 3 days later RFLA was per-
formed on their genomic DNA. Open and solid arrowheads point to unedited and HR-edited 
CCR5 sequences, respectively. e Comparing CCR5 mutagenesis in cells exposed to RGNs in-
ducing DSBs vs. SSBs. HeLa cells were co-transfected with the indicated plasmids and T7EI 
genotyping assays were carried out 3 days later. T7EI products diagnostic for indel footprints 
left after NHEJ-mediated DSB repair are pinpointed by the flat arrowhead
Discussion
In this study, we have demonstrated that in trans paired nicking based on combin-
ing RGN “nickases” with RGN-targetable donors can trigger robust and seamless 
chromosomal insertion of small and large genetic payloads into specific genomic 
sequences in human cells without the catalytic induction of DSBs. We speculate that 
the rate-limiting HR steps of single-stranded DNA invasion, donor–acceptor synap-
tic formation and heteroduplex expansion are, to a great extent, overcome by coor-
dinated presentation of 3′ termini on both interacting partners after in trans paired 
nicking. These events are shared by recent working models invoking SSBs as re-
combination-initiating substrates30. In addition, recent experiments indicate the in-
derance of T7EI-digested products, diagnostic for the cumulative build-up of NHEJ 
and HR events, was detected in cells subjected to DSB-inducing protocols (Fig. 6c, 
middle panel). This outcome is consistent with the prevalence of the former over the 
latter pathway during the repair of DSBs in mammalian cells4. Of note, T7EI-digest-
ed products corresponding to the in trans paired nicking protocol should mostly 
represent HR events as nicking exclusively at CCR5 (single nick) led to the lowest 
signals in both genotyping assays (Fig. 6c). In a follow-up experiment, in addition 
to the four experimental conditions tested earlier (Fig. 6c), we included in cis paired 
nicking at CCR5 by transfecting HeLa cells with pS.DonorR5 and pCas9D10A mixed 
with plasmids expressing the gRNA pair gRNAR5.1/gRNAR5.2. In agreement with 
the previous data (Fig. 2c), in trans paired nicking induced robust accumulation 
of HR-specific RFLA products. Importantly, cells exposed to DSB-inducing single 
and dual RGN complexes had a higher proportion of disrupted CCR5 alleles when 
compared to those subjected to the SSB-inducing Cas9D10A:gRNAR5.1 complex (Fig. 
6e). These results confirm that in trans paired nicking can achieve programmable 
nuclease-assisted genome editing without concomitantly introducing a high muta-
genic load into target cell populations.
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volvement of distinct factors underlying canonical and SSB-induced HR pathways. 
For instance, recombination between donor DNA and a nicked target sequence can 
proceed through RAD51/BRAC2-independent pathways30. In this regard, the versa-
tility of RGNs for inducing nicks at different positions and strands of HR templates, 
might constitute a valuable experimental system to dissect SSB-dependent HR path-
ways and, possibly, further improve genome editing based on in trans paired nick-
ing concepts.
Importantly, we also showed that avoiding the use of DSB-inducing nucleases con-
fers a low mutagenic load to this new genome-editing paradigm. Hence, our research 
complements and joins those of others on devising high-efficiency genome-editing 
strategies based on RGN “nickases”31, 32. In particular, a recent study has demonstrat-
ed that fusing cytidine deaminase and uracil DNA glycosylase activities to Cas9D10A 
results in a large “base editor” capable of inducing C-to-T substitutions within a ~5 
nt target window31. Another recent study revealed that cleaving and nicking RGNs 
expose a DNA flap accessible to single-stranded oligodeoxyribonucleotide (ssODN) 
annealing32. On the basis of this information, rationally designed ssODNs and RGN 
“nickases” were combined and shown to yield homology-directed gene repair in 
~10% of treated 293 reporter cells32. An intrinsic limitation of these approaches is, 
however, their unsuitability for effecting extensive genetic changes. Moreover, the 
fidelity of “base editors” depends on the absence of extra cytidines within the ~ 5 nt 
“activity window”, while that of coupling RGN “nickases” to ssODNs relies on the 
lack of adventitious mutations created during synthesis and processing of ssODNs 
in vitro and in cellula, respectively33.
The high specificity and accuracy conferred by in trans paired nicking genome ed-
iting coupled to its low mutagenic load should be particularly useful in instances 
in which the precise genetic manipulation of target cell populations is paramount. 
Examples include the modeling or the repairing of disease traits in stem/progenitor 
cells and the unbiased genetic screening of cellular phenotypes based on HR-medi-
ated chromosomal insertion of donor DNA libraries34. Of note, however, regardless 
of the DNA targeting specificity and fidelity attained by a particular genome-editing 
procedure, there is always the risk for uncontrollable random chromosomal inser-
tion of the exogenous DNA. Clearly, these unwanted events can take place in cells 
that lack or harbor the intended genetic modification.
We have confirmed that nicking RGNs are significantly less mutagenic than their 
cleaving counterparts at on-target sequences (Supplementary Fig. 1). Moreover, 
experiments done by others have demonstrated that, when compared to cleaving 
RGNs, nicking RGNs are also significantly less mutagenic at off-target sites25. How-
ever, regarding the use of “nickases” specifically, one should caution that SSBs can 
still trigger some mutagenic events if, for instance, after hitting such lesions, an 
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Methods
Cells
Human cervix carcinoma HeLa cells (American Type Culture Collection) and its EGFP ex-
pressing single cell-derived clone H2737 were cultured in Dulbecco’s modified Eagle’s medi-
um (DMEM; ThermoFisher Scientific) containing 5% fetal bovine serum (FBS; ThermoFisher 
Scientific). Human embryonic kidney (HEK) 293 T cells (American Type Culture Collection) 
were maintained in DMEM supplemented with 10% FBS. These cells were kept at 37 °C in an 
humidified-air 10% CO2 atmosphere. The human embryonic stem cell (ESC) line H1 (ref. 26; 
WiCell Research Institute) and the induced pluripotent stem cell (iPSC) lines LUMC0044iC-
trl44 and LUMC0044iCtrl44.9 were cultured in pluripotent stem cell (PSC) growth medium 
in the presence of irradiated ICR mouse embryonic fibroblasts (MEFs), and mechanically pas-
saged by a cut and paste method. The PSC growth medium consisted of DMEM/F12 medium 
with GlutaMax, 20% KnockOut Serum Replacement (KOSR), 10 mM non-essential amino ac-
ids (NEAAs), 25 U ml−1 penicillin, 25 μg ml−1 of streptomycin (all from ThermoFisher Scien-
tific), and 10 ng ml−1 of basic fibroblast growth factor (bFGF; Peprotech). PSCs were cultured 
at 37 °C in an humidified-air 5% CO2 atmosphere. The cells used in all the experiments were 
mycoplasma-free. All human materials were collected based on individual written (parental) 
informed consent after approval by the “Medical Ethics Committee” of the LUMC (reference 
numbers: P08-087 and P13-080). The experiments involving human materials were done in 
accordance with the principles outlined in the “Declaration of Helsinki”. All animal experi-
ments were approved by the “Animal Experiments Committee” of the LUMC (reference num-
ber: 12133) and were performed following the recommendations and guidelines set by the 
LUMC and the Dutch “Experiments on Animals Act”.
advancing replication fork collapses resulting in DSB formation5. These outcomes 
will be most problematic at off-target sites. In this regard, sensitive and unbiased 
assays allowing the genome-wide detection of nick-induced mutagenesis will be 
instrumental in the future for determining the mutagenic load of gene-editing pro-
tocols based on programmable “nickases”. Equally related with off-target activities, 
programmable “nickases” with improved specificities are in demand. Possible can-
didates include RGN “nickases” built on recently described high-specificity Cas9 
scaffolds such as Sp Cas9-HF135 and eSpCas9(1.1)36. We anticipate that the simple 
and versatile in trans paired nicking procedure will be compatible with these latest 
generation tools and, possibly, with other fast-emerging DNA targeting systems.
Concluding, the performance of genome editing depends on its overall efficiency, 
specificity and fidelity1. In this work, we have shown that testing combinatorial in-
teractions between different types of nucleases and foreign DNA structures, can 
improve these crucial parameters, expanding the options for high-fidelity genetic 
manipulation of mammalian cells.
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Recombinant DNA
The constructs AU26_pCAG.Cas9 and AU28_pCAG.Cas9D10A express Cas9 and Cas9D10A, re-
spectively, from the hybrid CAGGS promoter38. The “two-in-one” plasmids AV15_pCAG.
Cas9.gRNAS1 and AV44_pCAG.Cas9D10A.gRNAS1 encode Cas9 and Cas9D10A, respectively, to-
gether with the AAVS1-targeting gRNAS1. To serve as a negative control, construct AV13_
pCas9.gRNANT expresses Cas9 and the non-targeting gRNANT. This gRNA is irrelevant in 
human cells as it addresses Cas9 proteins to the recognition sequence of the S. cerevisiae 
I-SceI homing endonuclease. The annotated maps and full-length nucleotide sequences of 
AU26_pCAG.Cas9, AU28_pCAG.Cas9D10A, AV15_pCAG.Cas9.gRNAS1, AV44_pCAG.Cas-
9D10A.gRNAS1, AV13_pCas9.gRNANT, and AT61_pCas9H840A can be found in the Supplemen-
tary Figs. 17–22, respectively). Likewise for the DMD-targeting donor plasmids AL05_pDo-
norDMD (Addgene #100284), AL62_pDonorDMD.TS (Addgene #100287), AC62_pDonorDMD.TS.DR 
(Addgene #100288), and AZ28_pDonorDMD.TS.IR (Supplementary Figs. 23–26, respectively), the 
AAVS1-targeting donor constructs AX44_pS.DonorS1 (Addgene #100289; Supplementary Fig. 
27), AX53_pS.DonorS1.TS (Addgene #100290; Supplementary Fig. 28) and the CCR5-targeting 
donor plasmids AY42_pS.DonorR5 (Addgene #100291; Supplementary Fig. 29) and AY10_pS.
DonorR5.TS (Addgene #100292; Supplementary Fig. 30). The plasmids hCas9 (ref. 39; #41815) 
and hCas9_D10A39 (#41816), herein named pCas9 and pCas9D10A, respectively, were obtained 
from the Addgene repository. The constructs gRNA_Cloning Vector39 (#41824), gRNA_
AAVS1-T2 (ref. 39; #41818), and gRNA_GFP_T2 (ref. 39; #41820), herein called pgRNAEmpty, 
pgRNAS1, and pgRNAGFP1, respectively, were also acquired from Addgene. The plasmid pgR-
NAEmpty expresses no gRNA, whereas pgRNAS1 and pgRNAGFP1 express gRNAs addressing 
Cas9 proteins to AAVS1 and EGFP sequences, respectively. The gRNA expressing plasmids 
AL08_pgRNADMD (Addgene #100293), AD19_pgRNAS1.2, AD13_pgRNAS1.3, L06_pgRNAOUT.1, 
AA44_pgRNAOUT.2, X32_pgRNAIN.1, AA48_pgRNAIN.2, AY22_pgRNAR5.1 (Addgene #100294), 
and AY23_pgRNAR5.2 (Addgene #100295), were assembled by inserting the annealed oligonu-
cleotides described in the Supplementary Table 1 into the BveI-digested gRNA acceptor con-
struct S7_pUC.U6.sgRNA.BveI-stuffer40. The plasmids AM51_pUC.U6.gRNANT, herein called 
pgRNANT and Z46_pgRNAGFP2 encoding an irrelevant gRNA and an EGFP-specific gRNA, re-
spectively, have been described before40. The AAVS1-targeting donor constructs pSh.AAVS1.
eGFP and pAdV.donorS1/T-TS, herein named pDonor.ES1 and pDonor.ES1.TS, respectively, 
have been described elsewhere6, 41. The additional set of isogenic donor plasmids pDonorS1, 
pDonorS1.1×TS, and pDonorS1.TS contain the AAVS1-targeting module cloned in the pMOLUC 
vector backbone (Addgene #12514). The pDonorS1 plasmid has no gRNAS1 target sites, where-
as pDonorS1.1×TS and pDonorS1.TS have one and two gRNAS1 target sites, respectively, next to 
their AAVS1-targeting module. The AX35_pDonor.TurqS1 and AX28_pDonor.TurqS1.TS have 
the same composition of pDonorS1 and pDonorS1.TS except that they contain a mTurquoise2 ORF 
in place of that of EGFP. The AT58_pDonor.37S1 and AE32_pDonor.37S1.1×TS share the same 
EGFP-encoding expression unit present in pDonorS1 and pDonorS1.1xTS, respectively. However, 
they differ from pDonorS1 and pDonorS1.1xTS in the spacing between their regions of homology 
(Supplementary Fig. 5a, b). The final set of AAVS1-targeting donor plasmids AV11_pDonor.
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EPS1 (Addgene #100296) and AV09_ pDonor.EPS1.TS (Addgene #100297) have the same com-
position of pDonorS1 and pDonorS1.TS, respectively, except that they encode PuroR.T2A.EGFP 
in place of EGFP (Supplementary Fig. 31). The annotated maps and DNA sequences of the 
constructs generated for this study were assembled with the aid of SnapGene 3.3.4. Where 
indicated, plasmid pcDNA3.1 (ThermoFisher Scientific) was used as carrier DNA in transfec-
tion experiments.
Cell Transfections
One day before transfection, HeLa cells, H27 cells, and 293 T cells were seeded in wells of 24-
well plates (Greiner Bio-One; Supplementary Tables 2–20). The transfections were initiated 
by mixing each of the appropriate plasmids together with 1 mg ml−1 of polyethyleneimine 
(PEI, Polysciences) in 50 μl of a 150 mM NaCl solution (Merck). After ~10 s under vigorous 
vortexing, the transfection mixtures were incubated for 15 min at room temperature, after 
which they were directly added to the cell cultures (Supplementary Tables 2–20). At 3 days 
post-transfection, the transfection efficiencies were determined by EGFP-directed flow cy-
tometry. Subsequently, the cells were sub-cultured for at least 2 weeks, for the removal of 
episomal exogenous DNA, after which stable transfection levels were determined by EG-
FP-directed flow cytometry.
Prior to the transfection of PSCs, the cells were adapted to passaging as single cells by us-
ing TrypLE Select (ThermoFisher Scientific) and 10 μM of the Rho kinase inhibitor Fasudil 
(LC Laboratories). After 2 to 5 single-cell passages, transfections based on Lipofectamine 
(ThermoFisher Scientific) were initiated using different experimental conditions as detailed 
in Supplementary Tables 21 and 22. In general, single-cell suspensions were generated and 
incubated for 5–10 min in Opti-MEM (ThermoFisher Scientific) containing the relevant DNA 
mixtures and a specific Lipofectamine formulation (Supplementary Tables 21 and 22). Next, 
the cell suspensions were seeded on 1 day-old MEF cultures containing PSC growth medium 
supplemented with 10 μM Fasudil and lacking antibiotics. At 24 h post-transfection the me-
dium was replaced by complete PSC growth medium. After 3–4 days post-transfection, the 
PSCs were harvested and the transfection efficiencies were determined by EGFP-directed and 
TRA-1-81-directed flow cytometry. A fraction of the transfected PSCs were seeded and let to 
divide on MEF cultures for an additional period of 7 to 10 days, after which stable transfection 
levels were determined by EGFP-directed and TRA-1-81-directed flow cytometry (see below 
for details).
Adenoviral vectors
The production, purification and titration of adenoviral vector particles AdVΔ2P.Cas9.F50 and 
AdVΔ2U6.gRNAS1.F50, herein dubbed AdV.Cas9 and AdV.gRNAS1, respectively, have been 
specified before42. The same methods were applied to generate and characterize AdV.Cas9D10A 
particles. The genome of AdV.Cas9D10A differs from that of AdV.Cas9 exclusively at codon 10 
of the Cas9 ORF.
T7 endonuclease I-based genotyping assay
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Genotyping assays based on the detection of indels by the mismatch-sensing T7 endonu-
clease I (T7EI) were used for establishing targeted DSB formation activity at AAVS1. To this 
end, 293 T cells were transfected using PEI as indicated in Supplementary Table 2. At 3 days 
post-transfection, cell pellets were collected for subsequent genomic DNA extraction. Genom-
ic DNA was extracted by using the DNeasy Blood & Tissue kit (Qiagen) according to the man-
ufacturer’s instructions. The target region was amplified by PCR with GoTaq G2 Flexi DNA 
Polymerase (Promega) following the manufacture’s recommendations. The composition of 
the PCR mixtures and the PCR cycling parameters are specified in Supplementary Tables 
23 and 24, respectively. Next, the resulting 403 bp amplicons were subjected to T7EI assays42. 
In brief, PCR amplicons were first denatured and reannealed by applying the thermocycler 
program presented in Supplementary Table 25. Afterwards, 10-μl samples were incubated 
at 37 °C for 17 min in a 15-μl solution containing 1.5 μl of 10 × NEBuffer 2, 0.5 μl of 10 U μl−1 
T7EI (New England Biolabs) and Milli-Q water. After agarose gel electrophoresis, the DNA 
fragments were stained with ethidium bromide and were imaged by using a Molecular Im-
ager Gel-Doc™ XR+ apparatus together with the ImageLab 4.1 software (both from Bio-Rad).
Detection of DSBs after AdV-mediate delivery of RGNs
Hela cells were seeded in wells of 24-well plates at a concentration of 6 × 104 cells per well. 
The next day, they were transduced with different amounts and combinations of adenoviral 
vectors encoding Cas9, Cas9D10A, or gRNAS1 (Supplementary Fig. 1). Mock-transduced cells 
and cells transduced exclusively with each of these vectors alone served as negative con-
trols. Transduction experiments were carried out in duplicate to generate parallel samples 
for genotyping and western blot analysis. At 3 days post-transduction, genomic DNA was 
extracted and T7EI-based genotyping assays were performed as detailed under the previous 
section. Likewise, at 3 days post-transduction, protein lysates were prepared under ice-cold 
conditions for western blot analysis as follows. The cells were first washed twice with phos-
phate-buffered saline (PBS; pH 7.4), after which 60 μl of lysis buffer consisting of 10 mM Tris-
HCl (pH 7.5), 1% (v/v) Nonidet P-40, 150 mM NaCl, 0.1% sodium dodecyl sulphate(SDS), 
and 10 mg ml−1 sodium deoxycholate, was added onto the cells for 25 min under gentle plate 
tilting. The lysis buffer was supplemented with the protease inhibitors present in the cOm-
pleteTM, Mini Protease Inhibitor Cocktail Roche-11836153001 (Sigma-Aldrich). Protein concen-
trations were determined by using the BCA protein assay kit (ThermoFisher Scientific) and a 
Precisely 1420 Multilabel Plate Counter (PerkinElmer) with the absorption wavelength set at 
λ  = 545 nm. Next, 5-μg protein samples were diluted in bromophenol blue-containing load-
ing buffer consisting of 187.5 mM Tris (pH 6.8), 30% (v/v) glycerol, 9% (w/v) SDS, and 7.5% 
(v/v) β-mercapthoethanol. Next, the protein samples were heated at 95 °C for 5 min and were 
resolved through a SDS-8% polyacrylamide gel. After overnight electro-blotting onto Immo-
bilon-P membranes (Millipore), the subsequent blocking, antibody incubation and chemilu-
minescence protein detection steps, were performed essentially as detailed elsewhere43 using 
a monoclonal antibody specific for S. pyogenes Cas9 (Diagenode; clone 22B5) and a goat an-
ti-mouse horseradish peroxidase-conjugated IgG (Santa Cruz; sc-2005). These primary and 
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secondary antibodies were diluted 1:2000 and 1:10,000 in blocking buffer, respectively. To 
provide for an internal protein loading control, an antibody specific for the α/β tubulin het-
erodimer (Cell Signalling Technology; 2148) was combined with the aforementioned second-
ary antibody. These primary and secondary antibodies were diluted 1:5000 and 1:10,000 in 
blocking buffer, respectively.
Sanger sequencing
The amplicons specific for translocation events between AAVS1 and DMD sequences (Sup-
plementary Fig. 1e) and for AAVS1-exogenous DNA junctions (Supplementary Fig. 8) were 
amplified, isolated and purified from agarose gel by using the JETquick Gel Extraction Spin 
kit (Genomed) according to the manufacturer’s recommendations. The PCR mixtures and 
cycling conditions used are presented in Supplementary Tables 23 and 24, respectively. Next, 
the recovered fragments were inserted into pJET1.2/blunt cloning vector provided in the 
CloneJET PCR Cloning Kit (ThermoFisher Scientific) following the manufacturer’s instruc-
tions. After transformation, randomly selected clones were grown and subjected to Sanger 
sequencing (Baseclear, Leiden, the Netherlands). The AAVS1-specific PCR products derived 
from randomly selected iPSC clones (Fig. 3f) were purified and subjected to Sanger sequenc-
ing for identifying indel footprints generated after RGN activity. All nucleotide sequence 
reads were aligned and analyzed with the aid of AlignX, Vector NTI Advance R_11.5.0 soft-
ware. The Sanger sequencing chromatograms were generated by using the Chromas Lite 2.1.1 
software (Technelysium Pty).
Flow cytometry
The frequencies of cells expressing EGFP, mTurquoise2 and/or the TRA-1-81 antigen, char-
acteristic of uncommitted PSCs, were determined by using a BD LSR II flow cytometer (BD 
Biosciences). The TRA-1-81 labeling was carried out by incubating single-cell suspensions of 
PSCs with a phycoerythrin-conjugated TRA-1-81 antibody (eBioscience) diluted 1:100 in a 
buffer consisting of PBS supplemented with 0.5% BSA and 2 mM ethylenediaminetetraacetic 
acid (EDTA). After an incubation period of 30 min at 4 °C in the dark, excess antibody was 
removed by thorough successive washes with large volumes of the aforementioned buffer. 
Data was analyzed with the aid FlowJo 7.2.2 software (Tree Star). Non-transfected cells were 
used to set background fluorescence levels. At least 10,000 events, each representing a single 
viable cell, were measured per sample.
PCR analyses of gene-editing experiments
The composition of the PCR mixtures and thermocycling parameters used for the analyses 
of genome-modifying events are discriminated in the Supplementary Tables 23, 24, 26 and 
27. These analyses were performed on whole target cell population as well as on individu-
ally sorted cells. The sorting of EGFP+ HeLa and 293 T cells was conducted by using a BD 
FACSAria III flow cytometer (BD Biosciences) after sub-culturing transfected cell populations 
for more than 20 days. EGFP+ cells were collected in a 1:1 mixture of regular culture medium 
containing 2 × penicillin–streptomycin (ThermoFisher Scientific) and FBS. The sorted, EGFP+ 
cells, were seeded at a density of 0.3 cells per well in wells of 96-well plates (Greiner Bio-
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One). To increase the efficiency of cell cloning, the culture media were supplemented with 
50 μM α-thioglycerol and 20 nM bathocuprione disulphonate (both from Sigma-Aldrich)44. 
At ~3 weeks after seeding, single cell-derived clones were randomly collected for genomic 
DNA analysis by junction PCR with the Phire Tissue Direct PCR Master Mix (ThermoFisher 
Scientific) according to the manufacturer’s recommendations. The junction PCR screening of 
randomly selected puromycin-resistant iPSC colonies was also done by direct PCR. The var-
ious direct PCR conditions used in each experiment are specified in Supplementary Tables 
26 and 27.
Generation of iPSCs
Human fetal fibroblasts were isolated and reprogrammed to iPSCs as detailed elsewhere45. 
In brief, the cell reprogramming was induced by transducing 2 × 104 human fetal fibroblasts 
seeded in a 12-well plate with the multi-cistronic lentiviral vector LV.RRL.PPT.SF.hOKSM.
idTomato.-preFRT45, 46. The vector particles, encoding OCT3/4, KLF4, SOX2, and cMYC, were 
removed 24 h later. At 6 days post-transduction, the cells were harvested and 104 of them 
were seeded on a 10-cm dish with 2 × 106 MEFs cultured in KOSR PSC growth medium (Ther-
moFisher Scientific). The medium was replenished every other day until the appearance of 
ESC-like colonies. The resulting iPSCs were subsequently cultured on irradiated ICR MEFs in 
complete PSC growth medium. The iPSC clone LUMC0044iCtrl44, containing a single provi-
rus, was selected. Subsequently, the chromosomally inserted provirus was removed through 
hcAd.FLPe.F50-mediated expression of FLPe recombinase43. To this end, LUMC0044iCtrl44 
iPSCs were transduced with hcAd.FLPe.F50 at a multiplicity of infection (MOI) of 20 trans-
duction units/ml. The resulting provirus-free iPSC clone LUMC0044iCtrl44.9 was character-
ized by immunofluorescence microscopy, COBRA-FISH karyotyping and teratoma assays as 
described below.
Differentiation of iPSCs
The in vitro spontaneous differentiation of iPSCs into the three embryonic germ layers was 
triggered by culturing clumps of iPSCs on coverslips coated with Vitronectin XF (StemCell 
Technologies). The cells were incubated in PSC growth medium devoid of bFGF and con-
taining 20% FBS in place of KOSR. The medium was replenished every 2 days. After 3 weeks 
under differentiation conditions, the cells were stained for the endoderm, mesoderm and ec-
toderm markers alpha-fetoprotein (AFP), platelet and endothelial cell adhesion molecule 1 
(CD31), and tubulin beta 3 class III (TUBB3), respectively. The in vivo differentiation of iPSCs 
into cell types belonging to the three different embryonic germ layers was assessed through 
teratoma formation assays. To this end, immunodeficient female NOD.Cg-Prkdc scid Il2rg tm-
1Wjl/SzJ (NSG) mice (8–12 weeks old) were injected subcutaneously with 1 × 106 cells. After 
10–16 weeks post-injection, teratomas were isolated and fixed in 4% paraformaldehyde (PFA) 
and, subsequently, embedded in paraffin and sectioned. Finally, pigmented epithelium (ec-
toderm), trachea-like epithelium (endoderm), and cartilage (mesoderm) present in iPSC-de-
rived teratomas were identified by hematoxylin–phloxine–saffron (HPS) staining and stand-
ard visible light microscopy.
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Detection of apoptosis
Two days after transfecting H1 ESCs with Lipofectamine 3000™ (ThermoFisher Scientific) 
mixed with different construct combinations (Supplementary Table 22), the frequencies of 
apoptotic cells were measured by using Annexin-V Apoptosis Detection Kit-eFluro 450 ac-
cording to the manufacturer’s instructions (ThermoFisher Scientific). H1 ESC cultures treated 
for 2 h with 1 μg ml−1 of staurosporine, stained, or not stained with fluorochrome-conjugated 
Annexin V, served as positive and negative controls, respectively.
Immunofluorescence microscopy
The acquisition of pluripotency markers (i.e., TRA-1-81, SSEA4, OCT3/4, and NANOG) and 
differentiation markers (i.e., AFP, CD31, and TUBB3) by iPSCs and iPSC-derived cells, re-
spectively, was assessed via immunofluorescence staining. In brief, cells were first fixed for 
15 min in 4% PFA. After several washes with PBS, they were exposed for 1 h to a PBS solution 
containing 0.1% Triton X-100 and 4% normal swine serum (NSS; Jackson ImmunoResearch). 
Next, the cells were incubated overnight at 4 °C with primary antibodies directed against 
TRA-1-81 (1:125; Biolegend Cat. #330702), SSEA4 (1:30; Biolegend Cat. #330402), OCT3/4 
(1:100; Santa Cruz Biotechnology Cat. #sc-5279); NANOG (1:500; R&D Systems Cat. #963488); 
AFP (1:25; Quartett Cat. #2011200530), CD31 (1:100; Dako Cat. #M0823), and TUBB3 (1:4000; 
Covance Cat. #MMS-435P). These antibodies were diluted in PBS containing 4% NSS. After 
three 10-min washes with PBS containing 0.05% Tween-20, the specimens were incubated for 
1 h in the dark with secondary antibodies (ThermoFisher Scientific) conjugated with Alexa 
Fluor 488 (1:500) or with Alexa Fluor 568. For the detection of pluripotency and differentiation 
markers, the Alexa Fluor 568 secondary antibody was applied at 1:200 and 1:500 dilutions, 
respectively. Nuclei were stained for 5 min in the dark with 4′,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI; ThermoFisher Scientific). The DAPI was diluted 1:1000 and 1:200 in 
PBS for the detection of nuclei of pluripotent and differentiated cells, respectively. Finally, the 
specimens were rinsed with sterile Milli-Q water (Millipore) and were mounted with Mowiol 
(Calbiochem). The in vitro PSC differentiation analyses were performed with an IX51 inverse 
fluorescence microscope equipped with a XC30 Peltier-cooled digital color camera (Olympus) 
or a Confocal laser scanning microscope TCS SP8 (Leica). The images were processed with the 
aid of CellF 3.4 imaging software (Olympus) or LAS AF software (Leica).
COBRA-FISH karyotyping
Combined binary ratio labeling (COBRA)-FISH analysis was carried out for determining the 
karyotype of iPSCs essentially following the instructions indicated in a previously published 
protocol47. In short, slides with metaphase chromosomes from iPSCs were pre-treated with 
RNase I (Roche; 100 μg ml−1 in 2 × SSC) and pepsin (Sigma-Aldrich; 0.005% in 0.01 M HCl) at 
37 °C for 10 min and 5 min, respectively. After a 10-min fixation with 1% (v/v) formaldehyde 
in PBS, the specimens were dehydrated by sequential 3-min incubations in 70%, 90% and 
100% ethanol. Next, whole-chromosome painting probes, labeled with the fluorescent dyes 
diethylaminocoumarin, Cy3, Cy5, and rhodamine green using the Universal Linkage System 
(ULS) kit (Kreatech Biotechnology), were applied to the air-dried slides. After a denaturation 
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step at 80 °C for 45–90 s, DNA hybridizations were let to proceed in a humidified chamber at 
37 °C for 2 days. The unbound probes were removed by a series of post-hybridization wash-
es and the samples were subsequently dehydrated by exposing them to increasing concen-
trations of ethanol as aforementioned. Finally, the chromosome specimens were sealed and 
counterstained with Citifluor AF1 mounting solution (Citifluor Ltd.) containing 500 ng ml−1 of 
the DNA dye DAPI. Digital images were acquired with the aid of a Leica DMRA fluorescence 
microscope coupled to a CCD camera.
Colony-formation assays
In addition to flow cytometric analysis, stable transfections resulting from gene targeting 
experiments with pDonor.EPS1 and pDonor.EPS1.TS were also assessed by colony-formation 
assays. These assays were applied to puromycin-resistant HeLa and PSC colonies by using, 
respectively, a standard Giemsa staining and the leukocyte AP kit for detecting alkaline phos-
phatase (AP) activity (Sigma-Aldrich). These colonies were derived from cell cultures initially 
exposed to pDonor.EPS1 and pCAG.Cas9.gRNAS1 (standard setting) or to pDonor.EPS1.TS and 
pCAG.Cas9D10A.gRNAS1 (Nick2 setting). In brief, at 20 days post-transfection, HeLa cells were 
seeded at densities of 1 × 103 and 1 × 104 cells per 10-cm dish (Greiner Bio-One) in the presence 
of 1 μg ml−1 of puromycin. Puromycin-resistant HeLa cell colonies were identified by Giemsa 
staining 9 days later. Next to this, at 3–4 days post-transfection PSCs were seeded at a den-
sity of 2–3 × 105 cells per MEF culture and, 1 day later, were exposed to puromycin at a final 
concentration of 1 μg ml−1. After 5 days under puromycin selection was assessed by using the 
aforementioned AP detection kit following the manufacturer’s instructions.
Southern blot analysis
Genomic DNA was extracted from individual EGFP+/mTurquoise2+ HeLa cell clones and 
from a control EGFP+ HeLa cell clone according to a standard organic solvent-based protocol 
as follows. The cells were collected and incubated overnight at 50 °C in 250 μl of lysis buffer 
containing 10 mM Tris-HCl (pH 8), 25 mM EDTA (pH 8), 0.5% (w/v) SDS, and 100 mM NaCl. 
Prior to use, the lysis buffer was supplemented with freshly added proteinase K (ThermoFish-
er Scientific) at a final concentration of 0.1 μg μl−1. The resulting cell lysates were extracted 
twice by gentle pipetting in a 1:1 mixture with buffer-saturated phenol:chloroform:isoamyl 
alcohol (25:24:1). The aqueous phase was recovered and was subsequently subjected to one 
additional extraction cycle by gentle pipetting in a 1:1 mixture with chloroform. Next, the 
chromosomal DNA present in the aqueous phase was precipitated in 2.0 and 0.5 volumes of 
ethanol and 7.5 M ammonium acetate (pH 5.5), respectively. The recovered genomic DNA 
pellets were washed with 70% (v/v) ethanol, gently air-dried, and were finally dissolved in 
DNase-free sterile water at a concentration of 1–2 μg μl−1. Subsequently, DNA samples (10 μg 
each) were digested overnight with BlpI (New England BioLabs) and were resolved through 
a 1.0% agarose gel in 1 × Tris-acetate-EDTA buffer. The DNA was transferred by capillary 
action onto an Amersham Hybond-XL membrane (GE Healthcare Life Sciences) using an al-
kaline transfer buffer consisting of 0.4 N NaOH and 1 M NaCl. After overnight transfer, the 
membrane was neutralized with a pH 7.2 solution containing 0.5 M Tris-HCl and 1 M NaCl. 
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The EGFP-specific and mTurquoise2-specific probes (994 bp each) were isolated from agarose 
gel after AgeI/HindIII double digestion of AA63_pDonorS1 and AX28_pDonor.TurqS1, respec-
tively. The purified DNA probes were radiolabeled with [α-32P]dATP (GE Healthcare Life 
Sciences) by using the DecaLabel DNA labeling Kit following the manufacturer’s instruc-
tions (ThermoFisher Scientific). The Pre-hybridization and hybridization steps, 2 h and over-
night, respectively, were performed at 65 °C in Rapid-Hyb Buffer (GE Healthcare). Next, the 
membrane was washed at 65 °C once with a 2 × SSC solution supplemented with 0.1% (w/v) 
SDS (20 min) and twice with a 0.5 × SSC solution supplemented with 0.1% (w/v) SDS (20 min 
each). Finally, the membrane was gently air-dried, wrapped in Saran film and exposed to an 
Amersham Hyperfilm MP (GE Healthcare). The autoradiogram film was obtained by using 
standard developing solutions.
Statistical analyses
The researchers were not blinded to sample allocation during experiments and data anal-
yses. One-way ANOVA combined with Bonferroni tests were used for the statistical analy-
ses of data sets obtained from three independent experiments comparing the performance 
of donors with no, one, or two gRNA target sites (P < 0.05 was considered significant). The 
IBM SPSS Statistics 23 software package was employed for these analyses. The comparison of 
data sets retrieved from standard and in trans paired nicking gene targeting experiments was 
performed by applying two-tailed Student’s t-tests (P < 0.05 was considered significant). The 
GraphPad Prism 6 software package was used for these analyses.
Restriction-fragment length analyses
Amplicons spanning the AAVS1 and CCR5 target sites, and the BlpI polymorphism in the 
mTurquoise2 coding sequence were generated with the PCR reagents and subsequently ex-
posed to the restriction enzymes specified in Supplementary Table 28. The corresponding 
primers and PCR cycling conditions are indicated in Supplementary Tables 23, 24, 26, and 27.
Data availability
All relevant results generated in this study are available within the paper and respective Sup-
plementary Information or are available from the corresponding author on reasonable request. 
Sanger sequencing chromatograms are deposited in FigShare at 10.6084/m9.figshare.5208766.
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Abstract
Transcription activator-like effector nucleases (TALENs) and RNA-guided nucleases derived from clustered, regularly interspaced, short palindromic repeats (CRISPR)-Cas9 systems have become ubiquitous genome editing 
tools. Despite this, the impact that distinct high-order chromatin conformations 
have on these sequence-specific designer nucleases is, presently, ill-defined. The 
same applies to the relative performance of TALENs and CRISPR/Cas9 nucleas-
es at isogenic target sequences subjected to different epigenetic modifications. 
Here, to address these gaps in our knowledge, we have implemented quantitative 
cellular systems based on genetic reporters in which the euchromatic and het-
erochromatic statuses of designer nuclease target sites are stringently controlled 
by small-molecule drug availability. By using these systems, we demonstrate 
that TALENs and CRISPR/Cas9 nucleases are both significantly affected by the 
high-order epigenetic context of their target sequences. In addition, this outcome 
could also be ascertained for S. pyogenes CRISPR/Cas9 complexes harbouring 
Cas9 variants whose DNA cleaving specificities are superior to that of the wild-
type Cas9 protein. Thus, the herein investigated cellular models will serve as val-
uable functional readouts for screening and assessing the role of chromatin on 
designer nucleases based on different platforms or with different architectures or 
compositions.
Introduction     
Transcription activator-like effector (TALE) nucleases (TALENs) and RNA-guided 
clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated 
Cas9 (CRISPR/Cas9) nucleases, have become the prevalent tools for inducing target-
ed double-stranded DNA breaks (DSBs) in living cells 1,2.
Native TALE proteins have evolved in phytopathogenic bacteria (Xanthomonas sp.) 
to serve as transcriptional activators of specific host plant genes whose products 
promote infection 1,2. Typically, TALE DNA-binding domains consist of an array 
of 15.5–19.5 repeats composed of 33–34 residues containing polymorphisms called 
repeat variable di-residues (RVDs) at positions 12 and 13. Individual RVDs mediate 
the binding of the repeat in which they are embedded to a particular nucleotide. This 
direct one-to-one interaction between nucleotides and repeats permits the straight-
forward assembling of artificial proteins, among which TALENs, with specific DNA 
binding activities. Indeed, TALENs are built by fusing the DNA-binding program-
mable polymorphic repeats from TALE proteins to the nuclease domain of the type 
IIS restriction enzyme FokI 1,2. The recognition of preselected genomic sequences by 
TALEN pairs leads to in situ FokI dimerization resulting in nuclease activation and 
targeted DSB formation.
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Native CRISPR/Cas9 nucleases have evolved in bacteria and archaea as adaptive 
immune systems to fend off invading nucleic acids (e.g. bacteriophage and plasmid 
DNA) whose chromatin signatures are, clearly, fundamentally different from those 
present in and acquired by eukaryotic nuclear genes 3. Programmable CRISPR/Cas9 
nucleases are ribonucleoprotein complexes composed of a sequence-tailored single 
guide RNA (gRNA) and a Cas9 protein harboring two nuclease domains (i.e. RuvC 
and HNH). The 5′ and 3′ ends of the gRNAs serve as targeting and scaffolding moi-
eties for Cas9, respectively. The initial interaction between CRISPR/Cas9 complexes 
and DNA involves binding of Cas9 to a nucleotide sequence named protospacer 
adjacent motif (PAM; NGG in the case of the prototypic Cas9 from S. pyogenes). This 
initial engagement with DNA is mediated through a composite PAM-interacting 
domain located in two regions of the Cas9 protein 4. Subsequently, targeted DSB 
formation is triggered after the hybridization of the 5′ end of the gRNA to a comple-
mentary ~20-bp genomic target sequence located next to the PAM 1,2.
Therefore, TALENs and CRISPR/Cas9 nucleases operate in strikingly different man-
ners in that the target site specificity of the former is governed via protein–DNA 
interactions, whilst that of the latter is ultimately dictated by RNA–DNA hybridiza-
tions 1,2. The activation of cellular DNA repair pathways resulting from the activity 
of these sequence-specific designer nucleases is being harnessed in an ever-increas-
ing number of genome editing settings. For instance, the repair of targeted DSBs via 
non-homologous end joining (NHEJ) can result in the incorporation of small inser-
tions and deletions (indels) leading to gene knock-out or gene correction 1,2.
Well-defined parameters that can affect targeted DSB formation by TALENs and 
CRISPR/Cas9 nucleases in cellula include their specific construction, composition, 
primary target sequence and, in the case of TALENs, CpG methylation 5,6. In contrast, 
there has been no direct and quantitative assessment of the impact that high-order 
chromatin conformations have on these gene-editing tools at isogenic target sites 
7. By the same token, an investigation of the relative performance of TALENs and 
CRISPR/Cas9 nucleases at target sequences subjected to different epigenetic modi-
fications is equally lacking. Indeed, hitherto, studies based mostly on catalytically 
‘dead’ Cas9 enzymes have exclusively correlated preferential interactions of CRIS-
PR/Cas9 complexes with open chromatin regions bearing candidate off-target sites 
(e.g. 5-nucleotide seed sequences followed by the S. pyogenes’s PAM) 7-11. In this re-
gard, it is also of note that binding of CRISPR/Cas9 complexes to DNA is, for the 
most part, uncoupled from actual phosphodiester bond cleavage 7,8,11. Here, to cover 
these gaps in our knowledge, we have adapted and validated cellular systems for 
tracking and measuring the impact of the epigenetically regulated three-dimension-
al chromatin structure on gene editing processes. By using these reporter systems, 
we demonstrate that TALENs and CRISPR/Cas9 nucleases are both significantly 
hindered by the chromatin context in which their target sequences are embedded.
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Results and Discussion
To investigate and compare the impact that the chromatin structure has on the per-
formance of TALENs and CRISPR-Cas9 complexes, we have set-up two complemen-
tary quantitative cellular systems dubbed HER.TLRTetO.KRAB and HEK.EGFPTetO.KRAB. 
In these systems, the chromatin conformations (i.e. euchromatic versus heterochro-
matic) at isogenic target sequences are stringently controlled through small-mol-
ecule drug availability. In particular, these experimental models based on human 
cells, harbor reporter alleles whose transition from compact to relaxed chromatin is 
governed through doxycycline (Dox)-dependent release of a dominantly silencing 
tTR-KRAB fusion protein from its cognate TetO recognition elements (Fig. 1A). The 
Krüppel-associated box domain (KRAB) is the effector moiety of the largest class 
of transcriptional repressors in vertebrates. The binding of KRAB-containing pro-
teins to DNA triggers epigenetic silencing mechanisms involving the recruitment 
of, amongst others, scaffolding and chromatin remodeling factors such as KRAB-as-
sociated protein 1 (KAP-1) and heterochromatin protein 1 (HP-1) 27,28. The impinged 
facultative heterochromatin is characterized by epigenetic marks of silenced genes 
29,30.
The first system, HER.TLRTetO.KRAB, consists of tTR-KRAB-expressing human embry-
onic retinoblasts containing a Traffic Light Reporter (TLR) construct 12, which we 
have herein modified by flanking it with TetO (TLRTetO) elements (Fig. 1B). The orig-
inal TLR construct has an out-of-frame mCherry reporter located downstream of a 
T2A sequence and an EGFP ORF disrupted by an I-SceI recognition site 12. The repair 
by NHEJ of DSBs made at sequences upstream of mCherry generates indels that can 
place the nucleotide sequence of mCherry in-frame. The resulting red fluorescent 
cells thus report sequence-specific nuclease activity. To validate the cellular model 
based on the adapted TLR construct TLRTetO, ChIP-qPCR assays were performed on 
HER.TLRTetO.KRAB cells incubated in the presence or in the absence of Dox. In these 
assays, antibodies directed against histone 3 acetylation (H3Ac) and histone 3 lysin 
9 trimethylation (H3K9me3), characteristic of open and closed chromatin, respec-
tively, were used. The ChIP-qPCR analysis established a Dox-dependent switch of 
TLRTetO sequences from a heterochromatic to a euchromatic state (Fig. 1C). Indeed, 
in HER.TLRTetO.KRAB cells not exposed to Dox, the enrichment factors for the het-
erochromatin mark H3K9me3 at six randomly-selected ChIP-qPCR target regions 
spanning the TLRTetO gene body varied from a minimum of 2.2-fold to a maximum 
of 14.4-fold when compared to those measured in their Dox-treated counterparts 
(Fig. 1C left panel). Conversely, in HER.TLRTetO.KRAB cells exposed to Dox, the enrich-
ment factors for the euchromatin mark H3Ac at the same ChIP-qPCR target regions 
ranged from a minimum of 1.1-fold to a maximum of 61.7-fold when compared to 
those measured in their Dox-negative counterparts (Fig. 1C, right panel). These var-
iations in histone modifications are well within those reported to induce biologi-
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cally relevant changes in cells 30,31. Taken together, these data validate the TLRTetO 
construction as a Dox-dependent epigenetically controlled system that can be used 
for studying the effect of chromatin conformation on the performance of gene edit-
ing tools. The second system, HEK.EGFPTetO.KRAB, entails tTR-KRAB-expressing hu-
man embryonic kidney cells with a TetO-flanked functional EGFP allele 12 (Fig. 1D). 
Fig. 1
Experimental systems for tracking designer nuclease-induced indel formation at target sites 
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In this system, the traceable cellular phenotype consists of non-fluorescent cells 
emerging from the incorporation of frame-shifting indels at EGFP sequences after 
NHEJ-mediated DSB repair. In conclusion, the generation of DSBs within isogen-
ic euchromatic and heterochromatic target sites located in TLR and EGFP reporter 
genes can readily be tracked in cellula by quantifying mCherry-positive and EG-
FP-negative cells, respectively (Fig. 1E).
with alternate epigenetic states. (A) Drug-dependent control over the chromatin confor-
mation of designer nuclease target sites. In this system, the binding of the trans-acting 
tTR-KRAB fusion protein to cis-acting TetO sequences leads to the recruitment of epige-
netics modulators consisting of, amongst others, KAP1 and HP1 proteins. In the presence 
of doxycycline, tTR-KRAB cannot bind its cognate TetO elements, resulting in the transition 
of a compact heterochromatic to a relaxed euchromatic conformation. (B) Designer nucle-
ase-induced gain-of-function system (ORF correction). HER.TLRTetO.KRAB reporter cells contain 
a TetO-flanked TLR allele. Subjecting tTR-KRAB-expressing HER.TLRTetO.KRAB cells to designer 
nucleases targeting TLR sequences yields ORF-correcting indels generated by NHEJ-me-
diated DSB repair and the appearance of mCherry-positive cells. (C) ChIP-qPCR analysis 
on HER.TLRTetO.KRAB cells. ChIP-qPCR signals detected by using antibodies directed against 
open and closed chromatin marks (H3Ac and H3K9me3, respectively). Six different regions 
spanning the TLRTetO gene body were probed. The targeted sequences were located in the 
EF1α promoter (EF1α), the puromycin resistance ORF (PuroR), the spleen focus-forming vi-
rus regulatory elements (SFFV), the EGFP ORF (EGFP a and EGFP b) and the mCherry ORF 
(mCherry). Standard positive and negative controls (Ctrl) are indicated. (D) Designer nucle-
ase-induced loss-of-function system (ORF disruption). HEK.EGFPTetO.KRAB reporter cells harbor 
a TetO-flanked EGFP target allele. Exposing tTR-KRAB-expressing HEK.EGFPTetO.KRAB cells to 
designer nucleases targeting EGFP yields ORF-disrupting indels generated by NHEJ DSB re-
pair and the emergence of EGFP-negative cells. (E) Experimental settings. HEK.EGFPTetO.KRAB 
and HER.TLRTetO.KRAB cells exposed or not to Dox are transfected with designer nuclease-en-
coding constructs. After the generation of site-specific DSBs and ensuing NHEJ-mediated 
indel formation in each of the two parallel settings (yellow boxes), target gene expression is 
activated allowing to quantify the frequencies of NHEJ-based gene editing by flow cytometry.
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Fig. 2
Detailed diagrammatic representation of the experimental designs used in the present study. 
The tTR-KRAB-expressing reporter cells HEK.EGFPTetO.KRAB(A) and HER.TLRTetO.KRAB (B) were 
used for tracking and quantifying designer nuclease-induced gene editing events at target 
sites subjected to different epigenetic states. The TetO-negative and tTR-KRAB-expressing 
reporter cells HER.TLRKRAB(C) were also generated to provide for negative controls. The HEK.
EGFPTetO.KRAB and HER.TLRTetO.KRAB systems are complementary in that they allow for measuring 
ORF disruption and ORF correction, respectively. The initial high-order chromatin confor-
mation of both model alleles is controlled through Dox-dependent regulation of tTR-KRAB 
binding. Reporter cells HEK.EGFPTetO.KRAB and HER.TLRTetO.KRAB, containing target sequences in 
a heterochromatic (–Dox) or euchromatic (+Dox) state, are transiently transfected with dif-
ferent sets of designer nuclease-encoding constructs. DsRed and hrGFP expression plasmids 
are included in the transfection mixtures to serve as internal controls for transfection effi-
ciency. After the generation of targeted DSBs in each of the two parallel settings (i.e. –Dox 
and +Dox), target gene expression is activated allowing to quantifying the frequencies of 
NHEJ-based gene editing by flow cytometry.
We started by transfecting HER.TLRTetO.KRAB and HEK.EGFPTetO.KRAB cells, cultured in 
the presence or in the absence of Dox, with expression plasmids encoding TALENs 
and CRISPR/Cas9 nucleases (Supplementary Fig. S5). Parallel cell cultures trans-
fected with constructs expressing a single TALEN monomer, Cas9 plus a non-target-
ing gRNA or Cas9 plus an ‘empty’ gRNA, served as negative controls (Ctrl). After 
the action of the various designer nucleases had taken place, all cell cultures were 
exposed to Dox in order to allow for transgene activation and ensuing flow cyto-
metric analysis  (Fig. 1E and 2). The resulting data revealed that in HER.TLRTetO.KRAB 
and HEK.EGFPTetO.KRAB cells (i.e. ORF correction and ORF disruption readouts, re-
spectively), the frequencies of DSB formation were significantly lower in cells whose 
target sites were embedded in heterochromatin (-Dox) when compared to those at-
tained when the same sites were located in euchromatin (+Dox) instead (Fig. 3A–D 
and Supplementary Fig. S6). Indeed, euchromatic target sequences in reporter HER.
TLRTetO.KRAB and HEK.EGFPTetO.KRAB cells were cleaved by CRISPR/Cas9 complexes on 
average 2.7- and 2.2-fold, more frequently than when they were in a heterochromat-
ic state (Fig. 3A and B, respectively). Similarly, euchromatic target sites in reporter 
HER.TLRTetO.KRAB and HEK.EGFPTetO.KRAB cells were cut by TALEN dimers on average 
5.2- and 3.0-fold more often than their isogenic heterochromatic counterparts (Fig. 
3C and D, respectively). Thus, these ratios between the levels of targeted DSB forma-
tion in epigenetically open versus closed DNA can be referred to as the chromatin 
impact index of a particular nuclease.
Of note, the TALEN pairs TALEN-43-L/TALEN-43-R and TALEN-GA-L/TALEN-
GA-R (Fig. 3C and D, respectively) are based on different architectures consisting 
of TALE scaffolds from Xanthomonas axonopodis pv. citri and Xanthomonas campestris 
pv. armoraciae, respectively 32,33. Importantly, no differences in designer nuclease-in-
duced targeted DSB frequencies were measured in HER.TLRKRAB cells whose TLR se-
quences are not subjected to conditional KRAB-mediated epigenetic regulation (Fig. 
3E). HER.TLRKRAB and HER.TLRTetO.KRAB cells differ from each other in that the former 
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lacks the cis-acting TetO elements (Fig. 1A and 3E, respectively). In particular, ex-
pression of TALEN dimers and CRISPR/Cas9 complexes directed to TLR sequences 
in HER.TLRKRAB cells led to similar levels of site-specific DSB formation in Dox-con-
taining and Dox-free settings resulting in chromatin impact indexes of roughly 1 for 
both types of designer nucleases (Fig. 3F and G).
Fig. 3
The impact of distinct chromatin conformations on the frequencies of NHEJ-based gene 
editing achieved by TALEN and CRISPR/Cas9 nucleases. Reporter cells HER.TLRTetO.KRAB (A 
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Fig. 4
Gene editing experiments at EGFP target sequences subjected to alternative chromatin con-
formations. (A) Targeted mutagenesis induced by TALENs with different numbers of TALE 
repeats. HEK.EGFPTetOKRAB cells were either incubated or not with Dox and were subsequently 
and C) and HEK.EGFPTetO.KRAB (B and D), were subjected to the indicated experimental con-
ditions. The negative controls (Ctrl) in panels A and B, involved transfecting cells with 
expression plasmids encoding Cas9 mixed with a non-targeting gRNA or with an ‘empty’ 
gRNA construct, respectively. The negative controls (Ctrl) in panel C and in panel D involved 
exposing target cells exclusively to a single TALEN monomer. Representative flow cytometry 
dot plots are also presented next to each graph. Ten thousand events, each corresponding 
to a single viable cell, were measured per sample. Error bars indicated mean ± s.e.m. P 
values (by two-tailed t-tests) and the number of independent experiments (n) are shown. 
(E) Control HER.TLRKRAB cells. The chromatin status of TLR sequences in HER.TLRKRAB cells 
are not controlled by Dox since they lack cis-acting TetO elements for tTR-KRAB binding. 
(F) Gene editing in HER.TLRKRAB cells. HER.TLRKRAB cells were either exposed or not to Dox 
and were subsequently transfected with the indicated constructs. Differences between +Dox 
and –Dox values were not statistically significant as determined by three-way ANOVA (P = 
0.151; two independent experiments done in replicate). The ratios between EGFP knockout 
levels measured in the presence versus those determined in the absence of Dox. gRNANT, 
Non-targeting gRNA. (G) Representative flow cytometry dot plots corresponding to the ex-
perimental settings presented in panel F.
Next, we carried out another series of gene knockout experiments in HEK.EGFP-
TetO.KRAB cells by using a panel of TALENs composed of different numbers of TALE 
repeats in their DNA-binding arrays. Once again, the frequencies of targeted gene 
knockout were highest in cells containing euchromatic target sites (Fig. 4A and 
B). Interestingly, the TALEN complex built on monomers with the shortest TALE 
DNA-binding domains was the most hindered by having its target sequence embed-
ded in heterochromatin. In fact, under this condition, this TALEN pair led to gene 
editing levels barely above background (Fig. 4A). These data suggest that a mini-
mum TALEN DNA-binding energy is necessary in order to overcome the compact 
heterochromatic barrier and induce meaningful levels of site-specific DSB forma-
tion. Nonetheless, it is important to point out that the majority of TALEN proteins 
currently in use contain DNA-binding domains made up of well over 14.5 TALE 
repeats (i.e. typically, 17.5 to 18.5 TALE repeats per monomer) 1,2.
Probing the Impact of Chromatin Conformation on Genome Editing Tools
Chapter 3  /  070
transfected with expression plasmids encoding TALENs with 14.5, 16.5 and 18.5 TALE re-
peats. Negative controls consisted of parallel cultures exposed exclusively to TALEN-GA-L 
(Ctrl). After the generation of site-specific DSBs in each of the two parallel settings (i.e. -Dox 
and +Dox), target gene expression was activated in all cultures by adding Dox for determin-
ing the frequencies of NHEJ-mediated EGFP knockout by flow cytometry. The ratios between 
EGFP knockout levels measured in the presence versus those determined in the absence 
of Dox (open versus closed chromatin, respectively) are indicated. (B) Representative flow 
cytometry dot plots corresponding to the experimental settings presented in panel A.
Informed by structural data 4,34, two independent research groups have recently gen-
erated S. pyogenes Cas9 variants with targeting DNA specificities markedly superior 
to that of their parental wild-type counterpart 19,21. These high-specificity variants, 
dubbed SpCas9-HF1 19 and eSpCas9(1.1) 21, have amino acid substitutions which 
reduce nonspecific protein–DNA interactions and, as a result, constrain the respec-
tive ribonucleoprotein complexes to preferentially cut at the intended target sites. 
The SpCas9-HF1 mutations N497A, R661A, Q695A and Q926A reduce protein bind-
ing to the sugar-phosphate backbone of the complementary strand by removing 
hydrogen bridges; the charged-to-alanine eSpCas9(1.1) mutations K848A, K1003A 
and R1060A affect protein binding to the non-complementary stand by eliminating 
cationic amino acids along the nt-groove located between the HNH and RuvC-like 
nuclease domains. Regardless of their different point mutations and modus operan-
di, these engineered Cas9 variants contribute to addressing in a very direct manner 
a major issue in the genome-editing field, that is, the need for reducing off-target 
DNA cleaving activities as these can confound experimental outcomes and obstruct 
potential clinical applications. To determine the relative chromatin impact indexes 
of these new Cas9 variants, we carried out targeted gene knockout experiments in 
HEK.EGFPTetO.KRAB cells. In these experiments, constructs encoding wild-type Cas9, 
SpCas9-HF1 or eSpCas9(1.1) were transfected together with plasmids expressing 
five different EGFP-targeting gRNAs. Data presented in Fig. 5A show that, as previ-
ously established for wild-type Cas9, high-specificity Cas9 variants were both hin-
dered by heterochromatin. Interestingly, of the two variants, the SpCas9-HF1 pro-
tein was the most affected in these experiments as indicated by its higher chromatin 
impact index (Fig. 5B).
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Fig. 5
Testing the impact of chromatin conformation on high-specificity Cas9 variants. (A) Screen-
ing of CRISPR/Cas9 complexes with different Cas9 proteins in HEK.EGFPTetOKRAB cells. HEK.
EGFPTetOKRAB cells were incubated in the presence or in the absence of Dox and were subse-
quently transfected with expression plasmids encoding the indicated CRISPR/Cas9 nuclease 
components. The chromatin impact index was determined by computing the ratios between 
EGFP knockout levels measured in the presence versus those determined in the absence of 
Dox. Error bars indicate mean ± s.e.m. corresponding to three independent experiments. 
Ten thousand events, each corresponding to a single viable cell, were measured per sam-
ple. (B) Cumulative chromatin impact indexes. Boxplot of the chromatin impact indexes 
presented in panel A. Whiskers, minimum and maximum. One-way ANOVA compared the 
experimental groups with a subsequent comparison between groups being done by Bonfer-
roni analysis (P < 0.05 was considered significant).
Taken together, our data establishes that distinct high-order epigenetically regulated 
chromatin conformations can have a significant impact on DNA cleaving activity 
regardless of the type of the designer nuclease tested and of the specific nucleotide 
sequence targeted. Moreover, of the two main designer nuclease platforms currently 
in use, TALENs seem to be the most influenced by the high-order chromatin status 
of their target DNA as revealed by the cumulative data presented in Fig. 6. In this re-
gard, it is interesting noting that although the RNA-guided system has not evolved 
to assess and cleave chromosomal DNA in eukaryotic cell nuclei, it can nonetheless 
perform relatively well in human cells when compared to TALENs (Fig. 6). Howev-
er, regardless of the nuclease platform ultimately chosen, chromatin impact indexes 
of two or higher (Fig. 6) are relevant for the ultimate performance of genome editing 
protocols in different experimental settings, including those aiming at bi-allelic or 
multi-allelic target gene knockouts. Our results complement recent biochemical data 
demonstrating that nucleosome occupancy obstructs CRISPR/Cas9-mediated DNA 
cleavage 35. Interestingly, comparison of targeted DSB formation by TALENs and 
CRISPR/Cas9 nucleases at different CCR5 sequences in induced pluripotent stem 
cells did not show a correlation between indel frequencies and the distribution of 
DNaseI hypersensitive sites retrieved from the ENCODE database 36. Whether this 
finding is specific to the DNaseI hypersensitive site profile selected or to the experi-
mental design used, would need further investigation.
In the present work, we have presented and validated two complementary func-
tional readouts for investigating and comparing in a quantitative manner the role 
of high-order chromatin structures on genome editing events resulting from the 
use of sequence-specific designer nucleases. By using these quantitative assays, 
we have demonstrated that TALENs and CRISPR/Cas9 nucleases are both signifi-
cantly hindered by closed chromatin in living cells. We conclude that, in addition 
to the well-established parameters mentioned earlier, the chromatin conformation 
constitutes yet another determinant of the ultimate efficiencies resulting from us-
ing TALENs and CRISPR/Cas9 nucleases. The approaches described in our work 
should be directly applicable for screening and selecting specific designer nuclease 
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reagents from different platforms or with different architectures and compositions 
(e.g. hybrid nucleases, engineered homing endonucleases, Cas9 orthologues, novel 
Cas9 variants and gene editing tools co-opted from new DNA-targeting systems). In 
addition, they should also be valuable for assessing the impact of chromatin on dif-
ferent gene editing strategies, including those based on paired ‘nickases’, truncated 
guide RNAs and homology-directed gene repair.
Fig. 6
Cumulative chromatin impact indexes for the TALEN and CRISPR/Cas9 nuclease systems. 
Boxplot of the ratios between EGFP knockout levels measured in the presence versus those 
determined in the absence of Dox presented in Figures  Figs. 3B, D, 4A and 5B (Cas9 data 
points). Whiskers, minimum and maximum. The data corresponding to the TALEN pair with 
the shortest DNA-binding domains (i.e. TALEN-26-L/TALEN-26-R) was not computed in this 
analysis to avoid skewing the data. Ten thousand events, each corresponding to a single 
viable cell, were measured per sample. The P-value was determined by two-tailed Student’s 
t-test analysis (P < 0.05 was considered significant).
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Methods
Recombinant DNA
The lentiviral transfer plasmid AD12_pLV.TetO.TLR.TetO (Supplementary Figure S1) was 
constructed by inserting tTR-KRAB binding elements upstream and downstream of the TLR 
construction 12 in pCVL Traffic Light Reporter 1.1 (SceI target) Ef1a Puro (Addgene plasmid 
#31482, herein referred to as pLV.TLR) by using standard recombinant DNA techniques. The 
lentiviral transfer plasmid pLVCT-tTR-KRAB 13 used to assemble LVCT-tTR-KRAB vector 
particles for the generation of reporter cells HEK.EGFPTetO.KRAB, was obtained from Addgene 
(#11643). Likewise for the TALEN expression plasmids TAL2050 (#39408), TAL2051 (#39409), 
TAL2072 (#39442), TAL2073 (#39443), TAL2076 (#39446), TAL2077 (#39447), TAL2094 (#39428) 
and TAL2095 (#39429) encoding, respectively, TALEN-26-L, TALEN-26-R, TALEN-43-L, 
TALEN-43-R, TALEN-45-L, TALEN-45-R, TALEN-36-L and TALEN-36-R proteins based 
on the Xanthomonas axonopodis pv. citri TALE scaffold 14. The TALEN expression plasmids 
AR36_pTALEN-GA-L and AR37_pTALEN-GA-R code for, respectively, TALEN-LEGFP and 
TALEN-REGFP 15; herein referred to as TALEN-GA-L and TALEN-GA-R, respectively. The 
TALEN-GA-L and TALEN-GA-R proteins are based on the Xanthomonas campestris pv. armo-
raciae TALE scaffold and were custom-designed by GeneArt Gene Synthesis (ThermoFish-
er Scientific). The expression plasmid hCas9 16; herein referred to as pCMV.Cas9, contains a 
human codon-optimized ORF coding for the Streptococcus pyogenes Cas9 nuclease (Addgene 
plasmid #41815). The gRNA acceptor plasmid S7_pUC.U6.sgRNA.Bvel-stuffer has a U6 
RNA Pol III promoter for driving gRNA expression and was constructed as follows. The 
construct pLKO.1-puro.U6.sgRNA.BfuAI.stuffer 17 (Addgene plasmid #50920) was treated 
with BclI and, subsequently, with the Klenow fragment (both from ThermoFisher Scientif-
ic). Next, this vector backbone was dephosphorylated with FastAP (ThermoFisher Scientific) 
and ligated to a Klenow fragment-blunted 3431-bp DMD cDNA fragment harboring four 
BveI sites. This fragment was isolated after digesting pDysE 18 with EcoRI (ThermoFisher 
Scientific). Of note, the presence of extra BveI sites aids in achieving complete BveI digestion 
of the respective gRNA acceptor plasmid. These manoeuvres yielded AA19_pLKO.1-puro.
U6.sgRNA.BveI-stuffer (Supplementary Fig. S2). Finally, after digesting AA19_pLKO.1-
puro.U6.sgRNA.BveI-stuffer with BveI (ThermoFisher Scientific) and EcoRI, the result-
ing 3822-bp insert was ligated to a 2676-bp fragment obtained by treating cloning vector 
pUCBM21 (Boehringer Mannheim) with HincII (ThermoFisher Scientific) and EcoRI. This 
cloning step led to the generation of gRNA acceptor plasmid S7_pUC.U6.sgRNA.Bvel-stuffer 
(Supplementary Figure S3). The expression plasmids coding for gRNATLR, gRNAGFP2, gR-
NAGFP3, gRNAGFP4, gRNAGFP5, gRNAGFP6 and gRNAGFP7 were assembled by inserting annealed 
oligonucleotide pairs 5′-ACCGGTGAGCTCTTATTTGCGTA-3′/5′-AAACTACGCAAATAA-
GAGCTCAC-3′, 5′-ACCGCTGCCGTCCTCGATGTTG-3′/5′-AAACCAACATCGAGGACGG-
CAG-3′, 5′-ACCGCCGTCCTCGATGTTGTGG-3′/5′-AAACCCACAACATCGAGGACGG-3, 
5′-ACCGGGCACGGGCAGCTTGCCGG-3′/ 5′-AAACCCGGCAAGCTGCCCGTGCC-3′, 
5-ACCGTCGCCCTCGAACTTCACCT-3′/ 5′-AAACAGGTGAAGTTCGAGGGCGA-3′, 
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5′-ACCGTAGGTCAGGGTGGTCACGA-3′/ 5′-AAACTCGTGACCACCCTGACCTA-3′ and 
5′-ACCGGCGAGGGCGATGCCACCTA-3′/ 5′-AAACTAGGTGGCATCGCCCTCGC-3′ into 
BveI-digested S7_pUC.U6.sgRNA.Bvel-stuffer, respectively.
The EGFP target sequences for gRNAGFP4, gRNAGFP5, gRNAGFP6 were described previously as 
NGG site 1, NGG site 2 and NGG site 3, respectively 19. The target sequence for gRNAGFP7 
was also described before 20. The construct gRNA_GFP_T2 17 expressing the herein named 
gRNAGFP1 was obtained from Addgene (plasmid #41820). Plasmid gRNA_Cloning Vector 
expressing the herein called gRNAEmpty (Addgene plasmid #41824) and plasmid AM51_ pUC.
U6.gRNANT encoding, respectively, no gRNA and an irrelevant, non-targeting, gRNA, were 
used to serve as negative controls. The AM51_ pUC.U6.gRNANT construct was generated by 
cloning into BveI-digested S7_pUC.U6.sgRNA.Bvel-stuffer the annealed oligonucleotide pair 
5′-ACCGGTGAGCTCTTATTTGCGTAGCTAGCTGAC-3′/ 5′-AAACGTCAGCTAGCTACG-
CAAATAAGAGCTCAC-3′.
The generation of the isogenic set of expression plasmids encoding wild-type Cas9, Sp-
Cas9-HF1 19 and eSpCas9(1.1) 21 was done as follows. The plasmid C55_pU.CAG.hrGFP.rBG-
pA (Supplementary Fig. S4) was first digested with NotI and HincII, to remove the hrGFP 
ORF, after which the 5019-bp backbone fragment was extracted from the agarose gel. Next, 
the backbone was blunted and dephosphorylated by using the Klenow Fragment of the E. 
coli DNA polymerase I and FastAP, respectively (both from Thermo Fisher Scientific). The 
constructs VP12 (Addgene plasmid #72247) 19 and eSpCas9(1.1) (Addgene plasmid #71814) 
21 encode the high-specificity Cas9 variants SpCas9-HF1 and eSpCas9(1.1), respectively. The 
ORFs coding for wild-type Cas9, SpCas9-HF1 and eSpCas9(1.1) were isolated from agarose 
gel after double digesting pCMV.Cas9 16, VP12 and eSpCas9(1.1) with XbaI/MssI, NotI/MssI 
and AseI/EcoRI, respectively. The insert fragments corresponding to Cas9, SpCas9-HF1 and 
eSpCas9(1.1) were then blunted and ligated to the aforementioned plasmid backbone yield-
ing expression plasmids AV62_pCAG.Cas9.rBGpA, AV64_pCAG.SpCas9-HF1.rBGpA and 
AW01_pCAG.eSpCas9(1.1).rBGpA, respectively.
Cells
HEK293T cells (American Type Culture Collection) and HEK293T cell-derived clone HEK.
EGFPTetO.KRAB were cultured as indicated elsewhere 22. HER.TLRTetO.KRAB cells and their con-
trol TetO-negative counterparts HER.TLRKRAB cells were maintained in DMEM supplemented 
with 10% fetal bovine serum (FBS), 10 mM MgCl2 and hygromycin B (ThermoFisher Scientif-
ic) at a final concentration of 45 μg/ml. These cells were stably transfected with a tTR-KRAB 
expression plasmid based on the pcDNA3.1/Hygro(+) backbone (Life Technologies). The var-
ious cell types were kept at 37°C in a humidified-air 10% CO2 atmosphere.
Lentiviral vectors
The generation of lentiviral vectors LVCT-tTR-KRAB, LV.TetO.TLR.TetO and LV.TLR was 
done by transfecting, respectively, pLVCT-tTR-KRAB, pLV.TetO.TLR.TetO and pLV.TLR into 
HEK293T cells together with packaging construct psPAX2 (Addgene #12260) and pseudotyp-
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ing plasmid pLP/VSVG (Life Technologies), essentially as described in detail elsewhere 23,24.
Experimental models
The single cell-derived clone HEK.EGFPTetO.KRAB, harboring a tTR-KRAB-regulated EGFP al-
lele, was generated by transducing HEK293T cells with LVCT-tTR-KRAB. In brief, 5 × 104 cells 
were seeded in wells of 24-well plates (Greiner Bio-One). After 24 h, the cells were exposed 
to 1, 0.5, 0.25, 0.125 and 0.062 Hela cell-transducing units (HTU)/cell of LVCT-tTR-KRAB. At 
48 h post-transduction, the cells exposed to each vector multiplicity of infection (MOI) were 
split into wells of 6-well plates (Greiner Bio-One). At 6 days after transduction, these cells 
were either kept in regular culture medium or in culture medium supplemented with 500 ng/
ml doxycycline (Dox). Three days later EGFP-directed flow cytometry analysis was carried 
out. The cell culture transduced with an MOI of 0.125 HTU/cell contained 6.9% and 0.34% of 
EGFP-positive cells in the presence and absence of Dox, respectively. This cell culture was se-
lected for isolating LVCT-tTR-KRAB-transduced clones by adding 200 μl of a cell suspension 
with a concentration of 1.5 cells/ml into wells of 96-well plates (Greiner Bio-One). To increase 
the cloning efficiency, the culture medium was supplemented with 50 μM of α-thioglycerol 
and 20 nM of bathocuprione disulphonate (both from Sigma-Aldrich) 25. Analysis of Dox-de-
pendent epigenetic regulation of target sequences in individual LVCT-tTR-KRAB-transduced 
clones by flow cytometry led to the selection of reporter cell clone HEK.EGFPTetO.KRAB, which 
was kept in the presence of Dox (200 ng/ml) where indicated. The HER.TLRTetO.KRAB and the 
control HER.TLRKRAB reporter cells were generated by transducing HER clone A2 with LV.Te-
tO.TLR.TetO and LV.TLR particles, respectively. Clone A2 is derived from PER.C6 cells 26 and 
expresses, in a constitutive fashion, tTR-KRAB from a stably integrated pcDNA3.1/Hygro(+) 
backbone (Life Technologies). In brief, 2 × 105 A2 cells were seeded in wells of 24-well plates 
(Greiner Bio-One). One day later, 4-fold serial dilutions of LV.TetO.TLR.TetO and LV.TLR 
clarified supernatant were applied onto the cells. At 48 h post-transduction, the cells were 
transferred to wells of 6-well plates. At approximately 2 weeks post-transduction, hygromy-
cin (45 μg/ml) and Dox (200 ng/ml) were added into LV.TetO.TLR.TetO transduced cells. The 
addition of Dox allowed one week later the start of cell selection with puromycin at a final 
concentration of 1 μg/ml. LV.TLR transduced cells were exposed to hygromycin and puro-
mycin. After 2 weeks in selection medium, puromycin-resistant polyclonal cell populations 
were expanded for carrying out transfection experiments and, where indicated, kept in the 
presence of Dox (500 ng/ml).
DNA transfections
Transfections were started by mixing each of the relevant plasmids and 1 mg/ml polyeth-
yleneimine (PEI, Polysciences) in 50 μl of a 150 mM NaCl solution (Supplementary Tables 
S1–S4). These transfections were done in cells cultured in the absence or in the presence of 
Dox. In addition, for determining gene delivery efficiencies, all transfection mixtures con-
tained a reporter-encoding plasmid. After around 10 s of vigorous vortexing, the DNA-PEI 
complexes were incubated at room temperature for 15 min and were subsequently directly 
applied into the medium of the target cells that had been seeded one day before. After 6–8 h, 
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the transfection mixtures were removed and fresh regular culture medium was added onto 
the transfected cells. At 3 days post-transfection, reporter-directed flow cytometry was carried 
out to establish the frequency of transfected cells in the various cultures. Subsequently, the 
cells were sub-cultured about every 3–4 days. In order to activate target gene expression, cul-
tures of HEK.EGFPTetO.KRAB and HER.TLRTetO.KRAB cells were exposed to Dox at 10 and 14 days 
post-transfection, respectively. Reporter-directed flow cytometry was performed on HEK.
EGFPTetO.KRAB and HER.TLRTetO.KRAB cells 7 and 10 days later, respectively. Where indicated, Te-
tO-negative control HER.TLRKRAB cells were subjected to the same conditions as those applied 
to their HER.TLRTetO.KRAB counterparts.
Flow cytometry
The quantification of reporter-positive cells was done by a BD LSR II flow cytometer (BD 
Biosciences). The results were analyzed with the aid of BD FACSDiva 6.1.3 software (BD Bi-
osciences) or FlowJo 7.2.2 software (Tree Star). Mock-transfected target cells were used to set 
background fluorescence. At least 10,000 viable single cells were analyzed per sample.
Chromatin immunoprecipitation (ChIP) and qPCR
The HER.TLRTetO.KRAB cells were cultured in the presence or in the absence of Dox (500 ng/ml) 
for 11 days, after which a cell fixation protocol available at https://www.activemotif.com, was 
applied. In brief, 2 ml of a freshly prepared formaldehyde solution was added into the cell 
culture medium. The culture flasks were subsequently agitated for exactly 15 min at room 
temperature. Next, 1.1 ml of 2.5 M glycine was applied to stop the fixation process. After a 
5-min incubation period at room temperature, the cells were scraped and transferred to a 
50-ml tube. The collected cells were subjected to two cycles of centrifugation at 800 ×g for 10 
min. After the first cycle, the cells were resuspended in 10 ml of pre-chilled Igepal solution 
(0.05% Igepal in phosphate buffered saline (PBS)), whilst after the second cycle a 10 ml 0.05% 
Igepal solution mixed with 100 μl phenylmethanesulfonyl fluoride (Sigma P-7626, 100 mM 
in ethanol), was used instead. A final centrifugation at 800 ×g for 10 min was carried out to 
harvest the fixed cell pellets. Subsequently, the ChIP-qPCR assays were performed on 30 μg 
of cross-linked chromatin according to the HistonePath™ ChIP-qPCR protocol (Active Mo-
tif). The ChIP-validated antibodies H3 pan-acetyl (Active Motif, cat # 39139) and H3K9me3 
(Active Motif, cat # 39161) were used for the ChIP. Next, qPCR amplifications with primer 
pairs (Supplementary Table S5) targeting six different TLRTetO regions (i.e. SFFV promoter, 
EF1α promoter, puromycin resistance gene, mCherry sequence, 5′ and 3′ EGFP gene segments) 
were performed. Additional primer pairs were used for the quality control of the ChIP-qPCR 
assays (Supplementary Table S5).
The qPCR amplifications were performed with the aid of a Bio-Rad CFX Connect Real-time 
detection system running the CFX ManagerTM software. The qPCR amplifications were car-
ried out in triplicate for each sample and primer pair. The qPCR mixtures consisted of 12.5 ng 
of input DNA, 1x iQ SYBR Green Supermix (Bio-Rad) and 250 nM of each primer in a total 
volume of 20 μl. The qPCR program started with a 2-min incubation period at 95°C. This was 
Probing the Impact of Chromatin Conformation on Genome Editing Tools
Chapter 3  /  077
followed by 40 cycles consisting of 15 s at 95°C, 20 s at 58°C and 20 s at 72°C. Next, the samples 
were sequentially incubated at 95°C and 55°C for 1 min. The melting curves were derived by 
increasing the temperature from 55°C to 95°C with a rate of 0.5°C for every 10 s. The binding 
events detected per 1000 cells were calculated based on chromatin input amounts, final ChIP 
volumes and primer efficiencies. Finally, the data were normalized using the algorithm avail-
able at https://www.activemotif.com.
Statistical analysis
The comparison of data sets resulting from a minimum of three independent experiments 
were analyzed by using the GraphPad Prism 6 software package and monitored for signifi-
cance by applying two-tailed Student’s t-tests with P < 0.05 considered significant. The data 
sets derived from two independent experiments done in biological replicate in HER.TLRKRAB 
were analyzed by using the IBM SPSS Statistics 23 software package and monitored for signif-
icance by employing a three-way ANOVA test with P < 0.05 considered significant. One-way 
ANOVA combined with Bonferroni tests were used for the statistical analysis of the data 
corresponding to the screening of the high-specificity Cas9 variants. P < 0.05 was considered 
significant. The IBM SPSS Statistics 23 software package was used in this analysis.
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Genome editing technologies based on RNA-guided nucleases (RGNs) de-rived from prokaryotic type II CRISPR-Cas9 adaptive immune systems, such as that from Streptococcus pyogenes1, 2 and, more recently, Staphylo-
coccus aureus,3, 4 are becoming increasingly pervasive in both basic and applied re-
search.5, 6 RGNs are ribonucleoprotein complexes whose sequence-specific guide 
RNA (gRNA) moieties address a Cas9 nuclease to a DNA target site (Figure S1A). 
Base pairing between the 5′-terminal nucleotides of the gRNA (spacer) and DNA 
sequences connected to a protospacer-adjacent motif (PAM), triggers Cas9-mediated 
double-stranded DNA break (DSB) formation.5, 6 RGNs based on S. pyogenes Cas9 
(SpCas9) and on S. aureus Cas9 (SaCas9) typically have spacers with a length of 
20 and 21–24 nucleotides, respectively. The PAM of SpCas9 is NGG, while that of 
SaCas9 is NNGRRT.3, 6 The repair of RGN-induced targeted DNA lesions by non-ho-
mologous end joining (NHEJ) or homologous recombination can result in either the 
deletion or addition of genetic information in cells from virtually any organism.5, 6
Despite their ease of use and broad applicability, a major limitation of convention-
al RGNs is that of off-target DNA cleavage. Indeed, it has been demonstrated that 
up to five gRNA-DNA mismatches can be tolerated, especially when located most 
distally to the PAM.7 Such mismatches can conceivably result in several hundreds 
of DSBs across the genome.7 Therefore, substantial efforts have been made in recent 
years to minimize RGN off-target activities. These efforts resulted in a set of im-
proved genome editing strategies, of which preeminent examples include: (1) RGNs 
harboring 5′-truncated gRNAs (tru-gRNAs),8 (2) rationally designed high-specificity 
SpCas9 variants,9, 10 (3) offset RGN pairs containing nicking SpCas9 mutants,11, 12 and 
(4) repurposing of RGNs with longer PAMs, such as those from the S. aureus CRIS-
PR/Cas9 system.3, 4 An overview of these approaches is presented in Figure S1.
Previous studies have shown a preferential interaction between SpCas9-based 
RGNs and genomic regions with euchromatic signatures.13, 14, 15, 16, 17 Recently, by 
using cellular models based on the conditional recruitment of epigenetic remode-
ling complexes to isogenic target sequences, our laboratory, and that of others, have 
demonstrated that the activity of conventional programmable nucleases, including 
RGNs, can be significantly hindered by compact heterochromatin in living cells.18, 
19 However, so far, the extent to which high-specificity CRISPR/Cas9 nuclease strat-
egies are affected by higher-order chromatin topologies remains to be determined.
Hence, here, we sought to investigate and compare the impact that epigenetically 
regulated three-dimensional chromatin “conformers” have on the performance of 
the aforementioned high-specificity genome editing principles (Figure S1). In these 
experiments, we deployed complementary loss-of-function and gain-of-function 
cellular systems in which the euchromatic and heterochromatic statuses of isogen-
ic target sequences are controlled by doxycycline (Dox).18 These systems, based 
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on clonal HEK.EGFPTetO.KRAB and polyclonal HER.TLRTetO.KRAB cell lines, permit the 
measurement of the frequencies of targeted DSBs made by different programmable 
nucleases through the quantification of EGFP− and mCherry+ cells,18, 20 respective-
ly, generated after NHEJ-mediated DSB repair (for details, see Figure 1A). In brief, 
reporter cells cultured without Dox (heterochromatic target sites; high H3K9me3/
low H3Ac) or with Dox (euchromatic target sites; high H3Ac/low H3K9me3) are 
exposed to different programmable nuclease combinations.18 After the action of the 
programmable nucleases takes place, all cultures receive Dox to allow for transgene 
expression and quantification of gene editing events (Figure 1A).
We started by comparing site-specific DSB formation by RGNs containing full-length 
gRNAs (FL-gRNAs) or Tru-gRNAs at euchromatic (“open”) versus heterochromatic 
(“closed”) target sequences. The former gRNAs have canonical, 20-mer spacers; the 
latter display shorter, mostly 18-mer to 17-mer spacers.8 The reduced DNA-binding 
energies of Tru-gRNAs is thought to cause the preferential binding of the respec-
tive SpCas9 partner to fully complementary target DNA (Figure S1B).8 Gene editing 
experiments were initiated by transfecting HEK.EGFPTetO.KRAB cells, cultured in the 
presence of Dox or on its absence, with plasmids encoding sets of SpCas9:FL-gRNA 
or SpCas9:Tru-gRNA complexes targeting five different positions along the EGFP 
ORF (Figure S2). After the action of the various RGN complexes had taken place, 
Dox was added to the different cell cultures for flow cytometric quantification of 
targeted gene knockout levels. We found that, independently of their lengths, the 
various RGNs had similar chromatin impact indexes (Figure 1B), as defined by the 
ratios between the frequencies of DSB formation at euchromatic versus heterochro-
matic target sites (Figure S3). Hence, despite their predicted lower DNA-binding en-
ergies, derived from a reduced Watson and Crick base-pairing potential, RGNs with 
Tru-gRNAs were hindered by heterochromatin to approximately the same extent as 
those harboring standard FL-gRNAs.
The recognition of the PAM by the PID domain of SpCas9 is the first event lead-
ing to targeted DNA cleavage.21 After this initial genomic DNA interrogation, lo-
cal double helix melting permits the nucleation of gRNA-DNA hybridization and 
subsequent R-loop expansion along a PAM-proximal to PAM-distal direction (i.e., 
3′ to 5′). Finally, full-length heteroduplex formation between unwound DNA and 
gRNA sequences triggers phosphodiester bond hydrolysis on both strands through 
a concerted, PAM-dependent, allosteric activation of SpCas9’s HNH and RuvC nu-
clease domains.21 Based on this series of events, our data (Figure 1B) indicate that, 
once a catalytically competent RGN complex manages to engage a heterochromatic 
PAM sequence, the epigenetic barrier has, for the most part, been overcome, with the 
length of the gRNA posing no significant limitations to the subsequent aforemen-
tioned downstream processes. As corollary, the ultimate activity of SpCas9:gRNA 
complexes at specific, PAM-defined, target sites seems to be primarily determined by 
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Figure 1 Assessing the effect of alternative chromatin topologies on high-specificity CRIS-
PR/Cas9 nucleases based on SpCas9 proteins (A) Cellular reporter systems for tracking 
programmable nuclease-induced DSB formation at isogenic target sequences possessing dif-
ferent chromatin conformations. Left panel: the binding of tTR-KRAB fusion proteins to TetO 
elements triggers heterochromatin spread after the recruitment of endogenous epigenetic 
remodeling complexes composed of, among others, KAP1 and HP1. The addition of doxy-
cycline (Dox) alters the tTR-KRAB conformation, preventing its interaction with the TetO 
elements, resulting in the transition of the associated DNA sequences from a compact/het-
erochromatic into a relaxed/euchromatic state. Top right panel: schematics of the HEK.EG-
FPTetO.KRAB loss-of-function system. The tTR-KRAB-expressing human embryonic kidney cells 
HEK.EGFPTetO.KRAB harbor a TetO-flanked EGFP expression unit. In this construct, an in-frame 
EGFP reporter can be placed out of frame after indel formation by NHEJ-mediated repair of 
site-specific DSBs. Thus, non-fluorescent cells report sequence-specific nuclease activity. 
Bottom right panel: diagram of the HER.TLRTetO.KRAB gain-of-function system. The tTR-KR-
AB-expressing human embryonic retinoblasts HER.TLRTetO.KRAB contain a Traffic Light Reporter 
(TLR)20 flanked by TetO elements (TLRTetO).18 In this construct, an out-of-frame mCherry ORF 
linked to a T2A sequence and an EGFP ORF with a disrupting I-SceI recognition site, can be 
placed in-frame after indel formation by NHEJ-mediated repair of targeted DSBs. Hence, in 
this case, the resulting red fluorescent cells are those reporting sequence-specific nuclease 
activity. (B) Chromatin impact indexes of RGNs with full-length and truncated gRNAs. HEK.
EGFPTetO.KRAB cells, treated and not treated with Dox, were exposed to SpCas9 together with 
the indicated gRNAs. The chromatin impact index for each RGN was determined by dividing 
the EGFP knockout levels measured at euchromatic by those gauged at heterochromatic 
conditions (i.e., +Dox and –Dox, respectively). Error bars indicated mean ± SD (n = 3 inde-
pendent experiments done on different days). (C) Testing the impact of chromatin on RGNs 
consisting of high-specificity Cas9 variants and Tru-gRNAs. HEK.EGFPTetO.KRAB cells, incubated 
in the presence and in the absence of Dox, received the indicated nuclease-gRNA pairs. 
Targeted mutagenesis levels at euchromatic (+Dox) and heterochromatic (−Dox) target 
sequences were quantified by EGFP-directed flow cytometry. The bars in both graphs corre-
spond to an individual experiment using RGNs with FL-gRNAs (n = 2) or Tru-gRNAs (n = 6) 
(D) Validation of HEK.EGFPTetO.KRAB cells for assessing paired RGN “nickases”. HEK.EGFPTetO.KRAB 
cells, treated and not treated with Dox, were exposed to SpCas9 and single gRNAs (DSBs) or 
SpCas9 nicking mutants together with two partially overlapping gRNAs (paired SSBs). Cell 
fractions with EGFP knockout (KO) alleles are indicated in the flow cytometry histograms. 
(E) Screening dual RGN “nickase” activities at euchromatic versus heterochromatic target 
sequences. HEK.EGFPTetO.KRAB cells, treated and not treated with Dox, were exposed to the 
specified dual RGN “nickases”. The frequencies of targeted mutagenesis under both Dox reg-
imens were determined by EGFP-directed flow cytometry. Error bars indicate mean ± SEM, 
corresponding to independent experiments (n) performed on different days. (F) Testing of 
dual RGN nicking complexes on the gain-of-function reporter system. HER.TLRTetO.KRAB and 
control HER.TLRKRAB cells, incubated in the presence and absence of Dox, received the indi-
cated dual RGN “nickases”. The frequencies of DSB-induced ORF correction under both Dox 
regimens were determined by mCherry-directed flow cytometry. Error bars indicate mean 
± SEM. A minimum of two and a maximum of four independent experiments were carried 
out. Representative flow cytometry dot plots of these experiments are presented below each 
graph. (G) Comparison of chromatin impact indexes between conventional and high-speci-
ficity RGN complexes. Scatterplot with bar, gathers the datasets obtained from gene editing 
experiments carried out in HEK.EGFPTetO.KRAB cells.
the degree of chromatin accessibility rather than the extent of gRNA-DNA hybridi-
zation at those sites. These results bode well for using 18-mer and 17-mer Tru-gRNAs 
for achieving strict target DNA cleavage8 and possibly deploying <16-mer Tru-gR-
NAs, which render RGNs catalytically inert, for multiplexing purposes. Indeed, the 
combination of these shortened, <16-mer Tru-gRNAs together with SpCas9 proteins 
fused to heterologous domains can be applied in a variety of orthogonal contexts, 
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such as those involving combinatorial editing and transcriptional modulation of dis-
tinct loci in individual cells.22, 23
In a previous study, our laboratory demonstrated that RGNs consisting of FL-gRNAs 
and SpCas9-HF1 or FL-gRNAs and eSpCas9(1.1) are hindered by heterochromatin18. 
Combining Tru-gRNAs with high-specificity Cas9 variant SpCas9-HF1 (Kleinstiver 
et al. 9) or eSpCas9(1.1)10 offers the prospect for further minimizing off-target DSB 
formation (Figure S1C). Previous experiments have, however, indicated that such 
Tru-gRNA-containing RGNs display reduced on-target activities when compared 
to those bearing FL-gRNAs.9, 10 Results presented in Figure 1C extend these find-
ings to isogenic target sequences subjected to distinct epigenetic states. In addition, 
our data indicate that the compatibility between Tru-gRNAs and eSpCas9(1.1) is 
higher than that between Tru-gRNAs and SpCas9-HF1 in that, when compared to 
the former, the latter setting yielded lower gene knockout frequencies at each of the 
tested PAM-defined target sequences. Indeed, combining SpCas9-HF1 and Tru-gR-
NAs with spacers a single nucleotide shorter than 20-mer FL-gRNAs (i.e., g11.19 
and g12.19) sufficed to abrogate RGN activity in cells subjected to both Dox regi-
mens, but this was not so when applying the same Tru-gRNAs together with eSp-
Cas9(1.1) (Figure 1C, left graph). Additional gene editing experiments using a pan-
el of <19-mer Tru-gRNAs (i.e., g5.17, g10.17, g1.18 and g6.18) in HEK.EGFPTetO.KRAB 
cells treated and not treated with Dox confirmed the higher catalytic impairment of 
SpCas9-HF1:Tru-gRNA complexes over their eSpCas9(1.1):Tru-gRNA counterparts 
(Figure 1C, right graph).
Offset gRNA pairs addressing SpCas9 “nickases” to opposite DNA strands guar-
antee that DSBs are, for the most part, restricted to the bipartite target site after the 
local coordinated formation of SSBs (Figure S1D). Indeed, specificity gains between 
200-fold to >1,500-fold have been reported for this dual RGN nicking strategy.12 Gene 
editing experiments with two gRNAs (i.e., g2.20 and g3.21), whose target sequences 
partially overlap (Figure S2), were individually combined with wild-type SpCas9 
(controls) or mixed together with SpCas9D10A or with SpCas9H840A. These experiments 
validated HEK.EGFPTetO.KRAB cells as a readout system for assessing the impact of 
chromatin on dual RGN “nickases” (Figure 1D). Albeit dependent on two different 
gRNAs, dual RGN “nickases” display a higher theoretical coverage of the genomic 
landscape when compared to that of conventional RGNs and other dimeric pro-
grammable nucleases, such as zinc-finger nucleases.5 This stems from the fact that 
dual RGN “nickases” are compatible with a broad range of DNA spacing between 
the target sites of their individual members (i.e., about –4-bp to +100-bp), which, in 
turn, increases the chances for locating suitable PAMs. Hence, to exploit this feature, 
in subsequent gene editing experiments performed in HEK.EGFPTetO.KRAB cells, we 
focused on using sets of gRNA pairs (i.e. g8.20/g6.20, g8.20/g9.20, and g8.20/g7.20) 
with non-overlapping target sequences (Figure S2). Flow cytometric quantification 
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of EGFP− cells generated in HEK.EGFPTetO.KRAB cultures after NHEJ-mediated DSB 
repair revealed that dual RGN “nickases” were significantly impaired at heterochro-
matic target sites (Figure 1E). This was independent of the nicking SpCas9 mutant 
used and, therefore, independent of the type of single-stranded DNA overhangs 
generated (Figure 1E). Similar results were obtained after flow cytometric quanti-
fication of mCherry+ cells in HER.TLRTetO.KRAB cultures subjected to both Dox reg-
imens and exposed to different gRNA pairs (i.e., g2.20/gI-SceI and g2.21/gI-SceI) 
combined with each of the two nicking SpCas9 mutants (Figure 1F and Figure S4). 
Importantly, there were no significant Dox-dependent differences in the frequencies 
of mCherry+ cells in control, TetO−, HER.TLRKRAB cultures subjected to the same 
experimental conditions that had been applied to HER.TLRTetO.KRAB cultures. Taken 
together, these experiments show that, in contrast to RGNs containing Tru-gRNAs, 
dual RGN “nickases” are significantly more affected by heterochromatin than con-
ventional RGNs (Figure 1G). We speculate that, when heterochromatinized, the in-
tervening sequences separating the two opposite SSBs made by dual RGN “nickas-
es” might become more resistant to double helix denaturation when compared to 
their euchromatinized isogenic counterparts. Interestingly, of the two types of dual 
RGN “nickases,” those based on SpCas9D10A are the least hindered by heterochroma-
tin. SpCas9D10A cuts the DNA strand complementary to the gRNA, whereas SpCa-
s9H840A cleaves the non-complementary strand. Moreover, in contrast to SpCas9D10A, 
SpCas9H840A has 3′ to 5′ exonuclease activity.2 Whether these or other biochemical 
traits underlie the observed differential impact of heterochromatin on the activity of 
these dual RGN “nickases” will be worthy of further investigation.
The relatively small size of the SaCas9 coding sequence (3.3 Kb) permits its incor-
poration, together with regulatory elements and gRNA expression units, into viral 
vector particles with limited packaging capacity, such as those of commonly used 
adeno-associated viral vectors.3 In addition, SaCas9-based RGNs increase gene edit-
ing versatility by permitting orthogonal (epi)genetic manipulations and potentially 
offer a higher degree of target site specificity owing to their extended spacer and 
PAM sequences. Recently, a molecular evolution strategy led to the selection of a 
SaCas9 variant with an expanded targeting range, i.e., SaCas9KKH (PAM = NNNRRT 
instead of NNGRRT), further increasing the versatility of SaCas9-based RGNs.4 As 
of yet, the impact of chromatin on these new gene editing tools has not been studied. 
Therefore, we next carried out gene editing experiments in HEK.EGFPTetO.KRAB cells 
using SaCas9:gRNA and SaCas9KKH:gRNA complexes targeting three different EGFP 
sites embedded in euchromatin or heterochromatin (Figure 2A). As references, we 
also targeted each of these target sequences with prototypic SpCas9:gRNA complex-
es (Figure 2A). Results presented in Figures 2B and 2C reveal that the SaCas9 RGNs 
were clearly hindered by heterochromatin. In fact, in contrast to SpCas9 RGNs, at 
heterochromatin, SaCas9 RGNs yielded frequencies of EGFP knockout that were at 
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or only slightly above background levels.
Figure 2. Assessing the effect of alternative chromatin conformations on CRISPR/Cas9 nu-
cleases based on SaCas9 proteins (A) Target sequences of RGNs consisting of SaCas9:gR-
NA or SpCas9:gRNA complexes. The sequences complementary to the S. aureus and S. 
pyogenes gRNAs are indicated underneath the green and orange arrows, respectively. The 
sequences corresponding to the PAMs of S. aureus and S. pyogenes RGNs are highlighted 
by green and orange boxes, respectively. (B) Testing the effect of chromatin on RGNs har-
boring SaCas9, SaCas9KKH, or SpCas9. HEK.EGFPTetO.KRAB cells, incubated in the presence and 
absence of Dox, received the indicated nuclease-gRNA pairs. Targeted mutagenesis levels 
at euchromatic (+Dox) and heterochromatic (−Dox) target sequences were quantified by 
EGFP-directed flow cytometry. Error bars correspond to mean ± SD (n = 3 independent ex-
periments performed on different days). (C) Representative flow cytometry dot plots of HEK.
EGFPTetO.KRAB cells treated with the indicated experimental conditions.
We conclude that the higher-order chromatin environment is an important parame-
ter to take into consideration while selecting and designing the tools and strategies 
underlying precise genome editing based on high-specificity CRISPR/Cas9 nuclease 
complexes.
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Methods
Cells
The generation of the human embryonic kidney cell-derived line HEK.EGFPTetO.KRAB was de-
tailed elsewhere.1 These cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Thermofisher Scientific)  supplemented with 10% FBS and 10 mM MgCl2. The generation and 
characterization of the human embryonic retinoblast-derived lines HER.TLRTetO.KRAB and HER.
TLRKRAB were equally detailed elsewhere.1 These cells were maintained in DMEM containing 
10% FBS, 10 mM MgCl2 and 45 μg/ml hygromycin B (ThermoFisher Scientific). The cultures 
of the various tTR-KRAB-expressing reporter cells were kept at 37°C in an humidified-air 10% 
CO2 atmosphere.
Recombinant DNA
The previously described isogenic set of constructs AV62_pCAG.Cas9.rBGpA, AV64_pCAG.
SpCas9-HF1.rBGpA and AW01_pCAG.eSpCas9(1.1).rBGpA contain human codon-optimized 
ORFs coding for the Streptococcus pyogenes proteins SpCas9, SpCas9-HF1 and eSpCas9(1.1), 
respectively.1 The generation of the isogenic set of expression plasmids BA15_pU.CAG.Sa-
Cas9.rBGpA and BA16_pU.CAG.dCas9.rBGpA and BA19_pU.CAG.SaCas9KKH.rBGpA was 
performed by inserting into the multiple cloning site of C55_pU.CAG.hrGFP.rBGpA (Figure 
S6), DNA fragments containing human codon-optimized ORFs coding for the Staphylococcus 
aureus proteins SaCas9 3, catalytically inert (“dead”) dSaCas9 3 and SaCas9KKH 4, respective-
ly. The DNA inserts containing the SaCas9, dSaCas9 and SaCas9KKH ORFs were isolated from 
constructs pAAV.CMV.NLS.SaCas9.NLS.3xHA.bGHpA (Addgene plasmid #61592),  pAAV.
CMV.NLS.dSaCas9.NLS.3xHA.bGHpA (Addgene plasmid #61594) and MSP1830 (Addgene 
plasmid #70708), respectively. 
The plasmid hCas9_D10A,2 Addgene plasmid #41816, herein named AT42_pSpCas9D10A, ex-
presses the nicking SpCas9D10A variant whose nuclease RuvC-like domain is disrupted by the 
D10A mutation. The plasmid AT61_pSpCas9H840A (Figure S5) expresses the nicking SpCa-
s9H840A variant whose nuclease HNH domain is disabled by the H840A mutation. This expres-
sion plasmid was generated as follows. The hCas9 construct,2 Addgene plasmid #41815, was 
digested with BstXI (ThermoFisher Scientific) and BmgBI (New England Biolabs), after which 
the plasmid backbone was purified from an agarose gel by using the JetQuick Gel Extraction 
Spin Kit (Genomed) according to the manufacturer’s instructions. The H840A mutation was 
introduced by site-directed PCR mutagenesis using as template hCas9 together with the prim-
er pair and cycling conditions indicated in Supplementary Tables 1 and 2, respectively. The 
resulting amplicon was subsequently digested with BstXI and BmgBI, purified from agarose 
gel as aforementioned and ligated to the isolated plasmid backbone. The resulting construct 
AT61_pSpCas9H840A was verified by Sanger sequencing. Control constructs gRNA_Cloning 
Vector (Addgene plasmid #41824) and AM51_pUC.U6.gRNANT, herein dubbed pgEmpty and 
pgNT, express no gRNA and an irrelevant non-targeting gRNA. Where indicated, expression 
plasmids C55_pCAG.hrGFP.rBGpA (Figure S6) and AM37_pCMV.DsRedEx2.1.bGHpA (Fig-
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ure S7) were used as internal controls for determining recombinant DNA delivery efficiencies 
at 3 days post-transfection. 
The construct gRNA_GFP_T2, herein named AT44_pg8.20, was obtained from Addgene plas-
mid #41820.2 The Streptococcus pyogenes gRNA expressing plasmids generated in this study 
were made by ligating annealed oligonucleotide pairs into the BveI-digested acceptor con-
struct S07_pUC.U6.sgRNA.BveI-stuffer.1 The Staphylococcus aureus gRNA expressing plas-
mids generated in this study were made by ligating annealed oligonucleotide pairs into the 
Esp3I-digested acceptor construct BPK2660 4 (Addgene plasmid #70709). The oligonucleotides 
used to clone the various gRNA expression constructs are listed in Supplementary Table 3. 
Gene editing experiments
Gene editing experiments in HEK.EGFPTetO.KRAB, HER.TLRTetO.KRAB and HER.TLRKRAB cells, cul-
tured in the presence or the in absence of doxycycline (Dox), were essentially carried out as 
detailed elsewhere.1 In brief, HEK- and HER-based lines were exposed for 7 and 11 days, re-
spectively, to regular medium or to medium supplemented with Dox, after which they were 
seeded in wells of 24-well plates (Greiner Bio-One). The next day, the cells were transfected 
according to the schemes listed in Supplementary Tables 4-8. The transfections were initiated 
by adding, dropwise, a 1 mg/ml polyethyleneimine solution (PEI, Polysciences) to each of 
the plasmid mixtures diluted in 150 mM NaCl. Subsequently, the resulting 50-μl transfec-
tion mixtures were subjected to vigorous vortexing for 10 sec. The DNA-PEI complexes were 
then let to be formed for 15 min at room temperature and were subsequently directly added 
into the culture medium of the target cells. After 6-8 hours, the transfection medium was 
changed for regular culture medium. At 3 days post-transfection, the transfection efficiencies 
were measured by reporter-directed flow cytometry. Next, the cells were sub-cultured every 
3-4 days. In order to activate target transgene expression, the parallel cultures of HEK- and 
HER-based lines that had not been initially exposed to Dox receive the drug at 10 and 14 days 
post-transfection, respectively. Finally, reporter-directed flow cytometry was used to quantify 
the levels of gene editing in HEK- and HER-based lines after an additional period of 7 and 10 
days, respectively.
Flow cytometry
Flow cytometry analyses were done with the aid of a BD LSR II flow cytometer (BD Bioscienc-
es). The data were analysed by using the FlowJo 7.2.2 software (Tree Star). Non-transfected 
cells were used to set the gates for the levels of background fluorescence. A minimum of 
10,000 viable single cells were acquired per sample.
Statistical analysis
Data sets resulting from independent experiments carried out in different days were analysed 
for significance with GraphPad Prism 7 software by applying two-tailed Student’s t-tests with 
P < 0.05 considered significant.
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Abstract
Gene editing based on homology-directed repair (HDR) depends on do-nor DNA and sequence-specific programmable nucleases. However, in addition to inducing HDR involving the mending of chromosomal dou-
ble-stranded breaks (DSBs) with donor DNA templates, programmable nucle-
ases also yield gene disruptions by triggering the competing non-homologous 
end-joining (NHEJ) pathway. Hence, it is crucial to identify parameters underly-
ing the choice between these two DNA repair pathways in the context of HDR-
based gene editing. Here, we implemented quantitative cellular systems based 
on epigenetically regulated isogenic target sequences and donor DNA of viral, 
non-viral and synthetic origins, to investigate gene editing outcomes resulting 
from the interaction between different chromatin conformations and donor DNA 
structures. We demonstrate that the chromatin topology influences gene editing 
endpoints by shifting the balance between HDR and NHEJ events. In particular, 
HDR increases in relation to NHEJ when chromosomal target sequences acquire a 
heterochromatic state. Moreover, albeit varying in degree, this shift in the balance 
between HDR- and NHEJ-induced chromosomal changes (1.5- to 6.4-fold) takes 
place independently of the types of episomal donor DNA. Besides establishing 
a direct relationship between specific gene editing outcomes and epigenetically 
regulated higher-order chromatin “conformers”, these findings might guide the 
development of improved genome engineering procedures.
Introduction
Genome editing based on inducing targeted chromosomal double-stranded DNA 
breaks (DSBs) by programmable nucleases permits altering, in a precise manner, the 
genetic make-up of eukaryotic cells. 1, 2 Normally, homology-directed repair (HDR) 
is the DSB repair pathway that participates in the targeted addition of new genetic 
information. In this case, exogenous DNA templates sharing sequences identical to 
chromosomal acceptor sites serve as surrogate HDR substrates for repairing the un-
derlying sequence-specific DSBs. Ultimately, this co-option of HDR yields precise 
genetic alterations at predefined genomic sequences.1, 2
Despite its patent usefulness, HDR-based gene editing is limited by the fact that, 
in mammalian cells, DSBs are primarily repaired through competing non-homol-
ogous end-joining (NHEJ) pathways instead of through HDR.3, 4 Moreover, HDR is 
commonly restricted to the mitotic G2/S phases of the cell cycle, when allelic sister 
chromatid sequences become available, while NHEJ, involving simply end-to-end 
ligation of broken chromosomal termini, takes place throughout the various stag-
es of the cell cycle.3, 4 Critically, NHEJ-mediated DSB repair often leads to the in-
corporation of small insertions and deletions (indels) at the target site resulting in 
disruptive and potentially deleterious byproducts, e.g., chromosomal translocations 
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and/or allelic mutations. Hence, it is important to expand our knowledge about the 
parameters governing the choice between these two major DNA repair pathways 
which, together, determine the performance of HDR-based gene editing and genom-
ic DNA stability. 
Chromatin is formed in the nucleus of eukaryotic cells by a dynamic association 
between genomic DNA and various types of molecules, including, histones and 
non-histone proteins. The basic unit of chromatin, the nucleosome, consists of ~ 
147 bps of double helix wrapped around an octamer of the four core histones H3, 
H4, H2A and H2B.5 The transition from compact, or “closed”, heterochromatin to 
relaxed, or “open”, euchromatin is controlled through a large number of macro-
molecular complexes and their respective catalytic activities, which include meth-
ylation-demethylation, acetylation-deacetylation and phosphorylation-dephospho-
rylation.5 Recently, our laboratory and that of others reported that NHEJ-mediated 
repair of single DSBs induced by programmable nucleases can be modulated by 
distinct chromatin structures.6, 7 As of yet, however, the role played by such 3D struc-
tures on the performance of HDR-based gene editing has not been assessed. To ad-
dress this matter, here, we sought to specifically investigate whether distinct high-
er-order chromatin conformations control gene editing outcomes by changing the 
balance between HDR and NHEJ at single, site-specific, DSBs. For these experiments, 
we combined programmable RNA-guided nucleases (RGN) based on the type II 
clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 adaptive 
immune system from S. pyogenes,8 with donor HDR substrates of viral, non-viral and 
synthetic origins. In particular, as donors, we tested integrase-defective lentiviral 
vector genomes (IDLVs),9 conventional recombinant plasmids and chemically syn-
thesized single-stranded oligodeoxyribonucleotides (ODNs) with both polarities. 
RGNs are ribonucleoproteins formed by a complex between a fixed Cas9 protein 
and a flexible guide RNA (gRNA). Typically, the 5’-terminal 20 nucleotides of the 
gRNA (spacer) are tailored to hybridize to a chromosomal target sequence located 
next to a protospacer adjacent motif (PAM; NGG in the case of S. pyogenes Cas9). 
The PAM sequence signals the position for the initial protein-DNA binding medi-
ated through the PAM-interacting domain positioned on two lobes of Cas9.10 Next, 
complementarity between the spacer portion of the gRNA and PAM-adjoined DNA 
sequences triggers DSB formation by the coordinated catalytic activation of the nu-
clease domains of Cas9 (i.e. HNH and RuvC).8  
By using the aforementioned DNA, RNA and protein tools, we performed gene-ed-
iting experiments in quantitative live-cell readout systems based on human reporter 
cells containing chromosomal target sequences whose epigenetic statuses are con-
trolled by small molecule drug availability.6 We report that the proportions between 
gene editing endpoints resulting from the repair of site-specific DSBs by NHEJ and 
HDR differ in a chromatin structure-dependent manner with HDR increasing its 
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prominence in relation to NHEJ when target sequences transit from an euchromatic 
to an heterochromatic state.
Results
Gene editing experiments were carried out in HER.TLRTetO.KRAB and HEK.EGFP-
TetO.KRAB cells (Figure 1A). These human reporter cells express the E. coli tetracy-
cline trans-repressor (tTR) fused to a mammalian Krüppel-associated box domain 
(KRAB). The tTR and KRAB components are the DNA-binding and effector domains 
of the tTR-KRAB fusion product, respectively. KRAB-containing proteins belong to 
the largest family of zinc-finger repressors in tetrapod vertebrates whose generic 
role is to recruit chromatin remodeling co-repressors via their KRAB domains after 
binding to specific genomic sequences through their zinc-finger motifs.15 In particu-
lar, KRAB domains interact with KRAB-associated protein 1 (KAP-1) oligomers that 
form a scaffold for the binding of heterochromatin protein 1 (HP-1) isoforms (i.e. 
HP1α, HP1β and HP1γ), histone deacetylases (i.e. HDAC1 and HDAC2), the nu-
cleosome remodeling factor CHD3 and the SET-domain histone methyl-transferase 
SETDB1 that lead to the recruitment of additional HP1 molecules via tri-methyla-
tion of lysine 9 on histone H3 (H3K9me3).16 Ultimately, these large protein-DNA 
assemblies create heterochromatic regions in the genome.17 In HER.TLRTetO.KRAB and 
HEK.EGFPTetO.KRAB cells, in the absence of Dox, the tTR-KRAB fusion protein binds 
to its cognate TetO sequences and recruits via its KRAB repressor domain the en-
dogenous epigenetic silencing apparatus involving, amongst other chromatin re-
modeling factors, KAP-1 and HP-1 (Figure 1B). Conversely, in the presence of Dox, 
tTR-KRAB suffers a conformational change that releases it from the TetO sequences, 
resulting in the transition of associated sequences from a compacted heterochromat-
ic state (H3K9me3 high; H3-Ac low) into a relaxed euchromatic state (H3-Ac high; 
H3K9me3 low).6
We reasoned that the complementary gain-of-function and loss-of-function assays 
offered by HER.TLRTetO.KRAB and HEK.EGFPTet.KRAB cells should be particularly suit-
ed for assessing the impact of epigenetically regulated chromatin conformations on 
specific gene editing endpoints. This is so owing to the fact that these live-cell sys-
tems permit the simultaneous quantification of HDR and NHEJ events at isogenic 
target sequences located either in euchromatin or heterochromatin depending on 
the presence or absence of Dox, respectively (Figure 1B). Indeed, in these cells, Dox 
availability regulates the tTR-KRAB-mediated recruitment of the aforementioned 
endogenous chromatin remodeling complexes to TetO sequences associated with 
each of the reporter alleles, i.e., TLRTetO and EGFPTetO (Figure 1A).
HDR-based gene editing experiments were started by transfecting HER.TLRTetO.KRAB 
cells, cultured in the absence or in the presence of Dox, with expression plasmids en-
coding the RGN complex Cas9:gTLR.1 (Supplementary Figure S1). The target site 
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of Cas9:gTLR.1 is located upstream of a nonsense mutation within the TLRTetO con-
struct (Figure 1A and Supplementary Figure S2) and is flanked by sequences “ho-
mologous” to those present in the EGFP-repairing donor template EGFPtrunc.12 This 
HDR substrate was delivered by transducing HER.TLRTetO.KRAB  cells with different 
amounts of the integrase-defective lentiviral vector IDLVd together with constructs 
expressing the RGN complex Cas9:gTLR.1 (Figure 1B). Negative controls were pro-
vided by HER.TLRTetO.KRAB cells that were neither transfected with expression plas-
mids nor transduced with IDLVd particles (Mock) and by HER.TLRTetO.KRAB cells that 
were exposed to an irrelevant, non-targeting, gRNA (gNT) together with Cas9 and 
IDLVd. After the action of the RGN complexes had taken place, all HER.TLRTetO.KRAB 
cultures were incubated in the presence of Dox for allowing transgene expression 
and quantification of HDR and NHEJ events by EGFP- and mCherry-directed flow 
cytometry respectively (Figure 1A and Supplementary Figure S1).
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Figure 1. Experimental systems for tracking gene editing outcomes at isogenic target se-
quences with alternative higher-order epigenetic states. (A) Modus operandi of the cellular 
systems for tracking gene-editing endpoints at heterochromatin versus euchromatin. Upper 
panel, the TetO-flanked TLRTetO construct in tTR-KRAB-expressing HER.TLRTetO.KRAB cells has 
an EGFP ORF interrupted by heterologous sequences and a stop codon located upstream of 
a T2A sequence and an out-of-frame mCherry reporter. HDR is scored by measuring EGFP+ 
cells resulting from the repair of site-specific DSBs by HR events between episomal donor 
templates (EGFPtrunc) and heterochromatic (-Dox) or euchromatic (+Dox) chromosomal 
DNA. This genetic exchange results in the substitution of the heterologous and stop codon 
DNA by an in-frame EGFP sequence. Concomitantly, NHEJ is scored by measuring mCher-
ry+ cells resulting from indels placing the mCherry in-frame. Lower pane, the TetO-flanked 
EGFP construct (EGFPTetO) in tTR-KRAB-expressing HEK.EGFPTetO.KRAB cells is functional. HDR is 
tracked by measuring the frequencies of blue light-emitting cells resulting from the conver-
sion of the EGFP fluorochrome to that of EBFP. Simultaneously, NHEJ is scored by measuring 
EGFP- cells resulting from indels placing the EGFP sequence out-of-frame. (B) Generic ex-
perimental designs. The reporter HER.TLRTetO.KRAB and HEK.EGFPTetO.KRAB cells, cultured in the 
absence or in the presence of Dox, are exposed to RGNs together with different donor DNA 
templates. Without Dox, tTR-KRAB binds to TetO and induces heterochromatin formation 
through the recruitment of, amongst others, KAP-1 and HP-1. With Dox, tTR-KRAB set free 
TetO leading the target sequences to acquire an euchromatic state. After the completion 
of the gene editing processes, Dox is added to the different cultures in order to determine 
the frequencies of HDR and NHEJ events at heterochromatic versus euchromatic target se-
quences by dual-color flow cytometry.
The results obtained from this experiment revealed that the frequencies of DSB-trig-
gered NHEJ at euchromatic target sequences (+Dox) were substantially higher than 
those measured at their heterochromatic (-Dox) counterparts as assessed by mCher-
ry-directed flow cytometry (Figures 2A and 2B). This outcome is in agreement with 
that of our previous study involving the exclusive delivery of RGNs into HER.TL-
RTetO.KRAB cells.6 In particular, RGN-induced DSBs are preferentially formed at eu-
chromatin over heterochromatin,6 which, in turn, correlates with the preferential 
binding of RGNs harboring catalytically inert (“dead”) Cas9 proteins to euchromatic 
over heterochromatic regions across the genome.18-20 Interestingly, despite of the in-
itial higher accessibility of gene editing tools to euchromatic over heterochromat-
ic genomic DNA, there were no corresponding increases in HDR levels in the for-
mer, Dox-treated, cells (Figures 2A and 2B). As a result, the ratios between NHEJ 
and HDR events at compact heterochromatin were substantially lower than those 
measured at relaxed euchromatin (4.6- to 5.3-fold), regardless of the amounts of ex-
ogenous HDR templates available for recombination (Figure 2C, top graph). This 
outcome translated in a relative increase in HDR (+) and a decrease in NHEJ (-) at 
heterochromatin (Figure 2C, bottom graph). The use of the alternative RGN complex 
Cas9:gTLR.2 (Figure 3A and Supplementary Figure S3) and a different transfection 
protocol (Figures 3B and 3C), led to similar NHEJ/HDR ratios and variations in the 
frequencies of HDR and NHEJ (compare Figure 3D with Figure 2C, respectively).
Next, we sought to determine RGN-induced gene editing endpoints at isogenic tar-
get sequences with distinct higher-order chromatin conformations after delivering 
donor DNA in the context of covalently closed double-stranded plasmids. In these 
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experiments, we deployed the lentiviral DNA construct Plasmidd,12 which had been 
utilized for assembling IDLVd particles. Again, these gene editing experiments in-
volved the use of two different transfection protocols for introducing donor Plas-
midd mixed with constructs expressing either Cas9:gTLR.1 or Cas9:gTLR.2 complex-
es into HER.TLRTetO.KRAB cells treated or not treated with Dox (Figures 3E-G). The 
resulting gene editing outcomes (Figures 3E-H) were similar to those obtained after 
Figure 2. Gene editing endpoints at euchromatin versus heterochromatin after IDLV donor 
DNA delivery. (A) Dual-color flow cytometric quantification of HDR and NHEJ events in HER.
TLRTetO.KRAB cells. HER.TLRTetO.KRAB cells were exposed to Cas9:gTLR.1 together with the indicat-
ed multiplicities of infection (MOI) of IDLVd. Negative controls consisted of mock-treated cul-
tures and of cultures exposed to a non-targeting gRNA (gNT), Cas9 and IDLVd at an MOI of 
8 vector particles per cell (VP/cell). The various experimental conditions were tested in HER.
TLRTetO.KRAB reporter cells incubated in the absence (-) or in the presence (+) of doxycycline 
(Dox). The frequencies of HDR and NHEJ events in the various target cell populations were 
determined by measuring EGFP+ and mCherry+ cells, respectively. (B) Dot plots corre-
sponding to HER.TLRTetO.KRAB cells transduced with different doses of IDLVd particles and sub-
jected to the indicated Dox regimens. (C) Relative participation of HDR and NHEJ pathways 
during IDLV-mediated repair of DSBs occurring at heterochromatin versus euchromatin. In 
the top graph, data of panel A are presented as the ratios between the frequencies of NHEJ 
and HDR in HER.TLRTetO.KRAB cells not treated and treated with Dox (top graph). In the bot-
tom graph, data of panel A are depicted as the variation in the proportion of HDR and NHEJ 
events at heterochromatin versus euchromatin.
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Figure 3. Comparing gene editing outcomes at euchromatin versus heterochromatin af-
ter viral and plasmid vector delivery of donor DNA. (A and B) IDLVd-based gene editing. 
Dual-color flow cytometric measurements of HDR and NHEJ frequencies in HER.TLRTetO.KRAB 
cells subjected to the indicated experimental conditions and treated (+) or not treated (-) 
with Dox. Two different transfection protocols (A and B) were used to introduce the DNA 
constructs into target cells. IDLVd particles were applied at an MOI of 8 VP/cell. (C) Rep-
resentative dot plots corresponding to HER.TLRTetO.KRAB cells exposed to IDLVd together with 
Cas9:gNT or Cas9:gTLR.1 complexes. (D) Comparative engagement of HDR and NHEJ path-
ways during IDLV-mediated repair of DSBs made at heterochromatin versus euchromatin. 
Top graph, data of panels A and B presented as the ratios between the rates of NHEJ and 
HDR in HER.TLRTetO.KRAB cells either incubated or not incubated with Dox. Bottom graph, data 
of panels A and B depicted as the variation in the fraction of HDR and NHEJ events at het-
erochromatin versus euchromatin. (E and F) Plasmidd-based gene editing. Dual-color flow 
cytometric quantification of HDR and NHEJ frequencies in HER.TLRTetO.KRAB cells. HER.TLRTetO.
KRAB cells incubated (+) or not incubated (-) with Dox, were either mock-transfected or were 
transfected with Plasmidd mixed with constructs encoding the indicated RGN complexes. Two 
different transfection protocols (A and B) were used to deliver the DNA constructs into tar-
get cells. (G) Representative dot plots corresponding to HER.TLRTetO.KRAB cells transfected with 
Plasmidd mixed with expression constructs coding for Cas9:gNT or Cas9:TLR.1 complexes. 
(H) Relative engagement of HDR and NHEJ pathways during plasmid-mediated repair of 
DSBs created at heterochromatin versus euchromatin. Top graph, results of panels E and F 
depicted as ratios between the frequencies of NHEJ and HDR in HER.TLRTetO.KRAB cells exposed 
or not exposed to Dox. Bottom graph, data of panels E and F shown as the variation in HDR 
and NHEJ events at heterochromatin versus euchromatin. Bars in graphs A, B, E and F cor-
respond to mean ± s.d. of the indicated number (n) of independent experiments (biological 
replicates done in different days).
IDLVd transduction of HER.TLRTetO.KRAB cells (Figure 2 and Figures 3A-D). In par-
ticular, in comparison with euchromatin, at heterochromatin, the balance between 
NHEJ and HDR shifts towards the latter pathway causing target cell populations to 
acquire a more even distribution between HDR- and NHEJ-derived genetic modifi-
cations (Figure 3H).
To serve as additional controls, gene editing experiments were also performed in 
tTR-KRAB-expressing HER.TLRKRAB cells whose target sequences are not under con-
ditional KRAB-mediated epigenetic regulation due to their lack of TetO cis-acting 
elements necessary for tTR-KRAB binding (Figure 4A). Importantly, regardless of 
the Dox regiment, neither the HDR levels nor the NHEJ levels changed in HER.
TLRKRAB cells, independently of whether the donor DNA was introduced into target 
cell nuclei in the context of linear IDLVd genomes (Figures 4B and 4C) or covalently 
closed Plasmidd molecules (Figures 4D and 4E). Hence, in contrast with gene editing 
experiments in HER.TLRTetO.KRAB cells, in control HER.TLRKRAB cells, there were no 
substantial Dox-dependent variations in the proportions between HDR and NHEJ 
events for both types of donor DNA templates used (Figure 4F).
Next, we performed gene-editing experiments in HEK.EGFPTetO.KRAB cells. In this in-
dependent experimental system, HDR can be promptly tracked by measuring cells 
in which the EGFP fluorochrome is converted into that of EBFP, while NHEJ can be 
monitored through quantifying cells with indel-derived EGFP knockouts (Figures 
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Figure 4. Gene editing endpoints in control HER.TLRKRAB cells exposed or not exposed to 
Dox. (A) Schematics of target DNA in HER.TLRKRAB cells. The tTR-KRAB-expressing HER.TL-
RKRAB cells have a Dox-insensitive TLR construct due to its lack of cis-acting TetO elements. 
(B) Dual-color flow cytometric quantification of HDR and NHEJ events in HER.TLRKRAB cells. 
HER.TLRKRAB cells, treated (+) or not treated (-) with Dox, were exposed to the indicated 
experimental conditions. IDLVd particles were applied at an MOI of 8 VP/cell. (C) Repre-
sentative dot plots corresponding to HER.TLRKRAB cells exposed to IDLVd particles together 
with Cas9:gNT or Cas9:TLR.1 complexes. (D) Dual-color flow cytometric quantification of 
HDR and NHEJ frequencies in HER.TLRKRAB cells. HER.TLRKRAB cells, incubated (+) or not in-
cubated (-) with Dox, were mock transfected or were transfected with plasmid mixed with 
constructs encoding the indicated RGN complexes. Two different transfection protocols (A 
and B) were used to deliver the DNA constructs into target cells. (E) Dot plots corresponding 
to HER.TLRKRAB cells transfected with Plasmidd mixed with expression constructs coding for 
Cas9:gNT or Cas9:TLR.1 complexes. (F) Comparative engagement of HDR and NHEJ path-
ways at site-specific DSBs created at heterochromatin versus euchromatin. Top graph, data 
of panels B and D presented as ratios between the rates of NHEJ and HDR in HER.TLRKRAB 
cells not incubated or incubated in the presence of Dox. Bottom graph, data of panels B and 
D shown as the variation in the fraction of HDR and NHEJ events at heterochromatin versus 
euchromatin.
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5A and 5B). In these experiments, HEK.EGFPTetO.KRAB cells, cultured in the absence or 
in the presence of Dox, were transfected with plasmid pTHG.Donor together with 
constructs encoding the Cas9:gEGFP complex targeting the EGFP fluorochrome 
coding sequence (Figure 5A). These data were in agreement with those obtained in 
HER.TLRTetO.KRAB cells (Figures 2 and 3) in that, notwithstanding the higher frequen-
cies of site-specific DSBs at euchromatin over those measured at heterochromatin, 
HDR levels were comparable at both chromatin states (Figure 5C). As a result, the 
NHEJ/HDR ratios at heterochromatin were consistently lower than those measured 
at euchromatin (Figure 5D, top graph), yielding a relative increase in HDR and a 
simultaneous decrease in NHEJ at the former chromatin state (Figure 5D, bottom 
graph).
Figure 5. Gene editing outcomes at euchromatin versus heterochromatin after plasmid 
donor delivery into HEK.EGFPTetO.KRAB cells. (A) Gene editing assay based on EGFP-to-EBFP 
fluorochrome conversion. Top panel, nucleic acid and amino acid sequences corresponding 
to the fluorochromes of GFP, EGFP and BFP (boxed). Bottom panel, nucleotide and amino 
acid sequences of the reporter target allele before and after its editing through the delivery 
of pTHG.Donor and expression constructs encoding the RGN complex Cas9:gRNAEGFP.  Hori-
zontal orange arrow, target site of Cas9:gRNAEGFP; vertical open arrowhead, position of the 
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DSB induced by Cas9:gRNAEGFP. (B) Schematics of the experimental design applied to HEK.
EGFPTetO.KRAB cells. (C) Flow cytometric quantification of HDR and NHEJ frequencies. HEK.
EGFPTetO.KRAB cells, incubated (+) or not incubated (-) with Dox, were exposed to pTHG.Donor 
and gRNAEGFP-containing RGNs. The frequencies of HDR and NHEJ events in the transfected 
cell populations were determined by measuring EBFP+ and EGFP- cells, respectively. A min-
imum of forty thousand events, each corresponding to a single viable cell, were acquired 
per sample. (D) Relative participation of HDR and NHEJ pathways during plasmid-mediated 
repair of DSBs made at heterochromatin versus euchromatin. Top graph, data of panel C 
presented as the ratios between the frequencies of NHEJ and HDR in HEK.EGFPTetO.KRAB cells 
treated and not treated with Dox. Bottom graph, data of panel C depicted as the variation in 
the proportion of HDR and NHEJ events at heterochromatin versus euchromatin. 
Finally, to complement the previous experiments testing linear and covalently 
closed double-stranded donors in the form of IDLV genomes and recombinant plas-
mids, respectively, we sought to assess ODN-based gene editing at euchromatin 
versus heterochromatin. For these experiments, we selected a single-stranded ODN 
pair corresponding to the sense and antisense polarities of the target polynucleotide 
chains of Cas9:gEGFP (i.e. ODN.s and ODN.as, respectively). Previous research has 
demonstrated that RGNs can display a long residence time on target DNA (~ 6 h) 
and that, after DNA cutting, the strand upstream of the PAM (non-target strand) is 
released from the Cas9-gRNA-DNA ternary complex forming a 3’-ended DNA flap 
(Figure 6A).21 This insight permitted the design of optimized single-stranded ODN 
donors which are complementary to the released strand. Indeed, when compared to 
double-stranded and single-stranded ODNs that cannot anneal to RGN-generated 
flaps, ODNs complementary to the released strand induced ~ 4- and ~ 2-fold higher 
frequencies of HDR in human cells, respectively.21 Results from an initial experiment 
in HEK.EGFPTetO.KRAB cells exposed to Cas9:gEGFP together with ODN.s or with 
ODN.as were consistent with the aforementioned data in that the ODN.as yielded 
~2-fold higher frequencies of HDR than the ODN.s (Figure 6B). Interestingly, ex-
panding these ODN transfection experiments to HEK.EGFPTetO.KRAB cells treated or 
not treated with Dox revealed that, at both euchromatin and heterochromatin, the 
flap-hybridizing donor ODN.as consistently yielded a more even distribution be-
tween HDR and NHEJ events when compared to its ODN.s counterpart (Figures 6C 
and 6D). These data suggest that base pairing assists in the engagement of flap-an-
nealing ODNs with the RGN-cleaved target site dampening the contribution of the 
NHEJ pathway to the repair of the underlying site-specific DSBs. Importantly, when 
comparing ODN-based gene editing endpoints at euchromatin versus heterocho-
matin, these and follow-up ODN.as dose-response experiments were in agreement 
with the previous experiments using IDLV and plasmid donor DNA (Figure 6E). In 
particular, the frequencies of HDR and NHEJ were more comparable at heterochro-
matin than at euchromatin independently of ODN.as concentrations (Figures 6F, 
top graph). As a result, when target DNA sequences transit from an euchromatic to 
an heterochromatic state, there is a shift towards an increase in the preponderance 
of HDR over NHEJ (Figrue 6F, bottom graph).
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Figure 6. Gene editing endpoints at euchromatin versus heterochromatin after ODN donor 
delivery in HEK.EGFPTetO.KRAB cells. (A) Schematics of ODN design and target site before and 
after RGN engagement. The RGN complex Cas9:gEGFP is presumed to generate a 3’-ended 
DNA flap complementary and non-complementary to ODN.as and ODN.s, respectively. HDR-
based gene editing with ODN.s and ODN.as donors should result in EGFP-to-EBFP conver-
sion. Open arrowheads, position of the DSB induced by Cas9:gEGFP. Orange triplet, PAM. 
(B) Probing HDR-based gene editing with sense and antisense ODNs. HEK.EGFPTetO.KRAB cells 
were transfected with ODN.s or with ODN.as each mixed with expression plasmids coding 
for either non-cutting Cas9:gNT or cutting Cas9:gEGFP complexes. HDR and NHEJ quanti-
fication in HEK.EGFPTetO.KRAB cells was assessed by EBFP- and EGFP-directed flow cytometry, 
respectively. (C) Testing the impact of chromatin structure on HDR-based gene editing with 
sense and antisense ODNs. HEK.EGFPTetO.KRAB cells, incubated (+) or not incubated (-) with 
Dox, were exposed to the indicated experimental conditions. The frequencies of HDR and 
NHEJ were assessed by dual-color flow cytometry. (D) Relative participation of HDR and 
NHEJ pathways during the repair of euchromatic versus heterochromatic DSBs with ODNs 
with different polarities. Data of panel C displayed as the ratios between the frequencies of 
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NHEJ and HDR in HEK.EGFPTetO.KRAB cells treated and not treated with Dox. (E) ODN-based 
gene editing. Dual-color flow cytometric quantification of HDR and NHEJ frequencies in HEK.
EGFPTetO.KRAB cells. HER.TLRTetO.KRAB cells incubated (+) or not incubated (-) with Dox, were ex-
posed to the indicated experimental conditions. Bars correspond to mean ± s.d. of the indi-
cated number (n) of independent experiments (biological replicates done in different days). 
(F) Relative participation of HDR and NHEJ pathways during ODN-mediated repair of DSBs 
taking place at heterochromatin versus euchromatin. Top graph, results of panel E shown as 
the ratios between the frequencies of NHEJ and HDR in HEK.EGFPTetO.KRAB cells exposed or not 
exposed to Dox. Bottom graph, data of panel E presented as the variation in HDR and NHEJ 
events at heterochromatin versus euchromatin.
Taken our data together, we conclude that site-specific DSBs generated within eu-
chromatin are mostly repaired through mutagenic NHEJ in detriment of error-free 
HDR. However, if the site-specific DSBs are made within heterochromatin instead, 
there is a more balanced participation of both cellular machineries in the repair of 
site-specific DNA lesions (Figure 7). Albeit varying in degree, this chromatin struc-
ture-dependent shift in the relationship between NHEJ and HDR takes place re-
gardless of whether the donor DNA is presented in the context of IDLV genomes, 
recombinant plasmids or single-stranded ODNs, which together, makeup the most 
commonly used sources of exogenous genetic information. 
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Figure 7. Summarizing illustration on the role of the chromatin structure on gene edit-
ing outcomes. The thickness of the curved arrows represents the relative contribution of 
homology-directed repair (HDR) and non-homologous end-joining (NHEJ) to gene editing 
endpoints at euchromatin versus heterochromatin.
Discussion
HDR-based genome editing is crucial for numerous research applications, including 
modelling, screening or correcting genotypes underlying human disorders in stem 
and/or progenitor cells. Crucially, accurate HDR takes place much less frequently 
than mutagenic NHEJ.3, 4 Thus, identifying the biological parameters governing this 
strong DNA repair bias has both scientific and practical relevance. In this study, we 
have investigated the outcome of the interaction between the molecular tools neces-
sary for HDR-based gene editing and the chromatin structure of target sequences. 
In particular, we assessed RGN-induced gene editing endpoints established after 
the engagement of donors of viral, non-viral and synthetic origins with isogenic tar-
get sequences located either in euchromatin or heterochromatin. We found that the 
relative proportions of gene editing endpoints resulting from mutagenic NHEJ and 
precise HDR events depend to a significant degree on the higher-order chromatin 
conformation of target sequences with a shift occurring towards HDR events at het-
erochromatin (Figure 7). This bias can vary in its extent, such as when using ssODNs 
with different polarities (~2-fold; Figures 6C and 6D), but takes place independently 
of the type of episomal donor DNA utilized.
These findings suggest that HDR-based gene editing can be impacted by the epig-
enomic landscape of specific cell types as well as by the dynamic and epigenetically 
regulated chromatin changes underlying organismal development and cellular dif-
ferentiation stages. Indeed, our experimental results support the hypothesis that the 
chromatin environment contributes to the well-known differential susceptibility of 
genomic sequences to gene editing interventions. Hence, the chromatin context of 
the target sequence should be taken into account whenever considering applying 
HDR-based gene editing procedures. 
There is a paucity of knowledge about the repair mechanisms of DSBs located with-
in different chromatin contexts in mammalian cells. In recent years, however, the 
classical view that heterochromatin simply poses a barrier to the DNA damage re-
sponse (DDR) is changing into one in which heterochromatin and heterochroma-
tin-associated proteins are active participants in it.22 For instance, SENP7 interacts 
with KAP-1 via HP1α resulting in the deSUMOylation of KAP-1.23 The removal of 
this post-translational modification from KAP-1 promotes the transient release of 
the co-repressors CHD3 and SETDB1 from chromatin, which in turn, creates a cel-
lular milieu favorable for HDR-mediated DSB repair.23 A similar milieu is conferred 
by the MRN-dependent recruitment of the histone acetyltransferase Trrap-Tip60 to 
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heterochromatic DSBs.24 It has also been shown that HP1α is transiently mobilized 
to both euchromatic and heterochromatic DSBs via an interaction with p150CAF-1, 
resulting in its higher accumulation at the latter lesions.25 Interestingly, in HP1α 
knockdown cells, in contrast to the buildup of the NHEJ factor XRCC4 at laser-in-
duced DNA lesions, there is a markedly reduction of the HDR factors RAD51 and 
BRCA1 at these lesions.25 Subsequent experiments, based on exposing cells to the 
restriction enzyme AsiSI, provided additional support for the participation of het-
erochromatin-resident HP1 proteins in associating BRCA1 with DSBs and facilitat-
ing HDR.26 
Recent experiments are also starting to shed light on the relationship between dif-
ferent cell cycle stages and DNA repair pathways at heterochromatic domains in 
mammalian cells. Study showed that DSBs created within pericentric heterochroma-
tin during G1 remain stationary and are repaired through NHEJ, whilst in S or G2, 
these DSBs relocate to the periphery of the heterochromatic domain and, once there, 
become substrates for RAD51/BRCA2-dependent HDR .27 This heterochromatic DSB 
migration to euchromatic regions might favor the finalization of proper HDR with 
sister chromatid or homologous chromosome sequences in detriment of ectopic 
HDR with repetitive DNA, common in heterochromatic regions. Remarkably, DSBs 
located within centromeric heterochromatin, recruit not only the NHEJ marker pro-
tein Ku80 but also the HDR factors RPA and RAD51 throughout the cell cycle with 
an enhancement observed during G2.27   
Collectively, these data provide compelling evidence for an active role of HDR dur-
ing heterochromatic DSB repair involving an intricate interplay between histone 
marks (e.g. H3K9me3), chromatin remodeling factors (e.g. HP1 isoforms, CHD3, Tr-
rap-Tip60 and KAP-1) and DNA repair proteins (e.g. BRCA1, RPA and RAD51). It 
is worth mentioning, however, that for the most part, these experiments have relied 
on generating supra-physiological amounts of different types of DSBs throughout 
the genome either by ionizing radiation, laser micro-irradiation or restriction en-
zyme exposure. Moreover, the relative proportions between HDR and NHEJ events 
at sequences with distinct chromatin states in individual test cell populations were 
not investigated. Finally, although certain DDR processes seem to be specific for 
repairing heterochromatic DSBs, e.g., ATM-mediated phosphorylation of KAP-1, 28 
some others appear to lack this specificity, e.g., p150CAF-1-mediated recruitment of 
HP1α to DSBs.25 It should thus be very instructive investigating which DDR com-
ponents and mechanisms are specific to heterochromatin, euchromatin or shared by 
both compartments.
Concluding, in the present study, we have implemented cellular assays based on 
epigenetically regulated genetic reporters, donor DNA templates and RGNs for the 
simultaneous quantification of HDR and NHEJ events at single target sequences 
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subjected to distinct chromatin conformations. The resulting data expand the afore-
mentioned findings by providing direct experimental evidence for a role of the high-
er-order chromatin structure on the differential regulation of the two major DNA 
repair pathways in mammalian cells. The recruitment of DDR factors and DNA 
recombination substrates into a well-defined genetic and epigenetic environment 
offered by these live-cell tracking systems should aid detailed investigations into the 
mechanisms of DDR under different chromatin contexts as well as their interplay 
with other cellular mechanisms and DNA metabolic processes such as replication. 
Finally, as illustrated in the current study through experiments testing viral, non-vi-
ral and synthetic donors, this epigenetically-regulated experimental systems should 
also serve for assessing in cellula the impact of chromatin on novel gene editing 
protocols involving, amongst others, donor DNA substrates from different origins 
or with different structures and compositions, NHEJ-inhibiting reagents,29, 30 and un-
exploited programmable nuclease systems.31, 32
Supplementary Figure S1. Schematic representation of the experimental settings used in 
the current study. The tTR-KRAB-expressing cells HER.TLRTetO.KRAB (A) and HEK.EGFPTetO.KRAB 
(B) contain the Dox-regulated TLRTetO 9 and EGFPTetO 33 constructs, respectively. These report-
er cells, containing target sequences in a heterochromatic (-Dox) or euchromatic (+Dox) 
state, are transiently transfected with different combinations of gene editing tools consisting 
of RGNs and donor DNA templates. After the generation of site-specific DSBs and the en-
suing modification of target DNA sequences in cells subjected to both experimental settings 
(i.e. –Dox and +Dox), target gene expression is activated to quantifying by flow cytometry 
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Supplementary Figure S2. Target sites of RGN complexes in the TLR construct. The target 
sequences for the RGN complexes Cas9:gTLR.1 and Cas9:gTLR.2 are indicated by horizontal 
lines linked to open boxes (PAM elements). The positions of the DSBs generated by each 
RGN are marked (vertical open arrowheads). STOP, nonsense codon located within the TLR 
ORF.
Supplementary Table S1. Oligonucleotide pairs to generate the gRNA expression 
constructs expressing gTLR.1, gTLR.2, gNT and gEGFP
Plasmids Oligonucleotide pairs (5’- 3’)
Z42_pgTLR.1
5’-ACCGGTGAGCTCTTATTTGCGTA-3’
5’-AAACTACGCAAATAAGAGCTCAC-3’
Z44_pTLR.2
5’-ACCGGGATAACAGGGTAATGTCG-3
5’-AAACCGACATTACCCTGTTATCC-3’
AM51_pgNT
5’-ACCGGTGAGCTCTTATTTGCGTAGCTAGCTGAC-3
5’-AAACGTCAGCTAGCTACGCAAATAAGAGCTCAC-3’
AX03_pgEGFP
5’-ACCGCTCGTGACCACCCTGACCTA-3’
5’-AAACTAGGTCAGGGTGGTCACGAG-3’
Supplementary Table S2. Experimental scheme corresponding to Figure 2 (Proto-
col A)
DONOR:
IDLVd
3.25 ×105 HER.TLRTetO.KRAB cells per well of 24-well plates (500 µl 
medium per well with or without Dox)
PEI (1mg/ml) 5.8 µl per well; Ratio DNA / PEI equivalents = 6
Reagents Cas9 gNT (Ctrl) gTLR.1 Total
(ng)
Construct length
(bp)
9551 3056 3046
DNA per well
(ng)
1327 423 1750
1327 423 1750
1327 1750
Note 1: One day after transfecting plasmids expressing Cas9 and gTLR.1, IDLVd particles were added 
at an MOI of 4, 8, 12 and 16 VP/cell; Note 2: One day after transfecting plasmids expressing Cas9 and 
gNT, IDLVd particles were added at an MOIs of 8 VP/cell.
the frequencies of gene editing events resulting from the engagement of HDR and NHEJ 
pathways. The tTR-KRAB-expressing HER.TLRKRAB reporter cells (C) have the Dox-insensitive 
TLR construct 11 and were used as an isogenic control cellular system.
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Supplementary Table S3. Experimental scheme corresponding to Figure 3A (Pro-
tocol A) 
DONOR:
IDLVd
3.25 ×105 HER.TLRTetO.KRAB cells per well of 24-well plates (500 µl medium 
per well with or without Dox)
PEI (1mg/ml) 5.8 µl per well; Ratio DNA / PEI equivalents = 6
Reagents Cas9 gNT  (Ctrl) gTLR.1 gTLR.2
Total
(ng)
Construct length
(bp)
9551 3056 3046 3046
DNA per well
(ng)
1327 423 1750
1327 423 1750
1327 423 1750
Note: One day after transfecting the indicated plasmids, IDLVd particles were added at an MOI of 8 
VP/cell.
Supplementary Table S4. Experimental scheme corresponding to Figure 3B (Pro-
tocol B)
DONOR:
IDLVd
3.25 ×105 HER.TLRTetO.KRAB cells per well of 24-well plates (500 µl medium 
per well with or without Dox)
PEI (1mg/ml) 9.6 µl per well; Ratio DNA / PEI equivalents = 10
Reagents Cas9 gNT (Ctrl) gTLR.1 Total
(ng)
Construct length
(bp)
9551 3056 3046
DNA per well
(ng)
1327 423 1750
1327 423 1750
1327 1750
Note: One day after transfection of the indicated plasmids, IDLVd particles were added at an MOI of 
8 VP/cell.
Supplementary Table S5. Experimental scheme corresponding to Figure 3E (Pro-
tocol A)
DONOR:
Plasmidd
3.25 ×105 HER.TLRTetO.KRAB  cells per well of 24-well plates (500 µl 
medium per well with or without Dox)
PEI (1mg/ml)5.8 µl per well; Ratio DNA / PEI equivalents = 6
Reagents Cas9 gNT (Ctrl) gTLR.1 gTLR. Plasmid
d
Total
(ng)Construct length
(bp)
9551 3056 3046 3046 6194
DNA per well
(ng)
890 284 577 1751
890 284 577 1751
890 284 577 1751
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Supplementary Table S6. Experimental scheme corresponding to Figure 3F (Pro-
tocol B)
DONOR:
Plasmidd
3.25 ×105 HER.TLRTetO.KRAB  cells per well of 24-well plates (500 µl medium 
per well with or without Dox)
PEI (1mg/ml) 9.6 µl per well; Ratio DNA / PEI equivalents = 10
Reagents Cas9 gNT (Ctrl) gTLR.1 gTLR.2 Plasmidd Total
(ng)Construct length (bp) 9551 3056 3046 3046 6194
DNA per well
(ng)
890 284 577 1751
890 284 577 1751
890 284 577 1751
Supplementary Table S7. Experimental scheme corresponding to Figure 5
DONOR:
pTHG.Donor
(Exp.1)
2.0 ×105 HEK.EGFPTetO.KRAB  cells per well of 24-well plates (500 µl medium per 
well with or without Dox)
PEI (1mg/ml) 6.2 µl per well; Ratio DNA / PEI equivalents = 9
Reagents eCas9 gEGFP gNT (Ctrl) pTHG.Donor Total
(ng)Construct length (bp) 9360 3046 3056 3561
DNA per well
(ng)
733 238 279 1250
733 238 279 1250
DONOR:
pTHG.Donor
(Exp.2)
2.0 ×105 HEK.EGFPTetO.KRAB  cells per well of 24-well plates (500 µl medium per 
well with or without Dox)
PEI (1mg/ml) 6.2 µl per well; Ratio DNA / PEI equivalents = 9
Reagents eCas9.2 gEGFP gNT (Ctrl) pTHG.Donor Total
(ng)Construct length (bp) 9403 3046 3056 3561
DNA per well
(ng)
733 238 279 1250
733 238 279 1250
Supplementary Table S8. Experimental scheme corresponding to Figure 6C
DONOR:
ODN.s / ODN.as
2.5 ×105 HEK.EGFPTetO.KRAB  cells per well of 24-well plates (500 µl medium per 
well with or without Dox)
PEI (1mg/ml) 6.2 µl per well; Ratio DNA / PEI equivalents = 9
Reagents Cas9 gNT (Ctrl) gEGFP ODN.s ODN.as Total
(ng)
Molar 
ratiosConstruct length (bp) 9551 3056 3046 120 120
DNA per well
(ng)
642 205 403 1250 1:1:50
766 244 240 1250 1:1:25
642 205 403 1250 1:1:50
642 205 403 1250 1:1:50
766 244 240 1250 1:1:25
642 205 403 1250 1:1:50
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Supplementary Table S9. Experimental scheme corresponding to Figure 6E
DONOR:
ODN.s / ODN.as
2.5 ×105 HEK.EGFPTetO.KRAB  cells per well of 24-well plates (500 µl medium per 
well with or without Dox)
PEI (1mg/ml): 6.2 µl per well; Ratio DNA / PEI equivalents = 9
Reagents Cas9 gNT (Ctrl) gEGFP ODN.as Total
(ng)
Molar ratiosConstruct length
(bp)
9551 3056 3046 120
DNA per well
(ng)
642 205 403 1250 1:1:50
766 244 240 1250 1:1:25
642 205 403 1250 1:1:50
553 176 521 1250 1:1:75
 
Supplementary Notes
>AX63_pTHG.Donor
GGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTACCCCTCACTAAAGGGAACAAAGCTGGTACGAGGACAGGCTGGAGC-
CATGGGCATGGCTACTCAAGCTGATTTGATGGAGTTGGACATGGCCATGGCTGGTGACCACGTCGTGGAATGCCTTCGAATTCAG-
CACCTGCACATGGGACGTCGACCTGAGGTAATTATAACCCGGGCCCTATATATGGATCCAATTGCAATGATCATCATGACAGATCTGCG-
CGCGATCGATATCAGCGCTTTAAATTTGCGCATGCTAGCTATAGTTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTTCTTTTTCCTA-
CAGCTCCTGGGCAACGTGCTGGTTATTGTGCTGTCTCATCATTTTGGCAAAGAATTAAATTTAATTAATCTCGACGGTATCGGTTA-
ACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAATTTAAAGAAT-
TACAAAAACAAATTACAAAAATTCAAAATTTTATCGATCACGAGACTAGCCTCGAGGTTTAAACTACGGGATCCAGGCCTAAGCTTACG-
CGTCCTAGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC-
GGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTG-
CACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACACATGGCGTGCAGTGCTTCAGCCGCTACCCCGAC-
CACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGG-
CAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG-
GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGG-
CATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATC-
GGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT-
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAGAGCTCGAGAAGTACTAGTG-
GCCACGTGGGCCGTGCACCTTAAGCTTTTAAATAAGGAGGAATAACATATGACCATGATTACGCCAAGCTCCAATTCGCCCTATAGT-
GAGTCGTATTACAATTCACTGGCCGTCGTTTTACTATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGG-
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CGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTA-
ATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG-
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAAC-
CCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA-
TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTC-
CAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG-
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT-
GGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG-
TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCT-
CAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTAT-
CAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGT-
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAAC-
TACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATA-
AACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTA-
GAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATG-
GCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC-
CGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTA-
AGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAA-
CACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCT-
TACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGT-
GAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATAT-
TATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCA-
CATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTC-
GTCTTCAAGAATT
Map and nucleotide sequence of pTHG.Donor for HDR-mediated editing of EGFP into EBFP. DNA se-
quences sharing identity to the target sequence in HEK.EGFPTetO.KRAB cells are indicated in orange; AmpR, 
β-lactamase ampicillin resistance gene; ori, high-copy number ColE1 prokaryotic origin of replication; 
cPPT/CTS, central polypurine tract and central termination sequence of HIV-1. As reference, the nucleo-
tide sequences corresponding to the EBFP flurochrome (Thr-His-Gly) and the ssODNs are highlighted in 
bold and underlined, respectively.
Methods
Cells
The human embryonic retinoblasts HER.TLRTetO.KRAB and their control TetO-negative coun-
terparts HER.TLRKRAB, were generated and cultured as detailed elsewhere.6 Likewise for the 
human embryonic kidney cells HEK.EGFPTetO.KRAB .6 The HEK293T cells (American Type Cul-
ture Collection) used for the generation of IDLVd preparations were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal 
bovine serum (FBS; Thermo Fisher Scientific). The cells used in this study were mycoplasma 
free and were kept at 37°C in a humidified-air 10% CO2 atmosphere. 
Recombinant DNA
The gRNA acceptor construct S7_pUC.U6.sgRNA.BveI-stuffer contains a human U6 RNA Pol 
III promoter and terminator sequence for gRNA expression.6 The gRNA expression plasmids; 
Z42_pgTLR.1, Z44_pgTLR.2, AM51_pgNT and AX03_pgEGFP were generated by ligating the 
annealed oligonucleotide pairs listed in Supplementary Table S1 into BveI-digested S7_pUC.
U6.sgRNA.BveI-stuffer. The plasmid hCas9 was used for expressing the Streptococcus pyogenes 
Cas9 nuclease (Addgene plasmid #41815).11 The sequence and annotated map of construct 
AX63_pTHG.donor used for HDR-mediated editing of EGFP into EBFP, are shown in Sup-
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plementary Notes. The Addgene plasmid #31475 pCVL SFFV d14 GFP ,12 herein named Plas-
midd, served as a source of donor DNA in the gene editing experiments performed on HER.
TLRTetO.KRAB and HER.TLRKRAB cells. Plasmidd is a lentiviral vector construct that harbours the 
TLR-targeting donor template EGFPtrunc.12
DNA transfections
The DNA transfections performed on cultures of HER.TLRTetO.KRAB were initiated by adding 1 
mg/ml of linear 25 kDa polyethyleneimine (PEI, Polysciences) to the different plasmid mix-
tures diluted in 50 μl of 150 mM NaCl (Supplementary Tables S2-S6). These cell cultures 
were pre-incubated for 10 days in medium lacking or containing doxycycline (Dox) at a final 
concentration of 0.5 μg/ml. An approximately 10-sec period of vigorous vortexing followed 
the addition of the PEI polycation to each of the DNA mixtures. Next, the DNA-PEI com-
plexes were let to be formed for 15 min at room temperature after which they were directly 
added to the culture medium of the various target cells seeded one day before in wells of 24-
well plates (Greiner Bio-One). The different transfection mixtures were substituted 6-8 hours 
later by regular culture medium with or without Dox. At 3 days post-transfection, the cells 
were sub-cultured every 3-4 days for a period of 10 days and the frequencies of EGFP- and 
mCherry-positive cells in the cultures containing Dox were determined by flow cytometry 
(Supplementary Figure S1). To activate transgene expression, the cultures initially lacking 
Dox were exposed to Dox (0.5 μg/ml) for 10 days, after which the frequencies of EGFP- and 
mCherry-positive cells were also determined in these cultures by flow cytometry. The experi-
mental design, transfection protocols and Dox regimens applied to TetO-negative HER.TLRKR-
AB cells were the same as those applied to HER.TLRTetO.KRAB cells (Supplementary Figure S1).
The DNA transfections carried out on cultures of HEK.EGFPTetO.KRAB cells started by adding 
1 mg/ml of PEI to the different plasmid mixtures diluted in 50 μl of 150 mM NaCl (Supple-
mentary Tables S7-S9). These cell cultures were pre-incubated for 7 days in medium lacking 
or supplemented with Dox at a final concentration of 0.2 μg/ml. After the addition of PEI to 
the DNA solutions, an approximately 10-sec period of vigorous vortexing followed. Subse-
quently, the DNA-PEI complexes were assembled for 15 min at room temperature after which 
they were directly added to the culture medium of the various target cells that had been 
seeded one day before in wells of 24-well plates (Greiner Bio-One). The various transfection 
mixtures were replaced 6-8 hours later by regular culture medium with or without Dox. At 3 
days post-transfection, the cells were sub-cultured every 3-4 days for a period of 7 days and 
the frequencies of EBFP-positive and EGFP-negative cells in the cultures containing Dox were 
determined by flow cytometry. To activate transgene expression, the cultures that initially 
had not received Dox were incubated in the presence of Dox (0.2 μg/ml) for an additional 
7-day period, after which the frequencies of EBFP-positive and EGFP-negative cells were also 
determined in these cultures by flow cytometry (Supplementary Figure S1).
IDLV production and titration
The assembly of IDLVd particles was carried out by transient transfections of HEK293T cells 
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with lentiviral vector construct Plasmidd,12 together with packaging plasmid AM16_psPAX2.
IND116N,13 and vesicular stomatitis virus glycoprotein-G-pseudotyping construct pLP/VSVG 
(Thermo Fisher Scientific), as detailed previously.13, 14 The protocols for the concentration and 
purification of IDLVd particles released into the producer-cell culture medium were equally 
detailed elsewhere.13, 14 Finally, the physical particle titers of the resulting IDLVd stocks were 
determined by measuring the HIV-1 p24gag antigen with the aid of the RETRO-TEK HIV-1 
p24 ELISA kit following the manufacturer’s instructions (Gentaur Molecular Products). 
Gene editing experiments with single-stranded ODNs
The 120 nucleotide-long single-stranded ODNs ODN.s (5’-GCCCGTGCCCT-
G G C C C A C C C T C G T G A C C A C C C T G A C A C A T G G C G T G C A G T G C T -
T C A G C C G C T A C C C C G A C C A C A T G A A G C A G C A C G A C T T C T -
TCAAGTCCGCCATGCCCGAAGGCTACGT-3’) and ODN.as 
(5’-ACGTAGCCTTCGGGCATGGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCG-
GGGTAGCGGCTGAAGCACTGCACGCCATGTGTCAGGGTGGTCACGAGGGTGGGC-
CAGGGCACGGGC-3’) were custom synthesized and HPLC-purified (Eurofins Scientific). 
These ODNs were reconstituted in a solution of 10 mM Tris-Cl and 1 mM EDTA (pH 8.0) 
to a concentration of 100 pmol/μl. A fifty-fold dilution of this stock was divided in aliquots 
and stored at -20°C prior to transfection. The ODNs were transfected together with RGN-en-
coding plasmids into HEK.EGFPTetO.KRAB cells cultured in the absence or in the presence of 
Dox (0.2 μg/ml) using the previously described PEI-based protocol and the DNA mixtures 
detailed in Supplementary Tables S8 and S9.
Flow cytometry
The measurements of EGFP-positive, EGFP-negative, EBFP-positive and mCherry-positive 
cells were performed using a BD LSR II flow cytometer (BD Biosciences). The data were ana-
lysed with the support of FlowJo 10.1 software (Tree Star) or BD FACSDiva 6.1.3 software (BD 
Biosciences). Mock-transfected cells served for establishing background fluorescence thresh-
olds. At least 40,000 viable single cells were analysed per sample.
Statistical analysis
The comparison of the indicated data sets resulting from independent experiments (biologi-
cal replicates done in different days) were analysed by applying two-tailed Student’s t-tests 
(P<0.05 considered significant). The GraphPad Prism 6 software package was used for this 
analysis.
The Chromatin Structure Governs Gene-editing Outcomes
Chapter 5  /  117
Reference
1. Kim H, Kim J-S. A guide to genome engineering with programmable nucleases. Nat Rev 
Genet. 2014;15:321-334. DOI: 10.1038/nrg3686
2. Maggio I, Goncalves MA. Genome editing at the crossroads of delivery, specificity, and 
fidelity. Trends Biotechnol. 2015;33:280-291. DOI: 10.1016/j.tibtech.2015.02.011
3. Chang HHY, Pannunzio NR, Adachi N et al. Non-homologous DNA end joining and alterna-
tive pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18:495-506. DOI: 
10.1038/nrm.2017.48
4. Heyer WD. Regulation of recombination and genomic maintenance. Cold Spring Harb 
Perspect Biol. 2015;7:a016501. DOI: 10.1101/cshperspect.a016501
5. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. DOI: 
10.1016/j.cell.2007.02.005
6. Chen X, Rinsma M, Janssen JM et al. Probing the impact of chromatin conformation on 
genome editing tools. Nucleic Acids Res. 2016;44:6482-6492. DOI: 10.1093/nar/gkw524
7. Daer RM, Cutts JP, Brafman DA et al. The Impact of Chromatin Dynamics on Cas9-Me-
diated Genome Editing in Human Cells. ACS Synth Biol. 2017;6:428-438. DOI: 10.1021/
acssynbio.5b00299
8. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. 
Science 2014;346. DOI: 10.1126/science.1258096
9. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. 
Mol Ther. 2009;17:1316-1332. DOI: 10.1038/mt.2009.122
10. Anders C, Niewoehner O, Duerst A et al. Structural basis of PAM-dependent target 
DNA recognition by the Cas9 endonuclease. Nature 2014;513:569-573. DOI: 10.1038/na-
ture13579
11. Mali P, Yang L, Esvelt KM et al. RNA-Guided Human Genome Engineering via Cas9. Sci-
ence  2013;339:823-826. DOI: 10.1126/science.1232033
12. Certo MT, Ryu BY, Annis JE et al. Tracking genome engineering outcome at individual 
DNA breakpoints. Nat Methods. 2011;8:671-676. DOI: 10.1038/nmeth.1648
13. Pelascini LPL, Janssen JM, Gonçalves MAFV. Histone Deacetylase Inhibition Activates 
Transgene Expression from Integration-Defective Lentiviral Vectors in Dividing and Non-Di-
viding Cells. Hum Gene Ther. 2013;24:78-96. DOI: 10.1089/hum.2012.069
14. Pelascini LP, Goncalves MA. Lentiviral vectors encoding zinc-finger nucleases specific for 
the model target locus HPRT1. Methods Mol Biol. 2014;1114:181-199. DOI: 10.1007/978-
1-62703-761-7_12
15. Urrutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol. 2003;4:231. 
DOI: 10.1186/gb-2003-4-10-231
16. Iyengar S, Farnham PJ. KAP1 Protein: An Enigmatic Master Regulator of the Genome. J 
Biol Chem. 2011;286:26267-26276. DOI: 10.1074/jbc.R111.252569
17. Groner AC, Meylan S, Ciuffi A et al. KRAB–Zinc Finger Proteins and KAP1 Can Mediate 
Long-Range Transcriptional Repression through Heterochromatin Spreading. PLoS Genet. 
Acknowledgments
The authors thank Rob Hoeben and Ignazio Maggio (Leiden University Medical Center, De-
partments of Molecular Cell Biology and Pediatrics, respectively) for  their critical reading of 
the manuscript. This work was partially supported by the Dutch Prinses Beatrix Spierfonds 
(W.OR11–18) and ProQR Therapeutics (Leiden, the Netherlands). X.C. holds a Ph.D. research 
grant from the China Scholarship Council-Leiden University Joint Scholarship Programme.
Conflict of interest statement. None declared.
The Chromatin Structure Governs Gene-editing Outcomes
Chapter 5  /  118
2010;6:e1000869. DOI: 10.1371/journal.pgen.1000869
18. Kuscu C, Arslan S, Singh R et al. Genome-wide analysis reveals characteristics of off-tar-
get sites bound by the Cas9 endonuclease. Nat Biotech. 2014;32:677-683. DOI: 10.1038/
nbt.2916
19. Wu X, Scott DA, Kriz AJ et al. Genome-wide binding of the CRISPR endonuclease Cas9 in 
mammalian cells. Nat Biotech. 2014;32:670-676. DOI: 10.1038/nbt.2889
20. O’Geen H, Henry IM, Bhakta MS et al. A genome-wide analysis of Cas9 binding specific-
ity using ChIP-seq and targeted sequence capture. Nucleic Acids Res. 2015;43:3389-3404. 
DOI: 10.1093/nar/gkv137
21. Richardson CD, Ray GJ, DeWitt MA et al. Enhancing homology-directed genome editing 
by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotech. 
2016;34:339-344. DOI: 10.1038/nbt.3481
22. Watts FZ. Repair of DNA Double-Strand Breaks in Heterochromatin. Biomolecules 
2016;6:47. DOI: 10.1042/BST20110631
23. Garvin AJ, Densham RM, Blair-Reid SA et al. The deSUMOylase SENP7 promotes chro-
matin relaxation for homologous recombination DNA repair. EMBO Rep. 2013;14:975-983. 
DOI: 10.1038/embor.2013.141
24. Murr R, Loizou JI, Yang YG et al. Histone acetylation by Trrap-Tip60 modulates loading of 
repair proteins and repair of DNA double-strand breaks. Nat Cell Biol. 2006;8:91-99. DOI: 
10.1038/ncb1343
25. Baldeyron C, Soria G, Roche D et al. HP1alpha recruitment to DNA damage by p150CAF-1 
promotes homologous recombination repair. J Cell Biol. 2011;193:81-95. DOI: 10.1083/
jcb.201101030
26. Lee YH, Kuo CY, Stark JM et al. HP1 promotes tumor suppressor BRCA1 functions dur-
ing the DNA damage response. Nucleic Acids Res. 2013;41:5784-5798. DOI: 10.1093/nar/
gkt231
27. Tsouroula K, Furst A, Rogier M et al. Temporal and Spatial Uncoupling of DNA Double 
Strand Break Repair Pathways within Mammalian Heterochromatin. Mol Cell. 2016;63:293-
305. DOI: 10.1016/j.molcel.2016.06.002
28. Goodarzi AA, Noon AT, Deckbar D et al. ATM signaling facilitates repair of DNA dou-
ble-strand breaks associated with heterochromatin. Mol Cell. 2008;31:167-177. DOI: 
10.1016/j.molcel.2008.05.017
29. Chu VT, Weber T, Wefers B et al. Increasing the efficiency of homology-directed repair for 
CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotech. 2015;33:543-
548. DOI: 10.1038/nbt.3198
30. Robert F, Barbeau M, Ethier S et al. Pharmacological inhibition of DNA-PK stimulates 
Cas9-mediated genome editing. Genome Med. 2015;7:93. DOI: 10.1186/s13073-015-
0215-6
31. Chylinski K, Makarova KS, Charpentier E et al. Classification and evolution of type II 
CRISPR-Cas systems. Nucleic Acids Res. 2014;42:6091-6105. DOI: 10.1093/nar/gku241
32. Burstein D, Harrington LB, Strutt SC et al. New CRISPR–Cas systems from uncultivated 
microbes. Nature 2017;542:237-241. DOI: 10.1038/nature21059
Chapter 6
Engineered Viruses
 as Genome Editing Devices. 
Molecular Therapy 24:447-457 (2016). 
Chen X, Gonçalves MA. 
This image is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
Engineered Viruses as Genome Editing Devices
Chapter 6  /  120
Abstract
Genome editing based on sequence-specific designer nucleases, also known as programmable nucleases, seeks to modify in a targeted and precise manner the genetic information content of living cells. Deliver-
ing into cells designer nucleases alone or together with donor DNA templates, 
which serve as surrogate homologous recombination (HR) substrates, can result 
in gene knockouts or gene knock-ins, respectively. As engineered replication-de-
fective viruses, viral vectors are having an increasingly important role as delivery 
vehicles for donor DNA templates and designer nucleases, namely, zinc-finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated 
Cas9 (CRISPR/Cas9) nucleases, also known as RNA-guided nucleases (RGNs). 
We review this dual role played by engineered viral particles on genome editing 
while focusing on their main scaffolds, consisting of lentiviruses, adeno-associ-
ated viruses, and adenoviruses. In addition, the coverage of the growing body of 
research on the repurposing of viral vectors as delivery systems for genome edit-
ing tools is complemented with information regarding their main characteristics, 
pros, and cons. Finally, this information is framed by a concise description of the 
chief principles, tools, and applications of the genome editing field as a whole.
Introduction
Genome editing based on sequence-specific designer nucleases, also known as, pro-
grammable nucleases (Figure 1) is opening a vast array of scientific and techno-
logical possibilities. Its broad range of action stems from granting researchers the 
means to modify, in a targeted and precise manner, the genetic make-up of cells 
from an increasing number of higher eukaryotes, including those of humans and 
other mammals.1,2,3 In general, this is achieved by inducing double-stranded DNA 
breaks (DSBs) at predefined chromosomal sequences after designer nuclease deliv-
ery into target cells. The delivery of designer nucleases alone (Figure 2) or together 
with so-called donor DNA (Figure 3) can result in different targeted genome mod-
ification outcomes, each of which resulting from the repair of site-specific DSBs by 
nonhomologous end-joining (Figure 2) or homologous recombination (HR) (Figure 
3), respectively.
Therefore, a crucial aspect pertaining to the application of genome editing strategies 
is that of introducing into target cells designer nucleases (Figure 2) and, whenever 
new genetic information needs to be added, surrogate HR substrates in the form of 
exogenous donor DNA templates (Figure 3). Viral vectors are particularly suitable 
options to introducing genome editing reagents into target cells because, while be-
ing replication-defective, they retain the efficient cell entry mechanisms evolved by 
their wild-type counterparts.2,4,5 Indeed, as engineered replication-deficient viruses, 
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viral vectors have been extensively used in academia and industry to deliver foreign 
genetic payloads into virtually any cell type of interest. Moreover, besides nucleic 
acids they are also starting to be adapted for the direct transduction of recombinant 
proteins into target cells, including designer nucleases. In these cases, designer nu-
cleases are fused to structural components of vector particles (for a recent review, 
see ref. 6).
The on-going adaptation of viral vectors to genome editing settings builds upon 
Figure 1
Diagrams of the three principal designer nuclease platforms. (a) Zinc-finger nucleases 
(ZFNs). ZFNs are based on artificial zinc-finger motifs in which two cysteine residues in a 
β-sheet hairpin and two histidines in an α-helix are tetrahedrally coordinated by a zinc ion. 
ZF, zinc-finger motif dictating the interaction with a specific nucleotide triplet; FokI, nucle-
ase domain of the type IIS restriction enzyme FokI. (b) Transcription activator-like effector 
nucleases (TALENs). TALENs are based on type III secretory systems of phytopathogenic 
bacteria (e.g., Xanthomonas sp.). TALE, transcription activator-like effector comprising a 
central DNA-binding domain consisting of an highly conserved 33–34 residue-long repetitive 
motif; FokI, nuclease domain of the type IIS restriction enzyme FokI; RVDs, repeat variable 
di-residues located at positions 12 and 13 of each TALE repeat governing the interaction 
with a particular nucleotide. (c) RNA-guided nucleases (RGNs). RGNs are based on prokary-
otic type II clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated 
(Cas) systems (e.g., Cas9 from Streptococcus pyogenes). sgRNA, chimeric single-guide RNA 
consisting of a fusion between a sequence-tailored CRISPR RNA (crRNA) and a scaffolding 
trans-activating crRNA (tracrRNA). PAM, protospacer adjacent motif (NGG, in the case of S. 
pyogenes); RuvC and HNH, the two nuclease domains of the Cas9 nuclease protein.
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Figure 2
Genome-editing approaches based on nonhomologous end-joining (NHEJ)–mediated re-
pair of chromosomal DSBs using designer nucleases. NHEJ DNA repair mechanisms acting 
at site-specifically generated DSBs can result in different genome editing outcomes. (a) 
NHEJ-mediated introduction of small insertions and deletions (indels) at the target site of-
ten leads to DNA sequence frame shifting, which in turn, can yield gene-specific knockouts 
whenever protein or RNA coding sequences are targeted (left panel). Conversely, targeted 
DSB-induced frame shifting can restore the proper reading frame usage (right panel). Of 
note, targeted mutagenesis resulting from the activity of designer nucleases might also gen-
erate protein variants whose mode of action involve dominant negative, or positive, effects 
(not drawn). (b) DNA-level exon skipping can be achieved by targeting genomic sequences 
corresponding to key splice acceptor elements. (c) Coordinated DSB formation by designer 
nuclease pairs (multiplexing) can yield specific deletions or inversions if the target sites 
are located in a particular chromosome (left panel) or translocations if they are present in 
different chromosomes (right panel). Solid boxes and horizontal lines, exons and introns, 
respectively; DSB, double-stranded DNA break (open vertical arrowheads); Broken arrows, 
cis-acting gene regulatory elements including promoters/enhancers. Indels, small insertions 
and deletions (open vertical bars); j, chromosomal DNA junctions formed by non-homolo-
gous recombination events triggered by designer nuclease multiplexing. SD and SA, splice 
donor and splice acceptor, respectively.
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Figure 3
Genome-editing approaches based on HR-mediated repair of chromosomal double-stranded 
DNA breaks (DSBs) using donor DNA templates and designer nucleases. Robust homolo-
gy-directed gene targeting, or knock-in, is achievable by combining designer nuclease-in-
duced DSB formation with the delivery of donor DNA templates whose sequences share 
identity to regions flanking the targeted chromosomal lesion. These genome-editing pro-
cedures, based on the activation and recruitment of the homologous recombination (HR) 
DNA repair machinery, are particularly useful for the precise modification of predefined 
chromosomal target sequences of choice. Indeed, these DNA-modifying approaches offer 
the possibility to (a) repair, mutate or modify endogenous genes in a site-specific manner, 
(b) introduce entire recombinant transcriptional units (transgenes) into predefined positions 
in the genome, such as at so-called “safe harbours”, and (c) endow endogenous proteins 
with new domains or tag endogenous genes, such as for tracing their expression patterns or 
isolating their encoded products. Asterisks, nucleotide change, such as, addition or deletion 
of a single nucleotide polymorphism (SNP) or mutation; Large and small open boxes, recom-
binant transcriptional unit (transgene) and heterologous motif (e.g., a tag), respectively. For 
a description of the other symbols and abbreviations see the legend of Figure 2.
a vast amount of knowledge gained from their development for “classical” gene 
therapy or gene replacement approaches in which the delivered foreign nucleic ac-
ids remain mostly in an episomal state or integrate randomly or semi-randomly 
throughout the target cell’s genome.2,4,5
Clearly, inserting instead transgenes, or any exogenous DNA for that matter, into 
specific genomic sequences reduces the chance for various problematic events 
sometimes emergent whenever using systems that lead to the uncontrolled chromo-
somal integration of foreign nucleic acids (e.g., retroviral vectors and transposons/
transposases). These unwarranted outcomes include positional-effect variegation, 
transgene silencing and, in some cases, insertional mutagenesis caused by transcrip-
tional deregulation or physical disruption of endogenous target-cell genes.7 The 
more defined genome modification outcomes resulting from the aforementioned 
designer nuclease-assisted genome editing strategies, are having a clear impact in 
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many fields. For instance, in functional genomics by helping deciphering the role 
of cis- and trans-acting nucleotide sequences, in transgenesis by speeding-up an-
imal model generation via direct zygote engineering and in disease modeling by 
mimicking the origins of certain cancers through the deliberate induction of specific 
mutations or oncogenic rearrangements. Likewise related to disease modeling, and 
besides its potential role in future cell therapies, the integration of genome editing 
with induced pluripotent stem cell (iPSC) technologies is already helping in estab-
lishing genotype–phenotype relationships underlying not only monogenic but also 
polygenic or complex illnesses.8
In addition, genome editing strategies are being investigated for developing new 
treatment modalities aiming at tackling infectious diseases and advancing gene- and 
cell-based therapies. A first example of the former already exists in the shape of 
clinical studies testing whether designer nuclease-induced knockout of the HIV-1 
coreceptor gene CCR5 confers therapeutic benefit to acquired immune deficiency 
syndrome patients.9,10 In parallel, the investigation of many other candidate gene 
therapies based on designer nuclease-induced gene knockout and gene knock-in 
approaches proceeds at the experimental and preclinical levels. These “genome 
surgery” research lines include deploying designer nucleases for disrupting alleles 
linked to dominant disorders and triggering homology-directed DNA targeting for 
repairing or complementing defective genes. The former entails the direct in situ 
correction of endogenous loci; the latter encompasses the targeted insertion of ther-
apeutic DNA at ectopic “safe harbour” loci such as the AAVS1 (19q13.42). Transgene 
insertion at such loci results in much higher probabilities for stable and homogene-
ous expression levels while lessening the chances for the deregulation of target-cell 
endogenous genes.11
In view of the many common goals and substantial overlap between “classical” gene 
therapy and therapeutic gene-editing research, the co-option of viral vector technol-
ogies for the latter purpose is logical and multifaceted in that they are being inves-
tigated for delivering not only designer nucleases but also donor DNA templates. 
Related to this, different types of viral vectors are, in some cases, combined in indi-
vidual gene-editing transduction protocols. Here we review the roles that the main 
classes of viral vectors are having on improving the performance of and expanding 
the scope for genome-editing technologies.
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Viral Vectors as Gene-Editing Tools
Lentiviral vectors
Conventional lentiviral vectors based on HIV-1 establish permanent genetic modi-
fication of target cells owing to the fact that their integrase-dependent mechanisms 
ensure semirandom chromosomal insertion of the transported foreign nucleic ac-
ids.12 In “classical” gene therapy settings, these mechanisms are a crucial feature 
for achieving stable complementation of genetic defects in proliferating target cells 
and effector progenies.13 In the context of genome editing approaches, however, the 
lentiviral DNA insertion mechanisms should best be disabled in order to ensure 
that the resulting episomal vector templates are available as substrates for HR or 
for transient designer nuclease expression. As previously mentioned, the short-term 
presence of designer nucleases in target cells is important for reducing the chanc-
es that deleterious effects caused by off-target activity arise. Therefore, by using 
trans-complementing packaging constructs harboring specific point-mutations in 
the HIV-1 pol region, researchers can assemble lentiviral particles whose integrase 
moiety contains disabling amino acid substitutions at crucial positions within its 
catalytic pocket (i.e., D64, D116, and/or E152) (Figure 4).12,14,15 Importantly, these so-
called class I integrase mutations are nonpleiotropic in that they interfere specifical-
ly with proviral establishment and not with any other of the viral transduction steps, 
such as, receptor binding, uncoating and nuclear import of the reverse-transcribed 
linear double-stranded vector genomes. Hence, integrase-defective lentiviral vectors 
(IDLVs), made with the aid of such packaging constructs serve as valuable vehicles 
for delivering nucleic acid templates for gene targeting and/or transient designer 
nuclease gene expression. Of note, similarly to their integration-proficient counter-
parts, the tropism of IDLV particles are normally altered by endowing them with 
envelop proteins derived from viruses whose cell surface receptors are different 
from those engaged by HIV-1. Accordingly, such pseudotyping manoeuvres permit 
narrowing or expanding the range of cell types transduced by vector particles.16 For 
instance, to confer broad host range and high physical particle stability to lentiviral 
vectors, the vesicular stomatitis virus glycoprotein-G (VSV-G) is often selected as 
the heterologous envelop moiety (Figure 4).
IDLVs were the first viral vectors to be tested in the context of designer nuclease-as-
sisted genome editing experiments.17 These experiments, involving ZFN technolo-
gy and various human target cell types (e.g., K562 erythromyeloblastoid leukemia 
cells, lymphoblastoid cells, and embryonic stem cells), provided an initial proof-
of-concept for using IDLVs in designer nuclease-induced gene addition and gene 
repair studies. The former and latter experiments comprised, respectively, inserting 
recombinant DNA at specific genomic sequences (i.e., CCR5) and correcting IL2RG 
mutations underpinning X-linked severe combined immunodeficiency (X-SCID). 
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Figure 4
Schematics of the main HIV-1-based vector systems. HIV-1-based vectors are assembled 
by cotransfecting producer cells (e.g., HEK293T cells) with transfer, envelop, and packaging 
constructs with the resulting particles being collected and purified after budding from pro-
ducer cells. Transfer plasmids harbor foreign nucleic acid sequences flanked by HIV-1 5’ and 
3’ long terminal repeats (LTRs). To confer HIV-1 Tat independence to vector genome expres-
sion, third-generation transfer plasmids have hybrid 5’ LTRs composed of HIV-1 and heterol-
ogous transcriptional elements (e.g., cytomegalovirus and Rous sarcoma virus). Self-inacti-
vating (SIN) vectors are deleted from specific LTR enhancers (ΔU3) to abrogate unwarranted 
transcriptional activity. Additional HIV-1 cis-acting elements include the packaging signal 
(Ψ), for vector genome encapsidation, the Rev-responsive element (RRE), for nuclear ex-
port of unspliced and singly spliced transcripts, and the central polypurine tract (cPPT), 
for transduction enhancement. The in trans-acting envelope plasmids typically encode the 
pseudotyping VSV-G moiety to confer a pantropic host range to vector particles. The also in 
trans-acting packaging constructs drive expression of HIV-1 Gag and Pol alone (third-gen-
eration) or together with Tat and Rev (second-generation). Owing to the Tat removal and 
the splitting of Rev from Gag-Pol templates, the former systems display a superior biosafety 
profile. The proteolytic processing of precursor Pol sequences yields mature reverse tran-
scriptase and integrase (IN) molecules. Crucially, integrase-defective lentiviral vectors are 
assembled by using packaging constructs encoding IN moieties with substitutions of one or 
more amino acids of the DDE triad; D64, D116, and E152. These so-called class I mutations 
(e.g., D116N) abrogate specifically proviral establishment.
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These data revealed that IDLV genomes can serve as efficient HR substrates yield-
ing, in some cell types, homology-directed DNA targeting frequencies exceeding 
10% of the total target cell population with the majority of cells harboring mono-al-
lelic insertions. These initial data has been followed-up by various other studies in 
which IDLV transfer of donor DNA templates resulted in the addition of reporter 
and therapeutically relevant transgenes into “safe harbour” loci in a diverse set of 
target cells, including human myocytes,18,19 human epithelial stem cells,20 and iPSC 
lines.21 Examples of these experiments are the site-specific chromosomal insertion 
of microdystrophin and FANCA transgenes into the “safe harbour” CCR5 locus in, 
respectively, human muscle progenitor cells18 and iPSCs from reprogrammed fibro-
blasts of Fanconi anemia patients.21 It is worth mentioning however that, in common 
with any other HR-based genome editing approaches, the recruitment of IDLV do-
nor DNA for gene addition or for gene repair purposes is limited in non-dividing or 
quiescent cells due to the fact that HR occurs preferentially during the G2/S phase of 
the cell cycle, when endogenous repairing templates are available.22 Hence, the cel-
lular DNA of quiescent primary cells, of which many display a high therapeutic rel-
evance, is particularly difficult to edit through HR. An outstanding example of such 
cells is provided by primitive CD34+ human hematopoietic stem cells (HSCs). HSCs 
are defined as cells capable of long-term multilineage repopulation of the hemato-
poietic compartment in conditioned immune-deficient mice.23 Of note, only genome 
modification at the HSC level is expected to ensure life-long correction of genetic 
disorders affecting components of the hematopoietic system. Aiming at improving 
HR-based genome editing of these cells, Genovese et al.24 have developed a protocol 
in which donor DNA and ZFN delivery into HSCs is carried out by IDLV transduc-
tion and synthetic mRNA electroporation, respectively. Crucially, this transduction/
electroporation protocol is combined with exposing target cells not only to cytokines 
but also to 16,16-dimethyl-prostaglandin E2 (dmPGE2) mixed with the aryl-hydro-
carbon receptor protein antagonist, StemRegenin 1 (SR1). The rationale for includ-
ing dmPGE2 and SR1 was to interfere with the loss of stem cell properties resulting 
from HSC exposure to extended ex vivo culture conditions and cell cycle-activating 
cytokines. By using these methods, the authors report that homology-directed gene 
targeting frequencies at AAVS1 and IL2RG in bona fide HSCs are increased, as strin-
gently demonstrated by serial transplantation of human CD34+ cells from primary 
to secondary NSG (NOD-SCID-Il2rg-/-) mice. In a subsequent study, Hoban et al.25 
have also tested an ex vivo protocol based on the transfer of ZFN-encoding mRNA 
and IDLV donor templates into bone marrow-derived CD34+ cells for correcting the 
A-to-T transversion in β-globin alleles causing sickle cell anemia.
Hitherto, the delivery of designer nucleases by IDLVs remains mostly restricted to 
ZFNs. Considering that the yields of functional lentiviral vector particles decrease 
sharply with increasing transgene size,26 it is possible that generating IDLVs contain-
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ing the 4.1-kb Cas9 open reading frame (ORF) from Streptococcus pyogenes results in 
IDLV preparations with low functional particle titers. In addition, experimental re-
sults indicate that the genetic instability resulting from frequent reverse transcriptase 
template switching events within TALE repeats in lentiviral vector genomes leads to 
defective particles.27 This makes the assembly of TALEN-encoding IDLVs dependent 
on substantial ORF optimization for minimizing the frequency and length of un-
stable repetitive tracts.28 Of note, the same principle of sequence identity reduction 
has permitted to package and deliver transcriptional units encoding two ZFN mon-
omers in single IDLV particles.29,30 This two-in-one approach is especially useful at 
low transduction rates since it ensures that each transduced cell is exposed to both 
members of a working ZFN pair at the proper 1:1 stoichiometry.
An issue pertaining to the optimal use of IDLVs as designer nuclease expression 
platforms is that of the susceptibility of their genomes to epigenetic silencing mech-
anisms in transduced cells.31,32,33 These mechanisms involve the action of cellular his-
tone deacetylases and have been shown to curtail DSB-induced targeted mutagen-
esis after IDLV-mediated transfer of ZFN expression units.34 Finally, another issue 
regards the susceptibility of free-ended double-stranded IDLV genomes to “illegit-
imate” recombination processes such as nonhomologous end-joining. As a result, 
IDLV templates can become “captured” at off-target or spontaneous DSBs and form 
undesirable DNA structures such as concatemers and non-HR-derived junctions in-
volving target or off-target sequences.17,19 These adverse genome-modifying events 
contribute to reduce the fidelity of the genome editing process as a whole.2
Adeno-associated viral vectors
In contrast to lentiviral vectors, recombinant adeno-associated viral vectors (rAAVs) 
lack an integration machinery (Figure 5).35,36 As a result, once in target cell nuclei, 
their genomes remain mostly in an episomal status with only a small fraction of 
them becoming incorporated in the cellular DNA (0.1–0.5 integrations per infectious 
unit)37 presumably upon nonhomologous end-joining–mediated repair of sporadic 
chromosomal DSBs.36 These vectors entered the scene of homology-directed gene 
targeting during the late 1990’s, after the demonstration that viral particle trans-
duction of single-stranded rAAV donor DNA yields more than 1,000-fold higher 
frequencies of gene repair (up to 1% of the total target-cell population) when com-
pared to those achieved by transfecting conventional donor plasmids.38 Despite the 
feasibility of this approach, including in in vivo settings,39 the dominance of off-target 
insertions combined with the high dependency on large multiplicities of infection 
(>104 total vector particles per cell) and cell selection schemes,40,41 has contributed 
to the initiation of research lines based on designer nuclease-assisted rAAV donor 
DNA targeting.
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Figure 5
Schematics of the main recombinant adeno-associated viral vector (rAAV) production sys-
tem. Recombinant AAV vectors are typically assembled by co-transfecting producer cells 
(e.g., HEK293T cells) with transfer, packaging and helper constructs with the resulting par-
ticles being purified after producer cell lysis. Transfer plasmids harbor foreign nucleic acid 
DNA flanked by 145 bp-long palindromic AAV-2 inverted terminal repeats (ITRs) whose 
primary sequence and T-shaped secondary structure form the origins of replication. The in 
trans-acting packaging plasmids contain the three AAV ORFs, rep, cap, and AAP. Transcrip-
tion of rep from two different promoters and splicing of each of the resulting transcripts 
yields four proteins. Rep78 and Rep68 participate in DNA replication; Rep52 and Rep40 are 
necessary for DNA packaging into preformed empty capsids. The cap ORF is transcribed 
from a single promoter with alternative splicing resulting in two mRNA templates for the 
synthesis of three viral capsomers (VP1, VP2, and VP3). VP2 and VP3 share the same 
mRNA template with the former being translated from a “weak” start codon (ACG) located 
upstream of that for the latter product (AUG). Moreover, another “weak” start codon (CUG) 
present within the VP2-VP3 mRNA marks the beginning of a third reading frame, which 
codes for the assembly-activating protein (AAP). Productive wild-type AAV infections depend 
on the presence of an unrelated virus for providing AAV helper gene functions (e.g., HAdV-5 
E1A-E1B, E2A, VAI-VAII, and E4ORF6). In the context of rAAV production, these functions 
are supplied by transfecting E1A-E1B-expressing cells (e.g., HEK293) with a helper con-
struct containing E2A, VAI-VAII and E4ORF6. Often, the packaging and helper functions are 
combined in a single plasmid.
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Like previous data had shown for HR substrates delivered in the context of stand-
ard plasmids,42,43 experiments based on inducing DSBs at chromosomally integrated 
reporter genes by the homing endonuclease I-SceI, provided a proof-of-concept for 
combining sequence-specific nucleases with rAAV donor DNA in gene-targeting 
settings. Indeed, these initial studies revealed that rAAV-based gene targeting can 
be enhanced by approximately 100-fold if a DSB is generated at a predefined target 
locus.44,45 In this realm, and similarly to IDLVs, rAAVs have been mostly used so far 
for delivering donor DNA templates and ZFNs. Of note, when compared to those 
of Cas9 and TALEN, ZFN ORFs are the smallest (i.e., ~1.2 kb per monomer versus 
~4.1 kb and ~3 kb for S. pyogenes Cas9 and TALEN ORFs, respectively). This permits 
the flexible construction and packaging of transcriptional units encoding one or 
even two ZFNs in single rAAV particles46 whose effective maximum capacity is only 
~4.5 kb (Figure 5). Clearly, in addition to TALEN and Cas9 nuclease delivery, the 
low packaging capacity of rAAV also introduces some limitations on the designing 
of HR substrates for the purpose of site-specific addition of whole transcription-
al units. In any case, the combination of ZFN and rAAV technologies has clearly 
proven its potential for not only targeted gene disruption and deletion46 but also for 
gene repair strategies. In what the latter genome editing approaches are concerned, 
these experiments involved the targeting of both reporter and endogenous loci after 
the delivery of ZFNs and gene correcting templates into a diverse panel of human 
cell types. These different cell types included, U2OS osteosarcoma cells,47,48 HEK 293 
cells,46 HeLa cervix carcinoma cells,48 HT-1080 fibrosarcoma cells,48 and bona fide hu-
man embryonic stem cells (ESCs) as well as iPSCs.49 Noticeably, due to the very 
diverse range of tools, experimental models and conditions, the gene-targeting fre-
quencies in both absolute and relative terms (i.e., targeted versus random insertion 
events), varied substantially. As an example, Asuri et al.49 compared ZFN-induced 
gene repair levels after transducing ESCs with a HR template packaged either in 
natural or variant AAV capsids. The latter capsid type, isolated by sequential cycles 
of biopanning of libraries of cap-mutant viruses on target cells, confers high-level 
rAAV transduction of hard-to-transfect ESCs and iPSCs. The authors showed, by 
using a highly quantitative readout system based on the rescue of defective report-
er gene expression, that the transfer of corrective donor DNA by the molecularly 
evolved rAAV variant (R459G) yielded significantly higher (~10-fold) ZFN-induced 
gene repair levels in ESCs (~1.3% of the total target cell population) when compared 
to those resulting from using a prototypic, serotype 2-based, rAAV. Importantly, 
the proportion of random rAAV DNA chromosomal insertions was not augmented 
by the presence of active ZFNs in the transduced cells. Collectively, this and the 
above-mentioned studies established that site-specific DSB formation serves as a po-
tent trigger for homology-directed gene targeting of donor DNA delivered in the 
context of single-stranded rAAV genomes.
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Owing to a favorable set of characteristics, rAAVs are particularly suited for testing 
genome-editing strategies in vivo. These characteristics include low immunogenicity 
in immunocompetent animal models and amenability to tissue tropism modifica-
tion methodologies based on engineered capsids generated by rational or directed 
evolution approaches.50 Moreover, reminiscent of the above-described tropism engi-
neering strategies involving enveloped lentiviral vectors; nonenveloped rAAVs can 
also be pseudotyped. In this case, rAAV genomes consisting of foreign DNA flanked 
by prototypic AAV serotype 2 inverted terminal repeats, are packaged within the 
capsids of other natural AAV isolates such as those of serotypes 1, 5, 6, 8, or 9.50 These 
novel capsid-modified rAAVs are powerful gene delivery tools in that they can by-
pass pre-existing immunity associated with the presence of neutralizing antibodies 
against particular rAAV serotype(s) and can overcome transductional blocks linked 
to the absence of viral receptor(s) on the surface of specific cell types or tissues. In 
addition to the previously mentioned work in which a molecularly evolved rAAV 
was used,49 another case in point is provided by the body-wide transduction of mu-
rine tissues by rAAV2/6 vectors, that is, AAV serotype 2-derived rAAV genomes 
pseudotyped by packaging in AAV serotype 6 capsids.51 Moreover, it has been 
shown that rAAV2/8 particles achieve frequencies of murine liver cell transduction 
that are 10- to 100-fold higher than those obtained by using vectors based on other 
serotypes.52 Importantly, these experiments equally revealed that the rAAV2/8 gene 
delivery activity was not hindered in animals preimmunized by exposure to other 
AAV serotypes.
The relevance and utility of rAAVs in in vivo settings is also underscored by the fact 
that a first proof-of-principle for designer nuclease-induced genome editing in vivo 
involved the use of these vectors in a murine model of hemophilia B, a blood coag-
ulation disorder caused by factor IX deficiency.53 In particular, rAAV2/8 particles 
containing a corrective cDNA spanning exons 2 through 8 of human F9 were admin-
istered to new-born hemophilia B mice together with rAAV2/8 particles encoding 
donor-matched ZFNs targeting intron-1 of a defective human F9 transgenic allele. 
Gene targeting was detected and meaningful in that it resulted in 3–7% of normal 
levels of circulating factor IX that led to the improvement of the disease phenotype 
as measured by clot-formation kinetic assays. Of note, molecular analysis of genom-
ic DNA from treated mice revealed that therapeutic construct insertions at the in-
tended target site occurred through both homologous and non-HR.53 The latter, 
vector genome capture events, were likely caused by end-to-end nonhomologous 
end-joining of broken chromosome and AAV inverted terminal repeat sequences. A 
subsequent study extended these findings of AAV/ZFN-mediated in vivo therapeu-
tic genome editing to adult hemophilia B mice.54
The in vitro and in vivo transfer of RGN components by rAAVs, has also been initiat-
ed. After constructing and validating shortened expression units encoding Cas9 and 
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sgRNAs, Senís et al.55 were able to demonstrate delivery of Cas9 alone or together 
with a sgRNA by single vector particles built on chimeric AAV-DJ capsids. The lat-
ter “all-in-one” rAAV construction achieved approximately 8% indel formation at a 
target miRNA locus in HEK 293T cells when applied at a multiplicity of infection of 
106 particles per cell. However, in mouse livers, RGN-induced indel formation at the 
conserved miRNA target locus by different rAAV constructs was invariably below 
1% at 2 weeks postadministration. These in vivo results have been complemented by 
other animal model experiments in which rAAV-mediated delivery of RGN com-
ponents served as a direct, transgenesis-free, approach for studying gene function 
in the mammalian brain.56 These initial studies together with the advent of shorter 
Cas9 variants bode well for the implementation of rAAV/RGN tools in different in vit-
ro and in vivo systems. Indeed, Ran et al.57 have recently used a comparative genomic 
analysis to isolate and characterize a Staphylococcus aureus Cas9 protein whose rela-
tively small size permits flexible rAAV design, including copackaging of both RGN 
components within single vector particles. The delivery of these tools into the livers 
of C57BL/6 mice by rAAV2/8 particles led 1 week after intravenous administration 
to approximately 5 and 40% indel formation at Apob and Pcsk9 sequences, respec-
tively.57
Adenoviral vectors
The sizable packaging capacity of adenoviral vectors (AdVs) combined with their 
high-titers and efficiency in transducing dividing and nondividing cells, makes 
them a broadly applicable option for in vitro and in vivo delivery of designer nucle-
ases and donor DNA templates (Figure 6). Similarly to rAAVs, AdVs started to be 
deployed in the context of homology-directed gene targeting experiments that did 
not involve designer nuclease-induced DSB formation. In these experiments, help-
er-dependent AdVs, also known as “gutless” AdVs, were chosen owing to their lack 
of viral genes, permitting the use of high multiplicities of infection, and high capaci-
ty, allowing for large donor DNA packaging and delivery. Indeed, Ohbayashi et al.58 
utilized helper-dependent AdVs with 18.6 kb homology arms to correct a mutation 
in HPRT through HR without the involvement of artificial DSB formation in mouse 
ES cells. With the emergence of iPSCs, helper-dependent AdVs were also shown to 
be useful for correcting disease-related mutations in these pluripotent stem cells. In 
particular, they were used to repair several mutations in LMNA alleles associated 
with laminopathies, thus expanding the application of this gene delivery system to 
human disease modeling and targeted gene repair.59 A follow-up study by Aizawa 
et al.60, demonstrated that regardless of the transcriptional status of the target gene, 
helper-dependent AdVs can mediate both gene knock-ins and gene knockouts by 
HR with high fidelity in both iPSCs and ESCs of human origin. Of note, however, 
the absolute gene targeting levels achieved by helper-dependent AdVs are rather 
low requiring as a result the use of drug-based selection pressure for isolating the 
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desired targeted clones.
Figure 6
Schematics of the principal adenoviral vector (AdV) systems. The genome structures of the 
main AdV classes are drawn in relation to that of the prototypic HAdV-5 from species C. The 
103 bp-long “left” and “right” inverted terminal repeats (L-ITR and R-ITR, respectively) con-
tain the origins of replication, with the viral DNA packaging signal (Psi) being located adja-
cent to the L-ITR. The early (E) and late (L) regions are expressed before and after the onset 
of viral DNA replication, respectively. The former regions (i.e., E1A-E2A, E2A-E2B, E3, and 
E4) encode proteins involved in gene regulation (viral and host) and viral DNA replication; 
the later encode gene products primarily responsible for virion maturation and assembly 
(L1-L5). Expression units corresponding to small RNAs (VAI-VAII) and intermediate gene 
products (IX and IVa2) are also shown. First-generation AdVs lack E1A-E1B or E1A-E1B plus 
E3. Since E3 is dispensable during in vitro replication, all these vectors can be produced 
in packaging cell lines expressing exclusively the E1 functions (e.g., HEK293 or PER.C6). 
Second-generation AdVs have deletions in additional early regions (e.g., E2A and/or E4) 
being, as a result, produced in their respective complementing cell lines. Third-generation 
AdVs (also known as “gutless” or high-capacity) lack all viral DNA sequences except for the 
cis-acting ITRs and packaging signal. These vectors are produced in E1-complementing cells 
in the presence of a first-generation helper AdV which furnishes in trans all the viral gene 
products necessary for the replication and assembly of “gutless” AdV particles. The helper 
has its packaging elements framed by target sites for a site-specific recombinase (e.g., Cre 
or FLP) so that in recombinase-expressing producer cells is rendered packaging-defective in 
a selective manner.
Similarly to lentiviral and adeno-associated viral vector systems, AdVs are equally 
amenable to tropism modification and Good Manufacturing Practice methodolo-
gies. The former strategies include exchanging the apical fiber motifs of prototypic 
species C serotypes, which interact with the Coxsackie B virus and adenovirus re-
ceptor (CAR), with those of other natural serotypes (e.g., species B adenoviruses), 
which interact with other primary receptors. This “fiber swapping” genetic retar-
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geting strategy allows by-passing the absence of CAR on the surface of human cells 
with scientific and therapeutic value such as hematopoietic stem/progenitor cells,61,62 
mesenchymal stromal cells,63,64,65 and muscle progenitor cells.65,66 Alternative AdV 
retargeting methods include capsid modifications by genetic fusion of fiber or pIX 
capsid proteins to heterologous ligands67 or by chemical binding of capsid compo-
nents to targeting moieties.68 In this regard, it is noteworthy mentioning that the first 
testing of a therapeutic approach based on genome editing entails ZFN-mediated 
CCR5 knockout in CD4+ T-cells from acquired immune deficiency syndrome pa-
tients after their ex vivo transduction with fiber-modified AdV particles.9,10 Examples 
of other genome-editing studies based on the integration of AdV and ZFN tech-
nologies include the targeted mutagenesis of endogenous T-cell receptor genes in 
lymphocytes69 and of CCR5 and β-globin alleles in hematopoietic stem/progenitor 
cells.70,71 Moreover, homology-directed gene targeting induced after AdV-mediated 
delivery of ZFNs, is equally being pursued in various cell types such as myoblasts, 
epithelial stem cells, and keratinocytes.18,20
Highlighting their versatility, AdV systems have in addition to ZFNs been validated 
for delivering TALENs and RGN complexes into human somatic cells regardless of 
their transformation status.27,72 Concerning the former research it was found that, in 
striking contrast to lentiviral vector systems, the direct repeat arrays coding for the 
DNA-binding domains of TALENs are stable during AdV production in comple-
menting packaging cell lines.27,73 Importantly, the resulting vector preparations led 
to dose-dependent and high-level (up to 67%) targeted DSB formation in exposed 
cells (e.g., muscle progenitor cells and mesenchymal stromal cells). The genetic sta-
bility of AdVs is also underscored by the fact that transcriptional units encoding 
ZFN9,74 or TALEN dimers can be packaged intact in single vector particles.71,75 Due 
to the sizable length of TALEN ORFs (~3.0 kb per monomer), the latter studies de-
ployed the high-capacity “gutless” AdV platform (Figure 6). In addition to the afore-
mentioned muscle progenitor cells and mesenchymal stromal cells, the combination 
of AdV and TALEN technologies has served for inducing site-specific DSB forma-
tion in iPSCs75 as well as in CD34+ cells isolated from G-CSF-mobilized peripheral 
blood mononuclear cells.71
Recently, various research groups started exploiting the efficient transduction of 
particular murine tissues by AdVs for studying genetic lesions underlying the emer-
gence of specific cancers and, subsequently, modeling their progression in vivo. Such 
approaches based on the direct induction of targeted genomic changes in vivo (e.g., 
mutations, inversions, and translocations) are more expeditious than those based on 
transgenic mice and mimic more accurately the stochastic mosaicism characteristic 
of many tumors. For instance, Zhang et al.76 succeeded in inducing higher rates of 
Apc mutations in the murine liver after tail vein injection of TALEN-encoding AdVs 
than those achieved after plasmid hydrodynamic injections (33 versus 7–19%, re-
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spectively). Maddalo et al.77 have in turn deployed RGN-encoding AdVs for induc-
ing an approximately 11 Mb chromosomal inversion involving the Alk and Eml4 loci 
to model the development of non–small-cell lung cancer in vivo.
Besides cancer modeling, other experiments sought to mutagenize Cebpα78 and Pcsk9 
(ref. 79) in murine livers after the administration of AdVs encoding RGN complexes. 
The former gene is a transcriptional factor involved in the activation of metabolic 
target genes; the latter is associated with low-density lipoprotein cholesterol lev-
els, with its loss-of-function correlating with reduced risk of coronary heart disease 
development. Collectively, these experiments strengthened the view that, together 
with rAAVs, AdVs serve as a valuable platform for introducing designer nucleases 
in vivo. However, with the expansion and finer follow-up of in vivo genome editing 
procedures, one can expect encountering the immunological hurdles identified pre-
viously in countless gene transfer studies in animals. These hurdles include the acti-
vation of innate and adaptive immune responses against viral particle components 
and foreign antigens derived from transgenic and, in the case of helper-independent 
AdVs, viral ORFs.80-82 Moreover, the long-term presence of designer nucleases in tar-
get tissues adds yet another hurdle that needs to be tackled by, for instance, incorpo-
rating regulatory devices for minimizing the risks of chromosomal mutations and/
or rearrangements.
In addition to the introduction of designer nucleases into target cells, AdVs are also 
being exploited as a source of donor DNA templates for homology-directed gene 
editing after site-specific chromosomal DSB formation by ZFNs,20,74 TALENs,19,75 and 
RGNs.19,75 In this regard, it has been shown that combining designer nucleases (i.e., 
TALENs and RGNs) and AdV-mediated donor DNA transfer induces homology-di-
rected gene targeting that is more specific and accurate than that resulting from 
delivering donor DNA templates through conventional nonviral vectors or IDLVs.19 
The finding of precise genome editing resulting from designer nuclease-induced 
AdV donor DNA targeting (“Ad.iting”, in short) could be attributed to the capping 
of linear AdV DNA by the 5’ covalently-attached viral terminal protein which, pre-
sumably, reduces non-HR events. The resulting targeted, single-copy, donor DNA 
integrants lead to uniform transgene expression in gene-modified cell populations.19
A synopsis of the main characteristics of the viral vector systems being repurposed 
as gene-editing devices is presented in Table 1, whereas their principal pros and 
cons are summarized in Table 2. On the basis of this review and on the information 
gathered in Table 1 and Table 2, there is no evidence for an “ideal” one-fits-all com-
bination of gene delivery and gene-editing tools. Instead, one can put forward the 
view that a specific arrangement(s) of these tools is best suited to achieve a particular 
goal.
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In conclusion, viral vectors can serve a dual role in genome engineering efforts by 
delivering into virtually any human cell type, templates for not only designer nucle-
ase expression but also for targeted chromosomal integration of foreign DNA. These 
features, combined with their well-established production systems and regulatory 
history build-up, are expected to foster and expand their application in genome ed-
iting settings, including in the realm of translational research.
Table 1. Overview of the main viral vector systems being repurposed as gene editing tools.
Main characteristics IDLV rAAV AdV
Parental virus family,
Genus (Prototypic element) 
Retroviridae,
Lentivirus (HIV-1)
Parvoviridae, 
Dependovirus (AAV-2)
Adenoviridae,
Mastadenovirus
(HAdV-5)
Particle structure
(Shape)
Enveloped 
Phospholipid bilayer 
with trimeric spikes
(spherical)
Non-enveloped
Protein capsid, fibreless
(icosahedral)
Non-enveloped
Protein capsid with 12 trimeric 
fibres   
(icosahedral)
Vector particle size ~120 nm ~20 nm ~90-100 nm
Vector genome structure HIV cis-acting LTRs 
and packaging signal 
flanking foreign DNA
AAV cis-acting ITRs 
flanking foreign DNA
HAdV cis-acting ITRs and pack-
aging signal flanking foreign DNA 
and vector backbone
Typical vector assembly 
schemes
in producer cell lines
Transfection of vector 
DNA, in trans com-
plementing (Gag, Pol, 
Rev) and pseudotyping 
(VSV-G) constructs
Transfection of vector 
DNA, in trans comple-
menting (rep, cap) and 
helper (HAdV genes) 
constructs
Transfection of vector DNA and 
propagation of assembled parti-
cles in complementing cells
Vector genome poly-
merases
Particle-associated 
Reverse transcriptase
Cellular DNA polymeras-
es
Virus-encoded DNA polymerase
Packaged genome struc-
ture, polarity (Topology)
2× ssRNA, + strand
(linear, free-ended)
1× ssDNA, + or - strand
(linear, hairpin-capped)
1× dsDNA, ± strands
(linear, protein-capped)
Vector particle assembly 
processes
Packaging of full-length 
vector genome tran-
scripts
Packaging of ssDNA from 
hairpin-primed dsDNA 
intermediates
Packaging of dsDNA from pro-
tein-primed dsDNA intermediates
Vector particle cell entry Receptor-mediated 
vector envelop/cell 
plasmalemma fusion
Receptor-mediated endocytosis
via clathrin-coated pits
Vector genome nuclear 
entry
Active ds cDNA import 
via a karyophil-
ic pre-integration 
complex
Remodelled or intact 
particle entry through 
the nuclear pore
Docking of remodelled capsids at 
the nuclear pore, DNA entry
Prevalent genome status in 
transduced cell nuclei
Episomal
Prevalent genome topolo-
gies in target cell nuclei
Linear: ds cDNA; circu-
lar: ds cDNA 1-LTR and 
2-LTR forms
Linear: ssDNA and dsD-
NA; circular: dsDNA sin-
gle- and multi-copy forms
Linear: dsDNA
Transduction potency
(Target cell 
 replication status)
High (dividing and non-dividing)
Tropism modifications, 
including pseudotyping
Straightforward
AAV-2, human adeno-associated virus type 2; cDNA, complementary DNA; ds, double-stranded; HIV-1, 
human immunodeficiency virus type 1; HAdV-5, human adenovirus type 5; IDLV, integrase-defective 
lentiviral vector; ITRs, inverted terminal repeats; LTRs, long terminal repeats; rAAV, recombinant ad-
eno-associated viral vector; ss, single-stranded; vsv-g, vesicular stomatitis virus glycoprotein-G gene.
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Table 2. Overview of the main pros and cons of IDLV, rAAV and AdV systems.
Parameters IDLV rAAV AdV
Production timelines (research-level 
batch) < 2 weeks < 2 weeks > 1 month
Vector production up-scalinga + ++ +++
Functional vector particle yields + ++ +++
Vector particle stability ++ +++ ++
Viral genesb Absent Absent Present or absent
Effective packaging capacity < 7 kb ~ 4.5 kb 5-37 kbc
Compatibility between packaging 
capacity and nuclease ORF sized ++ + ++ or +++
Genetic stability (mutations, rear-
rangements and deletions)e +++ + +
Transgene expression kineticsf ++ + +++
Transgene expression levels + ++ +++
Susceptibility to transgene silencing ++ + +
Background chromosomal insertiong ++ ++ +
In vivo
Immunogenicityh
+ ++ +++
In vivo vector neutralizing anti-
bodiesi + +++ +++
aTypically, lentiviral vector production involves transient transfection methods.Virtually all of the AdV and 
some of the rAAV production platforms encompass instead infection of producer cell cultures with rescued 
viral vector particles. In these cases, the viral gene-deleted vector genomes are complemented in trans 
by either another viral vector and/or by transgenes stably integrated in the producer cell’s DNA.80,83  
bLentiviral vectors, rAAVs, and helper-dependent, “gutless”, AdVs can be made without any of their paren-
tal virus coding sequences. The latter system requires, however, a coinfecting helper AdV modified in its 
packaging signal region to provide in trans all the replicative and structural elements needed for vector 
DNA amplification and packaging, respectively.80 
cThe AdV packaging capacity is contingent upon the particular system and varies from a lowest value of 
~5 kb for E1-deleted, helper-independent, AdVs to the highest value of ~37 kb for “gutless”, helper-de-
pendent, AdVs.80 
dThe approximate ZFN and TALEN ORF lengths are 1.2 and 3.0 kb per monomer, respectively. The com-
bined length of the S. pyogenes Cas9 ORF plus a typical gRNA expression unit is about 4.4 kb. 
eThe error rates of the HIV-1 reverse transcriptase exceeds those of viral dsDNA polymerases by several 
orders of magnitude.84 This contributes to make lentiviral vector genomes mutation-prone. 
fThe transgene expression kinetics of rAAVs is particularly slow due to rate-limiting transduction steps, 
e.g., vector genome uncoating, nuclear entry and ssDNA to dsDNA conversation for transcriptionally ac-
tive template generation.35 
gIDLV and rAAV genomes are often “captured” at chromosomal DSBs, presumably due to the action of the 
nonhomologous end-joining pathway. This contributes to their relatively high levels of basal chromosomal 
DNA integration.36,85 
hHelper-independent AdVs are particularly immunogenic in part because of adaptive immune responses 
triggered by “leaky” viral gene expression at high vector doses.80 rAAVs are immunogenic in part because 
of capsidspecific T-cell activation at high vector doses.82 
iAdVs and rAAVs based on prototypic serotypes 5 and 2, respectively, are particularly affected by pre-ex-
isting neutralizing antibodies due to the fact that a high fraction of the population has been exposed to 
these, or related, viral serotypes.81,86 
AdV, adenoviral vector; DSB, double-stranded DNA breaks; IDLV, integrase-defective lentiviral vector ; 
rAAV, recombinant adeno-associated viral vector.
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Abstract
Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mu-tations in the dystrophin-encoding DMD gene. The DMD gene, spanning over 2.4 megabases along the short arm of the X chromosome (Xp21.2), 
is the largest genetic locus known in the human genome. The size of DMD, com-
bined with the complexity of the DMD phenotype and the extent of the affected 
tissues, begs for the development of novel, ideally complementary, therapeutic 
approaches. Genome editing based on the delivery of sequence-specific program-
mable nucleases into dystrophin-defective cells has recently enriched the port-
folio of potential therapies under investigation. Experiments involving different 
programmable nuclease platforms and target cell types have established that the 
application of genome-editing principles to the targeted manipulation of defec-
tive DMD loci can result in the rescue of dystrophin protein synthesis in gene-ed-
ited cells. Looking towards translation into the clinic, these proof-of-principle 
experiments have been swiftly followed by the conversion of well-established 
viral vector systems into delivery agents for DMD editing. These gene-editing 
tools consist of zinc-finger nucleases (ZFNs), engineered homing endoculeases 
(HEs), transcription activator-like effector nucleases (TALENs), and RNA-guided 
nucleases (RGNs) based on clustered, regularly interspaced, short palindromic 
repeats (CRISPR)–Cas9 systems. Here, we succinctly review these fast-paced de-
velopments and technologies, highlighting their relative merits and potential bot-
tlenecks, when used as part of in vivo and ex vivo gene-editing strategies.
Background
Duchenne muscular dystrophy (DMD) is a lethal X-linked genetic disorder (affect-
ing approximately 1 in 5000 boys) 1 caused by mutations in the ~2.4-megabase DMD 
gene 2 which lead to irrevocable muscle wasting owing to the absence of dystrophin 
in the striated muscle cell lineage 3. Although dystrophin-disrupting mutations can 
be of different types, 68 % of them consist of intragenic large deletions 4. These de-
letions can be found along the entire length of the enormous DMD locus, with 66 
% nested within a major, recombination-prone, hotspot region spanning exons 45 
through 55 4. The resulting joining of exons flanking DMD-causing mutations by 
pre-mRNA splicing yields transcripts harboring out-of-frame sequences and pre-
mature stop codons, which are presumably degraded by nonsense-mediated mRNA 
decay mechanisms.
In muscle cells, the long rod-shaped dystrophin protein anchors the intracellular 
cytoskeleton to the extracellular matrix via a large glycoprotein complex embed-
ded in the plasma membrane called the dystrophin-associated glycoprotein com-
plex (DGC). This structural link is fundamental for proper cellular signaling and 
structural integrity. Indeed, in the absence of dystrophin, a relentless degenerative 
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process is initiated that consists of the substitution of muscle mass by dysfunctional 
fibrotic and fat tissues 3. As time elapses, patients with DMD become dependent 
on a wheelchair for ambulation and, later on, require breathing assistance. Crucial-
ly, with the aid of palliative treatments, which include supportive respiratory and 
cardiac care, the life expectancy of patients with DMD is improving and a greater 
proportion of these patients now reach their late 30s 5.
Targeting the root cause of DMD
The complexity of DMD, combined with the extent of affected tissue, demands the 
development of different, ideally complementary, therapeutic approaches. The 
goal of pursuing parallel approaches is to target different aspects and stages of 
the disease and hence maximize the length and quality of patients’ lives. Towards 
this end, various candidate therapies are currently under intense investigation 3, 5, 6. 
These research lines include: (1) mutation-specific exon skipping via modulation of 
pre-mRNA splicing by antisense oligonucleotides; (2) compensatory upregulation 
of dystrophin’s autosomal paralog utrophin by small-molecule drugs or artificial 
transcription factors; (3) cell therapies involving allogenic myogenic stem/progen-
itor cell transplantation; and (4) gene therapies based on the delivery of shortened 
versions of dystrophin (for example, microdystrophins) to affected tissues. Of note, 
these recombinant microdystrophins are devoid of centrally located motifs that 
are, to some extent, dispensable. The miniaturization bypasses the fact that the full-
length 11-kilobase (kb) dystrophin coding sequence is well over the packaging limit 
of most viral vector systems.
More recently, genome-editing strategies based on sequence-specific programma-
ble nucleases have been proposed as another group of therapies for DMD 7–10. Pro-
grammable nucleases are tailored to induce double-stranded DNA breaks (DSBs) 
at predefined positions within complex genomes 11–13. In chronological order of ap-
pearance, these enzymes are: zinc-finger nucleases (ZFNs) 14, engineered homing 
endonucleases (HEs) 15, transcription activator-like effector nucleases (TALENs) 16–18, 
and RNA-guided nucleases (RGNs) based on dual RNA-programmable clustered, 
regularly interspaced, short palindromic repeat (CRISPR)–Cas9 systems 19–22 (Fig. 
1). HEs, also known as meganucleases, from the LAGLIDADG family can be engi-
neered to cleave DNA sequences other than those of their natural target sites. The 
designing of new substrate specificities depends, however, on complex protein en-
gineering efforts involving the screening of large combinatorial assemblies of HE 
parts 15. Regardless, redesigned HE were shown to create indel footprints at intron-
ic DMD sequences, albeit at very low frequencies (<1 % of target alleles in human 
myoblasts) 23. In contrast to the construction of redesigned HEs, the modular na-
ture of the DNA-binding motifs of ZFNs and TALENs makes them more amenable 
to protein engineering 14, 16–18. Of note, the assembly of highly specific TALENs is 
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particularly straightforward owing to a simple one-to-one relationship between the 
binding of each of their DNA-binding modules, that is, transcription activator-like 
effectors (TALE) repeats, and a specific nucleotide 16, 17. Among other features, ZFNs 
and TALENs differ from RGNs in that they are chimeric enzymes that assemble 
at their target nucleotide sequences as catalytically active dimers through protein–
DNA binding, whereas RGNs are ribonucleoprotein complexes whose DNA cutting 
specificities are ultimately governed by DNA–RNA hybridization. Indeed, RGNs 
consist of a Cas9 endonuclease and a sequence-customizable single-guide RNA 
(sgRNA) moiety that addresses the protein component to a specific target site. Typi-
cally, the target site consists of 18–20 nucleotides complementary to the 5′ end of the 
sgRNA and a protospacer adjacent motif (PAM; NGG and NNGRRT in the case of 
the prototypic Streptococcus pyogenes Cas9 and its smaller orthologue Staphylococcus 
aureus Cas9, respectively) 19, 24. Hence, in comparison with the strictly protein-based 
systems, RGNs are more versatile owing to their mode of construction, which does 
Fig. 1
Milestones on the path towards somatic genetic therapies for Duchenne muscular dystrophy 
that rely on viral-based DMD editing. The time marks correspond to the first release date 
of the referenced articles (for example, advanced online publication). AdV adenoviral vec-
tor, CRISPR–Cas9 clustered regularly interspaced short palindromic repeats-associated Cas9 
nuclease, DMD Duchenne muscular dystrophy, DSB double-stranded DNA break, HE homing 
endonuclease, rAAV recombinant adeno-associated virus, TALE transcription activator-like 
effector
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not involve protein engineering 11–13.
Regardless of the DNA cutting system that is selected, the repair of the ensuing 
DSBs by different endogenous cellular DNA repair processes can yield specific ge-
nome editing outcomes. For example, the engagement of homologous recombina-
tion (HR) and non-homologous end joining (NHEJ) mechanisms can result in target-
ed exogenous DNA additions and endogenous DNA deletions, respectively 11–13. The 
incorporation of small insertions and deletions (indels) following the repair of DSBs 
by NHEJ can also be exploited for knocking out trans-acting and cis-acting genomic 
elements 11–13. By operating at the DNA level, such interventions can potentially lead 
to the correction of disease-causing mutations on a permanent basis.
DMD gene editing
DMD editing based on targeted addition of “exon patches” corresponding to miss-
ing or disrupted coding sequences might become ideal therapeutic options as they 
result in the synthesis of full-length dystrophin 8, 25. Proof-of-principle experiments 
demonstrated that combining DMD-repairing exon patches with engineered mega-
nucleases 25, RGNs, or TALENs 8 can indeed restore full-length message coding for 
dystrophin. At present, however, most DMD editing approaches under investiga-
tion are based on inducing NHEJ to disrupt or delete specific sequences 7–10. These 
strategies exploit the fact that, in contrast to HR, NHEJ is active in both dividing 
and post-mitotic cells 26, 27, which makes these approaches more amenable to both 
ex vivo and in vivo applications (Table 1). The NHEJ-based strategies also capital-
ize on the fact that internally truncated in-frame DMD transcripts, despite being 
shorter than the full-length DMD transcript, often yield functional dystrophins 
28–30. Indeed, such dystrophins are characteristic of patients with Becker muscular 
dystrophy, whose disease phenotypes are milder than those of their counterparts 
with DMD 28–30. Therefore, programmable nucleases have been tailored for correct-
ing defective DMD alleles by targeting: (1) splicing sites for inducing DNA-borne 
exon skipping; (2) exonic sequences for resetting reading frames and “overwriting” 
downstream premature stop codons; and (3) flanking intronic sequences for direct-
ly excising mutations through the use of pairs of programmable nucleases (multi-
plexing) 7–10. DNA-borne exon skipping by NHEJ-mediated splicing motif knockout 
and reading-frame resetting by frame shifting are mutation-specific and rely on the 
fraction of indel footprints that yield in-frame sequences. Importantly, the resulting 
indels might introduce immunogenic epitopes into de novo-synthesized dystrophin 
molecules. Depending on certain variables (for example, revertant mutation back-
grounds), these epitopes might be recognized as foreign by the immune system. 
Related to this potential issue, T-cell immunity to dystrophin epitopes was detected 
in two patients undergoing a clinical trial based on recombinant adeno-associated 
viral vector (rAAV) delivery of a microdystrophin construct 31.
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In contrast to those triggering single-exon deletions, the DMD correction approach-
es based on targeted multi-exon deletions do not give rise to indel-derived epitopes 
and are applicable to a wider range of DMD-causing genotypes, with de novo-gener-
ated intronic junctions leading to predictable in-frame mRNA templates 10, 32. How-
ever, multiplexing approaches carry increased risks for unwarranted, possibly del-
eterious, genome-modifying events (for example, off-target DSBs, inversions, and 
translocations), owing to their dependency on two programmable nucleases rather 
than one 12. These increased risks will be present despite the fact that targeted DSBs 
in boys with DMD will be restricted to a single allele.
Viral-based DMD editing
The clinical application of DMD-editing concepts will require improved methods 
for delivering large and complex molecular tools into target cells, as well as increas-
ing the efficiency, specificity, and fidelity of the ensuing DNA modifications 12. Sim-
ilarly to their effective contribution to “classic” gene replacement therapies 33, viral 
vectors are expected to become instrumental tools for investigating and developing 
therapeutic gene-editing approaches ex vivo and in vivo (for a recent review on the 
adaptation and testing of viral vector systems for genome editing purposes, see 34). 
Indeed, ZFNs, TALENs, and RGNs have all been shown to be amenable to viral vec-
tor delivery 35–37 (Fig. 1). More recently, adenoviral vectors (AdVs) and rAAVs have 
been successfully converted into DMD-editing agents in both patient-derived cells 
and mouse models of DMD 38–42 (Fig. 1).
In vivo
The Dmdmdx mouse model has a (mild) dystrophic phenotype that is due to a non-
sense mutation located in exon 23 of the Dmd gene; historically, this has been the 
principal animal model for investigating DMD-targeted therapies and certain 
pathophysiological aspects of the disease 43. In one study, conventional, common-
ly used, serotype-5 AdVs constructed to encode either S. pyogenes Cas9 or sgRNAs 
that targeted sequences flanking Dmd exons 21 through 23 were co-injected into the 
gastrocnemius muscles of newborn Dmdmdx mice 38. At 3 weeks post-injection, dys-
trophin synthesis was readily detected in transduced muscle fibers. A semi-quanti-
tative assay based on western blot analysis estimated that these fibers contained ~50 
% of the wild-type levels of dystrophin. The gene-edited muscle regions displayed 
reduced Evans blue dye uptake under rest and force-generating conditions, indicat-
ing improved muscle fiber integrity.
A notorious characteristic of prototypic serotype-5 AdVs is their immunogenicity 
and, although they can be made without viral genes 34, 44, capsid-cell interactions can 
still trigger strong innate immune responses 45, 46. In addition, the high prevalence 
of neutralizing antibodies directed against the capsids of serotype-5 AdVs in the 
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human population has contributed to spurring the development of AdVs based on 
alternative serotypes 45. Historically, these immunological determinants have in fact 
precluded the efficacious deployment of AdV technologies in “classic” gene therapy 
settings in which long-term maintenance of transduced cells is a prerequisite. AdVs 
are currently mostly used in human individuals either as oncolytic or vaccination 
agents 47. The use of AdVs in translational in vivo gene editing will require dampen-
ing their immunogenicity and improving their targeting to specific cell types or or-
gans. These efforts will be heavily guided by insights into the biology of host–vector 
interactions 45, 46. For example, while serotype-5 AdVs bind through their fibers to the 
coxsackievirus and adenovirus receptor (CAR) to enter cells in vitro 48, their uptake 
by liver cells after intravenous administration in vivo is CAR-independent and gov-
erned by the interaction of their hexons with blood coagulation factors 49.
Three other studies investigated the in vivo delivery of RGN components (that is, 
sgRNA and Cas9 nucleases) by capsid-pseudotyped rAAVs for inducing the in-
frame deletion of Dmd exon 23. These rAAV particles consist of rAAV DNA from 
serotype 2 packaged in capsids from AAV serotype 8 (rAAV-8) 40 or serotype 9 
(rAAV-9) 39, 41, whose tropism for striated mouse muscle had previously been estab-
lished 50, 51. Pairs of these vectors encoding sgRNAs and either S. pyogenes Cas9 39 or 
the smaller S. aureus Cas9 40, 41 were co-administered into newborn and adult Dmd-
mdx mice. Nelson and colleagues detected abundant dystrophin protein synthesis 8 
weeks after co-injecting a mixture of rAAV-8 particles encoding S. aureus Cas9 and 
cognate sgRNAs into tibialis anterior muscles 40. Importantly, treated muscles had 
improved contractibility and force-generating functions. Finally, by capitalizing on 
the well-established performance of rAAV-8 after systemic administration in mice 50, 
Nelson and colleagues were able to detect dystrophin in cardiac muscle tissue after 
a single intravenous injection 40.
Instead of rAAV-8, Long and colleagues used rAAV-9 to introduce S. pyogenes RGN 
complexes into striated muscle tissues of newborn Dmdmdx mice 39. Dystrophin was 
detected in striated muscle tissues after local and systemic administration of the en-
gineered viral vectors 39. Consistent with the slow kinetics of gene expression from 
rAAVs, which might in part be related to the processes underlying the conversion 
of vector DNA from a single-stranded to a transcriptionally active double-strand-
ed form 52, a time-dependent increase in dystrophin buildup was observed. For in-
stance, tibialis anterior muscles of postnatal day 12 Dmdmdx mice subjected to direct 
intramuscular injections with the engineered viral vector contained approximately 
8 and 26 % of dystrophin-positive fibers at 3 and 6 weeks post-administration, re-
spectively 39.
In the third study, Tabebordbar and coworkers used rAAV-9 pairs for delivering S. 
aureus Cas9 and sgRNAs to the tibialis anterior muscle of dystrophin-defective Dmd-
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mdx mice 41. Similarly to the results of the two other studies on rAAV-mediated Dmd 
exon 23 deletion experiments 39, 40, administration of the rAAV-9 pairs led to robust 
rescue of dystrophin protein synthesis in transduced muscles and to a concomi-
tant measurable improvement in functional parameters (that is, specific force and 
force drop) compared with those in unedited controls 41. In addition, intraperito-
neal co-injection of rAAV-9 particles into dystrophic mice led to frequencies of Dmd 
exon 23 excision in cardiac and skeletal muscle tissues ranging from 3 to 18 %, as 
determined by RT-PCR, depending on the muscle groups analyzed 41. Importantly, 
Dmd-editing rAAV-9 particles were also administered intramuscularly or systemi-
cally to Pax7-ZsGreen Dmdmdx mice whose satellite cells are marked by green fluores-
cence. Subsequently, after isolating, expanding, and inducing myogenic differenti-
ation of the Pax7-ZsGreen-positive cells, the authors reported in-frame Dmd exon 
23 deletions in myotubes derived from these cells 41. The population of Pax7-posi-
tive satellite cells harbors the resident mononuclear stem cell population of skeletal 
muscle and is typically lodged between the sarcolemma of muscle fibers and the 
basal lamina 53. The “stemness” qualities of self-renewal and lifelong differentiation 
capacity make these tissue-specific stem cells ideal substrates for regenerative medi-
cine approaches for treating muscular dystrophies as, in contrast to their committed 
progenitor offspring, these cells support robust long-term tissue homeostasis and 
repair 54, 55. Recent experiments in transgenic Dmdmdx mice showed that, in addition to 
its other functions, dystrophin has a transient but critical regulatory role in activated 
Pax7-positive satellite cells, which further supports the therapeutic relevance of this 
cell population. In particular, the 427-kilodalton dystrophin isoform is expressed at 
very high levels in these cells, where it governs asymmetric cell division, a process 
that is indispensable for maintaining the stem cell pool and for generating com-
mitted Myf5-positive myoblast progenitors for muscle repair 56. Among other pro-
cesses, this mechanism presumably involves interactions between the spectrin-like 
repeats R8 and R9 of dystrophin and Mark2, a protein that regulates cell polarity 56, 
57. If conserved in humans, this cell-autonomous mechanism would be evidence that 
DMD is also a stem cell disease, which would strengthen the view that satellite cells 
should be preferential targets for DMD therapies, in addition to differentiated cells. 
Interestingly, the very high amounts of dystrophin seen in activated Pax7-positive 
satellite cells are followed by very low and intermediate levels of the protein in myo-
blasts and differentiated muscle cells, respectively 56. Such differentiation-stage-spe-
cific oscillations in dystrophin amounts strengthen the rationale for repairing the 
genetic defects by direct endogenous DMD editing, as this strategy is expected to 
restore proper regulation of dystrophin synthesis.
Taken together, these findings demonstrate that rAAV delivery of RGN complexes 
can result in the structural improvement of treated striated tissues and also lead to 
the partial rescue of specific muscle functions in dystrophic mice. Although dystro-
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phin synthesis was detected at 6 months after a single injection in one experiment 
40, no long-term detailed assessments of these approaches were done. Regardless, 
the available data do support the potential of these vectors as in vivo DMD-repair-
ing agents, thus warranting further research. Future developments should include 
assuring the transient presence of programmable nucleases in post-mitotic tissues, 
preclinical testing in large outbred animal models 43, and identifying or engineering 
rAAV capsids that have preferential tropism for human striated muscle cells, includ-
ing satellite cells, while bypassing the host’s humoral immunity against prevalent 
AAV serotypes 58.
The administration of rAAVs to some human individuals resulted in clinical end-
points that had not been predicted on the basis of the available preclinical data. These 
findings are simultaneously sobering and illuminating. An example is provided by 
the elimination of transduced hepatocytes in patients with hemophilia B, which 
was due to the development of a dose-dependent T-cell response to capsid epitopes 
from an rAAV-2-encoding human factor IX 59. This type of dose-dependent cellular 
immune response has also been documented in human skeletal muscle cells trans-
duced with rAAVs 60, although it is of note that the emergence of T-cell responses di-
rected against rAAV capsid epitopes does not always equate with the elimination of 
transduced muscle cells 61. In addition, short-term immune suppression might help 
to dampen cellular immune responses in muscular dystrophy patients subjected to 
high-doses of rAAV particles 62. It is worth mentioning, however, that the altered im-
mune cell composition and inflammatory environment that characterize dystrophic 
muscle tissue might introduce potential confounding factors associated with in vivo 
rAAV delivery. Knowledge about these issues and preclinical data obtained from 
canine models of DMD 63–65 are guiding the design of new clinical trials based on the 
administration of rAAVs to patients with DMD 66. Further insights are being gath-
ered from the application of rAAVs to patients suffering from other muscular disor-
ders such as Limb-girdle muscular dystrophy caused by α-sarcoglycan deficiency 67. 
In particular, there is mounting evidence for the importance of restricting transgene 
expression to muscle cells by using tissue-specific promoters 67. In the future, mus-
cle-restricted transgene expression might be further improved by combining tran-
scriptional with transductional targeting through rAAVs with capsids with a strict 
tropism for human muscle tissue. The recently discovered pan-AAV receptor AAVR 
68 is likely to have an important role in this research; for instance, by shedding light 
on rAAV transduction profiles in different cell types, including immune-related 
cells. Therefore, although rAAVs have a substantially milder immunogenic profile 
than that of AdVs, they also need to be adapted for translational in vivo gene-edit-
ing purposes, which, as for AdVs, will be rooted in an increasing knowledge about 
vector-host interactions and biodistribution at the organismal level. Finally, in the 
context of future clinical protocols for in vivo DMD editing, the synthesis of pro-
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grammable nucleases should be restricted not only spatially but also temporally.
Ex vivo
Ex vivo DMD editing strategies to generate genetically corrected human cells with 
myoregenerative capacity for autologous transplantation can also be envisaged 
(Table 1). These approaches offer a controlled genome-modification environment, 
bypass vector-neutralizing antibodies, and minimize direct contact between the pa-
tient and immunogenic components, such as those from vector particles, gene-edit-
ing tools, and allogenic donor cells (Table 1). Importantly, provided that clinically 
applicable delivery vehicles of gene-editing tools become available, ex vivo DMD ed-
iting can naturally build upon the numerous investigations that are being conducted 
on the isolation, characterization, and testing of human myogenic cells isolated from 
different tissues for treating muscular dystrophies 69–73. These cellular substrates in-
clude satellite cells 53, 54 and their committed myoblast progeny 74, induced pluripo-
tent stem cells 75, mesenchymal stromal cells 76, 77, vasculature-associated mesoan-
gioblasts/pericytes 78, and blood-derived CD133+ cells 79. Of note, the latter two cell 
types have been shown to be amenable to systemic administration in animal models 
and, to some extent, can colonize their satellite cell niche 80–82. In addition, mesoan-
gioblasts/pericytes and CD133+ cells have entered early stage clinical testing in the 
context of allogenic cell therapies for DMD 83, 84. These clinical investigations com-
plement earlier and ongoing testing of allogenic myoblast transplantation that are 
based on intramuscular injections 71–73, 85, 86.
Despite these encouraging developments, the hurdles towards the clinical appli-
cation of ex vivo DMD cell therapies remain numerous and complex. Preeminent 
examples of such hurdles include achieving sufficient numbers of undifferentiated 
cells in vitro, as well as robust cell engraftment, migration, and differentiation of the 
transplanted graphs in vivo. Ideally, the transplanted cells should also be capable of 
homing to damaged tissue after systemic administration and should dedifferentiate 
or transdifferentiate (when belonging to muscle and non-muscle lineages, respec-
tively) into satellite cells (Table 1). Therefore, although certain therapeutic-cell can-
didates are well positioned to fulfil some of these criteria, none of them fulfils all of 
the criteria yet 69, 72. For example, CD133+ blood-derived cells and mesoangioblasts/
pericytes have been shown to be compatible with systemic administration proce-
dures in preclinical models of muscular dystrophies 78, 79 , but their contribution to 
effective myoregeneration requires further investigation. In contrast, the features 
of human satellite cells make them natural, highly potent, muscle-repairing enti-
ties. Besides being available in diverse human muscle groups, satellite cells have 
the capacity to readily engraft as functional stem cells and robustly contribute to 
de novo muscle repair in xenotransplantation experiments 72. However, harvested 
satellite cells are not amenable to systemic administration or current ex vivo culture 
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conditions, as they readily differentiate into myoblasts with reduced regenerative 
capacity 87. Importantly, the latter hurdle might not be insurmountable, as ongoing 
research indicates that extrinsic factors such as the composition and elasticity of cul-
ture vessels can be modulated to mimic the rigidity of the native satellite cell niche 
(that is, 12 instead of ~106 kilopascals) and, in doing so, enable the in vitro survival 
and self-renewal of bona fide satellite cells 88. The development of such biomimetic 
tissue-engineering technologies directed to the in vitro expansion of human satellite 
cells is in demand.
In addition to that of skeletal muscle, cardiac muscle impairment is a key component 
of DMD that also needs to be tackled in future therapies. Despite intense research 
on the isolation and characterization of stem and progenitor cells for the repair of 
damaged heart tissue (for example, after ischemia), so far there is no evidence for 
a significant functional improvement of the myocardium through the cell-autono-
mous differentiation of the transplanted cells into mature, electrically coupled car-
diomyocytes 89, 90.
Other equally important areas for further research in the field of DMD-targeted re-
generative medicine are: (1) deepening our knowledge about the origins and biology 
of the various cell therapy candidates and their interaction(s) with their respective 
niches; (2) gathering all possible information on the fate and behavior of transplant-
ed cells from ongoing and future cell therapy trials; (3) moving forward with gene 
replacement approaches involving stable transduction of recombinant constructs; 
and (4) testing different gene-editing reagents and strategies for developing autolo-
gous cell transplantation approaches. Regarding the latter research avenue, it will be 
crucial to efficiently introduce different gene-editing tools into human muscle pro-
genitor cells and non-muscle cells with myogenic capacity. AdVs outperform rAAVs 
in ex vivo settings owing to their higher functional vector particle titers, larger pack-
aging capacity (up to 37 kb), and faster kinetics of transgene expression 34, 52. Our lab-
oratory has recently reported that tropism-modified AdVs are particularly efficient 
and versatile vehicles for introducing RGNs and TALENs into CAR-negative myo-
blasts from patients with DMD 42. The strict episomal nature of the transduced AdV 
genomes enabled transient high-level expression of programmable nucleases that 
corrected native DMD alleles and yielded permanent and regulated dystrophin syn-
thesis. In this work, we exploited targeted NHEJ-mediated correction of DMD-caus-
ing intragenic deletions by reading-frame resetting, DNA-borne exon skipping, and 
in-frame excision of single or multiple exons 42. The rescue of dystrophin synthesis 
could be readily detected in unselected populations of target cells 42. Bypassing the 
need for cell selection expedients is expected to simplify and help translate ex vivo 
DMD editing protocols to the clinic. Moreover, AdV-based delivery systems will aid 
with assessing and comparing different DMD editing reagents and strategies in pan-
els of human myogenic cells harboring the various DMD mutations, which are not 
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represented in the currently available animal models. In addition, the well-defined 
in vitro conditions permit the straightforward monitoring of intended as well as un-
warranted or potentially deleterious interactions between the gene-editing reagents 
and the human genome (Table 1). Prominent examples of such quality controls will 
include the genome-wide tracking of adverse DNA-modifying events directly in pa-
tient cells (for example, off-target activities of programmable nucleases).
Conclusions and future directions
The application of genome-editing principles for DMD repair purposes is expand-
ing the range of genetic therapy options for tackling DMD. In this context, the coopt-
ing of viral vector systems as carriers of programmable nucleases is set to have an 
important role in the path to DNA-targeted DMD therapies and, along the way, in 
defining the best strategies and optimizing the corresponding reagents. In view of 
the complexity of the DMD phenotype and the extent of the affected tissues, it is 
sensible to consider that future DMD therapies will profit from integrating comple-
mentary approaches. For example, the simultaneous treatment of skeletal and cardi-
ac tissues from patients with DMD might be approached by combining ex vivo and 
in vivo gene-editing strategies, respectively. Such schemes can potentially address 
the skeletal and heart components of DMD while circumventing the current lack of 
cell entities capable of differentiating into functional cardiomyocytes. Regardless of 
the particular therapy or combination of therapies ultimately selected, there is wide-
spread agreement that they should preferably be applied as early as possible so that 
most striated musculature is still in place and the degeneration process can be halted 
or, ideally, reversed in the treated muscle groups. Finally, the insights gained from 
these DMD-targeted research efforts will probably also be useful for devising ad-
vanced genetic therapies for addressing other neuromuscular disorders for which, 
at present, there are no therapeutic options available.
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Table 1. In vivo approaches entail the direct administration of gene-editing viral vectors to 
the patient. Ex vivo approaches encompass the in vitro transduction of patient-derived cells 
(for example, myogenic stem or progenitor cells) with gene-editing viral vectors, which is 
followed by cell culture and autologous transplantation back into the patient. Both treatment 
modalities can, in principle, be applied either locally or systemically. APCs antigen-present-
ing cells, HR homologous recombination, iPSCs induced pluripotent stem cells, NHEJ non-ho-
mologous end joining, rAAVs recombinant adeno-associated viruses
 Pros
× Cons
Viral-based DMD editing
Ex vivo In vivo
Background × Knowledge about the grafting of different 
types of myogenic cells into recipient 
human muscles is scarce.
 Builds upon an increasing amount of knowledge 
on the in vivo administration of viral vectors 
into recipient human muscles (e.g. 
microdystrophin-encoding rAAVs).
Production  Potentially less dependent on large-scale 
viral vector batches.
× Reliant on the upscaling of cell culture 
systems.
× The required numbers of certain myogenic 
cell types might not be achievable owing
to senescence (e.g. myoblasts).
× The current protocols do not permit 
culturing bona fide skeletal muscle stem 
cells (i.e. satellite cells) in vitro.
 Independent from the upscaling of cell culture 
systems.
× More reliant on large-scale viral vector batches.
Delivery  Well-defined genetic modification 
environment that enables careful 
monitoring of procedures, events and 
outcomes.
 Lower stringency for monitoring the 
biodistribution (e.g. gonads and shedding 
of vector elements)
× Protocols for effective myogenic cell 
engraftment, migration and differentiation 
need to be improved (e.g. via signaling 
gradients and cell-autonomous 
reprogramming of iPSCs).
× Local and locoregional administration of 
myogenic cells might be difficult to apply 
to a broad range of muscle groups.
× Protocols for the systemic delivery and 
tissue homing of myogenic cells need to 
be developed.
 Direct exposure to gene-editing tools facilitates 
in situ correction of differentiated striated 
muscle tissues.
 Possible in situ transduction of resident tissue-
specific stem cells might generate a long-term 
source of gene-edited muscle progenitor cells.
 Expanding range of viral vector pseudotypes 
enables the investigation of different 
transduction patterns, e.g. tropism for affected 
tissues while avoiding APCs. Such 
transductional targeting can easily be 
complemented with transcriptional targeting 
(i.e. use of tissue-specific promoters).
× Local and locoregional administration of viral 
vector particles might be difficult to apply to a 
broad range of muscle groups.
× Protocols for the systemic delivery of viral 
vectors to affected tissues need to be improved.
× Higher stringency for monitoring the 
biodistribution (e.g. gonads and shedding of 
vector elements.
Strategy  Relies mostly on targeting replicating cells 
that are amenable to gene-editing 
approaches based on NHEJ as well as 
HR.
× Relies mostly on targeting post-mitotic cells, 
which are less amenable to HR-based gene 
editing principles.
Immunology  Minimizes the exposure of the patient to 
immunogenic components of viral vectors 
and gene-editing tools.
 Possibly compatible with the re-
administration of gene-edited autologous 
cells.
 Avoids the blocking of viral vector 
particles by neutralizing antibodies 
present in the majority of the human 
population.
× Patient exposure to immunogenic components 
of vector particles and gene-editing tools. 
Possible mounting of cellular responses to 
transduced cells displaying foreign epitopes.
× Anti-vector neutralizing antibodies in the 
majority of the human population. Serotype 
cross-neutralizing activity might render vector 
pseudotyping and vector re-administration 
ineffective.
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Abbreviations
AdV adenoviral vector
APC antigen-presenting cell
CAR coxsackievirus and adenovirus receptor
CRISPR clustered, regularly interspaced, short palindromic repeats
DGC dystrophin-associated glycoprotein complex
DMD Duchenne muscular dystrophy
DSB double-stranded DNA break
HR homologous recombination
indel insertion and deletion
iPSC induced pluripotent stem cell
kb kilobase
NHEJ non-homologous end joining
PAM protospacer adjacent motif
rAAV recombinant adeno-associated viral vector
RGN RNA-guided nuclease
sgRNA single-guide RNA
TALE transcription activator-like effector
TALEN transcription activator effector-like nuclease
ZFN zinc-finger nuclease
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               Summary and  
Concluding Marks
Clinical treatments are transitioning from traditional “one-fits-all” chemical drugs, to personalized or precision medicine based on the genetic informa-tion of each patient. Either in biomedicine as a whole or in precision medi-
cine exclusively, genome editing technologies are going to play an ever-increasing 
role by helping decipher the function of genomic sequences and by providing the 
tools for permanently correcting the underlying cause of genetic disorders - the ide-
al situation one can envision in the future. Related to this, engineered RNA-guid-
ed CRISPR-Cas9 nucleases are becoming one of the main driving forces to bring 
these ideas into reality. However, there are still crucial pitfalls associated with CRIS-
PR-Cas9 nucleases that need to be tackled before their implementation as agents in 
standard-of-care therapies. These bottlenecks include ineffective cellular delivery of 
the genome editing reagents, their off-target DNA cleaving activities and the ineffi-
cient and/or imprecise the exogenous DNA incorporation into the human genome. 
To tackle these issues, researchers are developing improved delivery agents, scal-
ing-up their production and, critically, enhancing the specificity of double-stranded 
DNA break (DSB) formation. Finally, researchers are also dissecting the cellular fac-
tors that can affect genome editing outcomes, notably among these, the chromatin 
status of target chromosomal sequences. It is under this context that, this thesis has 
investigated, on one end, a DSB-free genome editing strategy coined in trans paired 
nicking, and on the other, the impact of higher-order chromatin conformations on 
the activity of genome editing reagents and the choice of DNA repair pathway, i.e., 
non-homologous end joining (NHEJ) versus homology-directed repair (HDR). 
Chapter 1 reviews the expanding genome-editing tool armamentarium and associ-
ated DNA modification strategies, with an emphasis on programmable nucleases 
based on CRISPR systems. Chapter 2 demonstrates that in trans paired nicking ge-
nome editing can precisely incorporate small and large DNA segments at different 
loci in human cells, including the AAVS1 “safe harbor” locus in pluripotent stem cells. 
Different HDR genome editing strategies involving either DSBs or single-stranded 
DNA breaks (SSBs), were tested in parallel and assessed in terms of their relative 
efficiency, specificity and accuracy. Conventional genome editing based on DSB 
formation readily yielded mutation byproducts presumably derived from NHEJ; 
genome editing based on SSB formation was, in turn, inefficient. Critically, in trans 
paired nicking, resorting to the generation of SSBs at chromosomal and plasmid 
donor DNA using CRISPR-Cas9 “nickases”, led to efficient and seamless genome 
editing without attendant detection of NHEJ-derived mutations at target alleles.  
Consistent with the initial homologous recombination model proposed by Holliday 
in 1964, it is possible that the coordinated generation of SSBs at target and donor DNA 
substrates facilitates key rate-limiting HDR steps, e.g., reciprocal single-stranded 
DNA invasion by both interacting partners. In this regard, further investigations are 
warranted to tease apart the players and mechanisms governing nick-induced HDR 
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pathways through, for instance, unbiased library screens or knocking-out candidate 
DNA repair genes. From a practical point of view, it will be interesting to assess 
the potential of in trans paired nicking for endogenous gene tagging, and editing 
multi-copy genes or genes with overlapping sequences. Next to this, it will be worth 
determining whether in trans paired nicking is compatible with Cas9 orthologs and 
high-specificity Cas9 variants to further improve its versatility and accuracy, respec-
tively. Admittedly, a possible drawback of the in trans paired nicking strategy might 
be its unsuitability for the genetic modification of quiescent cells due to their lack of 
an active, canonical, HDR machinery. Hence, alternative strategies that can achieve 
efficient and non-mutagenic genome editing in post-mitotic cells are in demand and 
should thus be enthusiastically pursued. 
Chapter 3 probes, in a quantitative manner, the impact of alternate chromatin states 
on the performance of genome editing tools, in particular, programmable nucleas-
es based on S. pyogenes CRISPR-Cas9 nucleases and Xanthomonas sp. transcription 
activator-like effector (TALE) proteins. For these experiments, complementary gain-
of-function and loss-of-function cellular models were set-up to track targeted gene 
knockout levels by different CRISPR-Cas9 nucleases and TALE nucleases (TALENs) 
at euchromatin versus heterochromatin. In these human-cell systems, reporter tar-
get alleles transit from compact heterochromatin to relaxed euchromatin through 
the doxycycline-dependent release of a tTR-KRAB fusion protein whose effector do-
main Krüppel-associated box (KRAB) recruits, amongst other heterochromatin-as-
sembling factors, KAP-1 and HP-1. The data generated in these reporter systems 
demonstrates that TALENs and CRISPR-Cas9 nucleases are both significantly hin-
dered by KRAB-induced heterochromatin in living cells with the former more so 
than the latter. This finding is intriguing in view of the fact that, in contrast to TALE 
proteins, S. pyogenes CRISPR-Cas9 nucleases do not evolve to assess and cleave 
genomic DNA in the nuclei of eukaryotic cells. It is of note, however, Chapter 4 in-
dicate that S. aureus CRISPR-Cas9 nucleases are significantly more affected by closed 
chromatin than their S. pyogenes counterparts. Whether this differential “chromatin 
barrier” results from these nucleases having different protospacer adjacent motifs, 
conformational energy thresholds for ATP-independent helicase activation, or other 
downstream processes, warrants further investigation. 
As aforementioned, a preeminent shortcoming of RNA-guided nucleases is their 
off-target activity. To address this issue head-on, researchers are developing new 
reagents and strategies to enhance the specificity of genome editing protocols. For 
instance, target site discrimination by RNA-guided nucleases can be improved 
through rationally engineered high-specificity Cas9 variants, offset RNA-guided 
“nickase” pairs, and truncated gRNAs (Tru-gRNAs) whose shorter spacer sequenc-
es often bias DNA binding towards fully complementary sequences. Chapter 3 and 
Chapter 4 demonstrate that, albeit to different extents, all these high-specificity 
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RNA-guided nuclease platforms suffer from having their target sequences embed-
ded in KRAB-induced heterochromatin. In fact, with the exception of Tru-gRNAs, 
heterochromatin seems to impinge a higher activity barrier to these high-specificity 
platforms than to conventional RNA-guided nucleases. Future studies should seek 
to determine whether, not only on-target, but also off-target profiles of program-
mable nucleases change due to different epigenomes, such as those characteristic of 
specific cell types and cell differentiation stages.
Using the same tTR-KRAB reporter cells, Chapter 5 studys the impact of alternate 
chromatin conformations on the relationship between NHEJ versus HDR in genome 
editing. In these experiments, donor DNA templates were provided in the form of 
single-stranded oligodeoxyribonucleotides, standard plasmids or Integrase-defec-
tive lentiviral vector (IDLV) genomes. In contrast to the observation that hetero-
chromatin partially impairs NHEJ-mediated gene editing (Chapters 3 and 4), the 
absolute levels of HDR-mediated gene editing are similar at euchromatin and het-
erochromatin. Hence, the balance between NHEJ and HDR shifts towards HDR 
when target sequences transit from euchromatin to heterochromatin. As corollary, 
when compared to euchromatic sites, at heterochromatic sites, there are fewer muta-
genic NHEJ-derived indels for each HDR-derived gene editing event.  
Although the “downstream” chromatin transition in tTR-KRAB reporter cells entails 
recruiting endogenous chromatin-remodeling complexes and establishing “physio-
logical” KRAB-dependent chromatin states, the “upstream” epigenetic regulation 
of target sequences is surrogate in character. Thus, it should be insightful to com-
plement the data from tTR-KRAB-regulated reporter alleles with those from endog-
enous loci harboring different epigenetic marks and chromatin organizations. This 
line of inquiry should profit from the expanding set of epigenetic-remodeling tools 
which, in a targeted manner, can modulate DNA methylation and/or post-transla-
tionally alter nucleosome compositions, e.g., histone acetylation/deacetylation. Col-
lectively, the data presented in Chapters 3, 4 and 5 raise the possibility for directing 
genome editing outcomes by controlling the higher-order epigenetic states of target 
sequences. In particular, “opening-up” a heterochromatic target site might increase 
gene knockout efficiencies, while transiently “closing” a euchromatic target site 
might reduce NHEJ-derived indels upon HDR-based genome editing. Such ancillary 
approaches might become feasible with the aid of the aforementioned toolbox con-
sisting of epigenetic-remodeling programmable factors. Of note, besides higher-or-
der chromatin structures, recent in vitro studies have demonstrated that nucleosome 
positioning can, per se, influence target DNA cleavage by CRISPR-Cas9 nucleases. 
Interestingly, modulating the dynamics of nucleosome positioning in vitro through 
ATP-dependent chromatin remodelers greatly enhanced target DNA cleavage by 
CRISPR-Cas9 nucleases. 
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Chapter 6 provides an overview of the main characteristics, pros and cons of com-
monly used viral vector systems that are being converted into delivery vehicles for 
genome editing tools. In particular, IDLVs, adeno-associated viral vectors and ad-
enoviral vectors. As a case-in-point, Chapter 7 covers the emerging investigations 
using viral vectors for the ex vivo or in vivo correction of defective dystrophin-encod-
ing gene causing the lethal muscle-wasting X-linked disorder Duchenne muscular 
dystrophy (DMD). Regarding the in vivo delivery of programmable nucleases, it is 
important to consider the potential immunogenicity of genome editing reagents and 
delivery vehicle components, e.g., bacterial Cas9 proteins and viral vector capsids, 
respectively. In fact, recent experiments have identified pre-existing humoral and 
cellular immune responses to S. pyogenes and S. aureus Cas9 nucleases in the human 
population. These aspects are especially relevant in in vivo settings where genome 
editing components directly encounter the recipient’s immune system. 
In conclusion, the interplay between different donor DNA structures and target 
chromatin environments modulates the outcomes of genome editing in terms of 
their efficiency, specificity and accuracy. Hence, the findings of this thesis provide a 
new path for improving these three key parameters that underlie robust and seam-
less genetic modification of human cells. 
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Klinische behandelingen gaan over van een traditionele aanpak, zoals het toe-dienen van “one-fits-all” medicijnen, naar gepersonaliseerde- of precisiege-neeskunde op basis van de genetische informatie van elke patiënt. Of het nu 
in de context van de medische biologie in zijn geheel is of de precisiegeneeskunde 
in het bijzonder, het is redelijk om aan te nemen dat genoom-editing technieken 
een steeds grotere rol gaan spelen binnen deze gebieden door de functie van ge-
noomsequenties te helpen ontcijferen en door de hulpmiddelen aan te bieden voor 
het permanent corrigeren van de onderliggende oorzaak van genetische aandoe-
ningen - de ideale situatie die men zich voor de toekomst kan voorstellen. RNA-ge-
leide CRISPR-Cas9-nucleasen zijn een van de belangrijkste drijvende krachten aan 
het worden om deze ideeën tot werkelijkheid te maken. Er zijn echter nog steeds 
cruciale valkuilen die moeten worden aangepakt voordat CRISPR-Cas9-nucleasen 
geïmplementeerd kunnen worden in therapieën die voldoen aan de eisen voor zorg. 
Deze knelpunten omvatten inefficiënte cellulaire afgifte van de genoom-editing 
reagentia, hun “off-target” DNA knipactiviteiten en de inefficiënte en / of onnau-
wkeurige opname van het exogene DNA in het menselijk genoom. Met het oog op 
het oplossen van deze problemen ontwikkelen onderzoekers verbeterde methoden 
voor de cellulaire afgifte van de reagentia, voeren ze het productieniveau op en, van 
groot belang, verbeteren ze de specificiteit van de dubbelstrengs DNA-breuk (DSB) 
vorming. Om te helpen bij de keuze van programmeerbare nucleaseplatforms en 
om hun prestaties te verbeteren, beginnen onderzoekers ook de cellulaire factoren 
te ontleden die de uitkomst van genoom-editing kunnen beïnvloeden, met in het 
bijzonder de chromatine-status van chromosomale doelwitsequenties.
Het is in deze generieke context dat ik in dit proefschrift mijn onderzoek naar een 
DSB-vrije genoom-editingstrategie genaamd “in trans paired nicking” beschrijf en 
ook de invloed van hogere-orde chromatine-conformaties op de activiteit van ge-
noom-editingreagentia en keuze van de DNA-herstelroute, d.w.z. niet-homologe ein-
dverbinding (NHEJ) versus homologie gerichte reparatie (HDR), aan de orde komt. 
Hoofdstuk 1 biedt een overzicht van het uitbreidende assortiment aan genoom-ed-
iting reagentia en de bijbehorende DNA-modificatiestrategieën, met de nadruk op 
programmeerbare nucleasen op basis van CRISPR-systemen. Hoofdstuk 2 laat zien 
dat “in trans paired nicking” genoom-editing kan resulteren in de precieze incorpo-
ratie van kleine en grote DNA-segmenten op verschillende loci in menselijke cellen, 
inclusief het AAVS1 “safe harbor” locus in pluripotente stamcellen. Verschillende 
genoom-editingstrategieën waarbij de HDR-route werd geactiveerd door DSB’s of 
enkelstrengs DNA-breuken (SSB’s), werden parallel getest en beoordeeld op hun 
relatieve efficiëntie, specificiteit en nauwkeurigheid. Conventionele genoom-editing 
op basis van DSB-vorming op de doellocatie leverde frequent mutatiebijproducten 
op, vermoedelijk als gevolg van NHEJ; genoom-editing op basis van SSB-formatie 
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op de doellocatie was op zijn beurt inefficiënt. Bij “in trans paired nicking”, waarbij 
gebruik wordt gemaakt van de generatie van SSB’s op chromosomaal en plasmide 
donor DNA met behulp van CRISPR-Cas9 “nickases”, leidde tot een efficiënte en 
naadloze bewerking van het genoom zonder de aanwezigheid van NHEJ-afgeleide 
mutaties bij doelallelen.
In overeenstemming met het initiële homologe recombinatiemodel dat door Holli-
day in 1964 werd voorgesteld, is het mogelijk dat de gecoördineerde generatie van 
SSB’s op doel- en donor- DNA- substraten de uitvoeren van HDR-stappen verge-
makkelijkt, bijv. reciproke enkelstrengs DNA-invasie door beide samenwerkende 
partners. Verdere onderzoeken om de spelers en mechanismen die betrokken zijn bij 
nick-geïnduceerde HDR-routes te achterhalen zijn nodig, bijvoorbeeld door onbev-
ooroordeelde bibliotheek screening of gerichte knock-out van kandidaat-genen die 
betrokken zijn bij het DNA herstel mechanisme. Het beoordelen van het potentieel 
van “in trans-paired nicking” voor het labellen van endogene eiwitten, met als doel 
het live volgen van levende cellen, en het bewerken van multi-kopie genen of genen 
met overlappende sequenties is vanuit een praktisch oogpunt interessant. Daarnaast 
is het de moeite waard om te bepalen of “in trans-paired nicking” compatibel is met 
Cas9-orthologen en zeer specifieke Cas9-varianten om, respectievelijk, de veelzijdig-
heid uit te breiden en de nauwkeurigheid te verbeteren. Toegegeven, een mogelijk 
nadeel van de “in trans-paired nicking” strategie zou de ongeschiktheid voor gene-
tische modificatie van rustende cellen kunnen zijn, vanwege het ontbreken van de 
actieve, gebruikelijke, HDR-machinerie. Vandaar dat alternatieve strategieën die ef-
ficiënte en niet-mutagene genoom-editing in post-mitotische cellen kunnen bewerk-
stelligen gevraagd zijn en dus enthousiast moeten worden nagestreefd. Hoofdstuk 
3 beschrijft experimenten die zijn ontworpen om, op een kwantitatieve manier, de 
impact te bepalen van chromatine status op de prestaties van genoom-editingrea-
gentia, in het bijzonder van programmeerbare nucleasen op basis van component-
en van S. pyogenes CRISPR-Cas9 nucleasen en Xanthomonas sp. transcriptie activa-
tor-like effector (TALE) eiwitten. Voor deze experimenten werden complementaire 
“gain-of-function” en “loss-of-function” cellulaire modellen gegenereerd om de 
doelgen-knock-out levels, tot stand gekomen door de werking van verschillende 
CRISPR-Cas9-nucleasen en TALE-nucleasen (TALENs) bij euchromatin versus het-
erochromatine, te volgen.
In deze menselijke cel-systemen gaan reporter doelwitallelen over van compact 
heterochromatine naar ontspannen euchromatine via de doxycycline afhankelijke 
werking van een tTR-KRAB fusie-eiwit waarvan het effectordomein, Krüppel-geas-
socieerde box (KRAB), onder andere de heterochromatine-assemblerende factoren 
KAP-1 en HP-1 rekruteert. De met deze reportersystemen gegenereerde gegevens, 
gepresenteerd in hoofdstuk 3, tonen aan dat TALEN’s en CRISPR-Cas9-nucleasen 
beide aanzienlijk worden belemmerd door KRAB-geïnduceerde heterochromatine 
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in levende cellen, de eerste meer dan de laatstgenoemde. Deze bevinding is intrig-
erend met het oog op het feit dat, in tegenstelling tot TALE-eiwitten, S. pyogenes 
CRISPR-Cas9-nucleasen niet zijn geëvolueerd om genomisch DNA in de kernen 
van eukaryote cellen te benaderen en te knippen. Het moet echter worden opge-
merkt dat RNA-geleide nucleasen van andere prokaryotische CRISPR-systemen 
meer worden belemmerd door de eukaryote context van doelsequenties, in het 
bijzonder bij heterochromatische gebieden, dan die afgeleid van S. pyogenes CRIS-
PR-Cas9-componenten. De in hoofdstuk 4 vermelde experimentele gegevens, ver-
kregen bij gebruik van dezelfde  cellulaire modellen als in hoofdstuk 3, tonen inder-
daad aan dat S. aureus CRISPR-Cas9-nucleasen significant meer worden beïnvloed 
door gesloten chromatine dan hun S. pyogenes tegenhangers. Of deze differentiële 
“chromatinebarrière” het gevolg is van de verschillende “protospacer adjacent mo-
tifs” van deze nucleasen, de conformationele energiedrempels voor ATP-onafhanke-
lijke helicase-activering of andere downstream processen die leiden tot het knippen 
van DNA verdient verder onderzoek. Zoals reeds eerder vermeld, is een bekende 
tekortkoming van RNA-geleide nucleasen hun off-target activiteit. Om dit probleem 
rechtstreeks aan te pakken, zijn onderzoekers actief bezig met het ontwikkelen van 
nieuwe reagentia en het onderzoeken van nieuwe strategieën om de specificiteit van 
genoom-editing protocollen te verbeteren.
Deze pogingen resulteerden in een verbetering van doellocatie herkenning door 
RNA-geleide nucleasen via het rationeel construeren van hoog-specifieke Cas9-var-
ianten, het gebruik van offset-RNA-geleide “nickase”-paren en het ontwerpen van 
ingekorte gRNA’s (Tru-gRNA’s) waarvan de kortere DNA-hybridiserende spac-
ersequenties vaak productieve DNA-binding van volledig complementaire doelse-
quenties bevorderen. De in hoofdstuk 3 en hoofdstuk 4 gepresenteerde resultaten 
laten zien dat al deze hoog-specificiteit RNA-geleide nucleaseplatforms lijden, al-
hoewel in verschillende mate, wanneer hun doelwitsequenties zijn ingebed in door 
KRAB geïnduceerd heterochromatine. Heterochromatine lijkt een grotere impact te 
hebben op platforms met hoge specificiteit dan op conventionele RNA-geleide nu-
cleasen, met uitzondering van de Tru-gRNA’s. Toekomstige studies moeten prob-
eren vast te stellen of niet alleen on-target maar ook off-target profielen van pro-
grammeerbare nucleasen veranderen door verschillende epigenomen, zoals die die 
kenmerkend zijn voor specifieke celtypen en celdifferentiatiestadia. 
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